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ABSTRACT
This study was designed to explore the effects of the anti-folate drug methotrexate 
(MTX) on bone formation and turnover in rheumatoid arthritis (RA), using 116 RA 
subjects, bone histomorphometry and bone cell culture.
Low dose MTX is a disease-modifying drug (DMARD) used in RA treatment. 
Evidence exists that high dose MTX causes osteoporosis. As RA is a risk factor for 
osteoporosis, the study was performed to determine whether therapy with MTX 
results in bone loss.
There were four groups of subjects: those who had taken MTX continuously for the 
past five years; those on another DMARD for the same time; those starting MTX; and 
those starting sulphasalazine (another DMARD). Data collected included: annual 
bone mineral density (BMD) measurements at the spine, hip and forearm; serum 
and urinary markers of bone turnover; measurement of RA disease activity and joint 
damage. Paired bone biopsies from four subjects before and after one year’s MTX 
treatment were analysed by histomorphometry. MTX was added to cultures of 
normal human marrow-derived stromal cells and trabecular-derived osteoblast-like 
cells.
Analysis of the clinical data revealed that MTX was associated with significantly 
reduced BMD of the forearm which remained significant at the mid-portion forearm 
site after adjustment for confounding factors. No significant adverse effect of MTX on 
bone formation or resorption was found in the markers of bone turnover or by 
histomorphometry of the cancellous envelope. In cultures of normal human bone 
cells MTX affected proliferation and colony formation in a dose-dependent way. 
Differentiation was also affected, resulting in population shifts on flow cytometry.
MTX therapy was associated with reduced bone mass of the forearm, most of which 
could be explained by confounding factors. However, a significant adverse 
treatment effect persisted at the forearm mid-portion site which is predominately 
cortical and not prone to fracture. A preferential effect on cortical bone has been 
predicted from case reports and may explain the lack of effect seen on 
histomorphometry of the cancellous bone. In vitro, the anti-folate effect of MTX 
dominated, impairing proliferation of normal bone cells. These findings are 
reassuring for clinicians and patients using low-dose MTX in the treatment of RA.
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1.1.1 Functions of Bone
Vertebrates are unique in possessing an internal skeleton. The 206 bones of the 
human skeleton are a specialised form of connective tissue and perform many 
functions including the following three vital ones. These are: (1) the protection of 
vulnerable internal organs including the bone marrow, (2) the mechanical provision 
of levers for the striated muscles to act on thereby permitting locomotion, and (3) 
the metabolic reservoir of calcium, phosphate and bicarbonate ions available from 
bone and essential for homeostasis (Baron, 1996).
There are two forms of bone with distinct features at the macroscopic and 
microscopic levels which result in different functions.
1.1.2 Cortical Bone
Cortical, or compact, bone comprises 80% of the adult skeletal mass and is found in 
the long bones and the outer aspects of the flat bones (the ilium and skull) and 
vertebral bodies. Cortical bone is dense and strong and 85% by volume is calcified. 
Only 10% is soft tissue and thus cortical bone provides most of the protective and 
mechanical functions of bone (Monier-Faugere et al, 1998).
1.1.3 Trabecular Bone
Trabecular, cancellous or spongy bone is much more porous than cortical bone, 
consisting of a meshwork of connecting struts with cells of the bone marrow, blood 
vessels and connective tissue filling the spaces. Trabecular bone in the adult is 
found mainly in the vertebral bodies, iliac crest, calvariae and at the ends of the long 
bones (metaphysis and epiphysis) (Baron, 1996). It is only 20% calcified, with bone
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marrow making up more than 75% of tissue volume. Although trabecular bone only 
contributes 20% towards the total skeletal mass, it is four times more metabolically 
active than cortical bone and so the metabolic function is divided equally between 
the two bone types (Monier-Faugere et al, 1998).
1.1.4 Bone Matrix
In normal or lamellar bone, collagen fibres are aligned in a preferential direction 
whereas in woven bone the collagen fibres are laid down in random bundles. The 
pattern of collagen fibres is seen best under polarised light or by electron 
microscopy. Primitive woven bone occurs in various pathological states such as 
fracture healing, Paget’s disease of bone, osteogenesis imperfecta and in primary 
and secondary hyperparathyroidism (Ng et al, 1997).
Type 1 collagen fibres account for 90% of the protein in bone. Calcification of the 
collagen results in the formation of spindle-shaped or plate-shaped crystals of 
hydroxyapatite [3Ca3(P 04)2«(0H)2] on and within the collagen fibres and within the
ground substance between the fibres (Glimcher, 1998). Woven bone is less able to 
undergo calcification and is therefore weaker than lamellar bone. Collagen 
synthesis is described in Section 1.1.10 below. The bone matrix contains many 
growth factors, proteolytic enzymes and their inhibitors, all of which contribute to the 
modelling and remodelling of bone as described in Section 1.1.12 (Ng et al, 1997).
1.1.5 Osteoblasts
The primary function of the osteoblast is bone formation. Osteoblasts are small 
cuboidal cells which differentiate from bone marrow stromal stem cells initially into 
pre-osteoblasts, then osteoblasts (Beresford, 1989). Fully differentiated osteoblasts
16
express alkaline phosphatase on their cell surface and synthesize osteocalcin (also 
called bone gla-protein), which can be used as a marker of bone formation (Section 
1.1.12) (Raisz et al, 1998).
In the normal adult skeleton, bone formation only occurs on a bone surface which 
has previously been eroded (Monier-Faugere et al, 1998). Mature osteoblasts are 
found in a cluster along a bone surface where they synthesise osteoid at a bone 
forming site (Raisz et al, 1998). Osteoid is uncalcified bone tissue which can 
undergo calcification by the association of hydroxyapatite (section 1.1.4) to form 
mature bone. It is thought that each osteoblast can produce a pre-determined 
quantity of osteoid in its functional life-span which has been estimated as between 
three days and three months (Parfitt, 1995).
1.1.6 Osteocytes
Osteocytes are cells found deeper within the bone matrix. Originally osteoblasts 
which have become trapped within the matrix they produced, osteocytes are 
thought to have a regulatory role in bone turnover. They have long processes which 
extend through small canals or canaliculi in the bone and are in contact by gap 
junctions with the cell processes from other osteocytes as well as with osteoblasts 
and lining cells (Puzas, 1996). Recent work has suggested that cortical bone 
osteocytes undergo apoptosis in response to mechanical stimuli, affecting bone 
formation and resorption on a bone surface not adjacent to the osteocyte location 
(Noble et al, 1997).
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1.1.7 Osteoclasts
Osteoclasts are bone resorbing cells which develop from the fusion of several cells 
derived from a haematopoietic stem cell of different lineage from osteoblasts and 
chondrocytes (Mundy, 1996). They can have between four and twenty nuclei and 
are found on the surface of bone which is being resorbed, usually only one to four 
such fused cells for each resorption area. The osteoclast makes a resorption pit by 
using integrins on the cell membrane to attach to the bone surface, creating a 
sealed region (Ng et al, 1997). The cell membrane adjacent to the bone surface is 
deeply folded and the osteoclast can secrete various compounds across this ruffled 
border which result in bone resorption. Because the space is sealed off from the rest 
of the extracellular environment, concentrations of enzymes such as collagenase 
can become high enough to enable efficient bone resorption to occur and the 
osteoclast makes the pH of the fluid in the space optimal by secreting protons 
(Mundy, 1996).
1.1.8 Chondrocytes
Chondrocytes synthesise cartilage and are located in the growth plates at the ends 
of the long bones. Like osteoblasts, they are derived from bone marrow stromal 
stem cells (Beresford, 1989). Chondrocytes are arranged in columns in the growth 
plate and as they mature they undergo hypertrophy (Baron, 1996). Endochondral 
ossification involves chondrocytes (Section 1.1.9).
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1.1.9 Intramembranous and Endochondral Ossification
There are two ways in which bones can develop in the fetus. Flat bones such as the 
calvariae, scapulae and ilia form by intramembranous ossification while the long 
bones of the limbs form by endochondral ossification (Baron, 1996).
During intramembranous ossification, mesenchymal stem cells within the embryonic 
connective tissue proliferate and then differentiate into pre-osteoblasts and 
subsequently osteoblasts. These cells produce a bone matrix of woven bone with 
the embryonic bone marrow within it. The woven bone is gradually remodelled 
(Section 1.1.12) to form mature lamellar bone (Baron, 1996).
During endochondral ossification, the mesenchymal stem cells divide and 
differentiate into pre-chondroblasts and then chondroblasts. The chondroblasts 
synthesise cartilage which in the embryo is avascular. Across the growth plate of a 
developing long bone different zones have been identified. The zone in which the 
chondrocytes initially proliferate and synthesise the cartilage matrix is termed the 
proliferative zone. The cells hypertrophy before undergoing apoptosis in the 
hypertrophic zone. The cartilage then calcifies partially (zone of provisional 
calcification) and is partially resorbed by osteoclasts. The portion of the long bone 
which is destined to become the mid-shaft is a ring of woven bone formed by 
intramembranous ossification. As this woven bone becomes calcified, blood vessels 
which will form the bone marrow invade it and also extend into the cartilage (zone of 
invasion). Osteoblasts are now present in the growth plate and lay down woven 
bone on the sites of resorbed cartilage. This primitive trabecular bone is called the 
primary spongiosum and is later remodelled to form mature lamellar trabecular 
bone, or the secondary spongiosum (Baron, 1996).
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1.1.10 Collagen Synthesis
There are at least nineteen genetically distinct collagenous proteins (Rowe et al, 
1998). Cartilage contains mainly Type n, and basement membranes Type IV. Bone 
collagen is almost exclusively Type I, the most abundant collagen type in the body. 
It is present in many connective tissues including tendons, skin, ligaments, dentine 
and sclerae and, to a lesser extent, in blood vessels, lungs and other visceral 
supporting tissues (Rowe et al, 1998). Type I collagen is a complex molecule,
consisting of three polypeptide chains, two of a  1(1) collagen and one of a  2(1)
collagen (Monier-Faugere et al, 1998). The synthesis of collagen is illustrated in 
Figure 1.1.
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Collagen molecules laid down in bone.
5 molecules arranged in a cylinder to form 
a fibril.
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The type I collagen molecule consists of multiple glycine-X-Y repeats, where X is 
often proline or hydroxyproline. Glycine has no side chain, which is important in the 
conformation of the protein as it allows tight coiling of the polypeptide chain to form 
the a -helix.
The three coiled monomers (two a  1 and one a 2) are super-coiled together, 
creating a rope-like structure.
Type I collagen undergoes several post-translational modifications. Intra-cellularly, 
before secretion from the osteoblast, some of the proline and lysine residues are 
hydroxylated. Hydroxyproline provides conformational stability to the helix at 
physiological temperatures (Rowe et al, 1998). The three a chains of procollagen
spontaneously adopt a triple helical conformation within the cell and the helix is 
secreted from the cell. Cleavage of the amino-terminal and carboxy-terminal pro­
peptides is done by specific peptidases. These released pro-peptides have been 
utilised as serum markers of bone formation (Section 1.2.6). In the matrix of the 
bone, collagen forms fibrils consisting of five collagen molecules arranged in a 
three-dimensional cylinder with staggering of the molecules. The regular 
overlapping pattern can be seen on electron microscopy, when cross-striations are 
separated by 640 A (Rowe et al, 1998). The collagen molecules complex with non- 
collagenous proteins such as proteoglycans (Ng et al, 1997) and the covalent bond 
associated may also confer strength. However, the main reason for collagen’s 
durability are the collagen crosslinks (Section 1.1.11).
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1.1.11 Collagen Crosslink Formation
The final maturation stage of a collagen fibril is the extra-cellular formation of intra- 
and inter-molecular covalent pyridinium crosslinks, which are unique to mature 
bone (Termine et al, 1996). Multiple cross-linking sites can combine to form 
pyridinium ring structures, binding several collagen monomers together. Lysyl 
oxidase acts on the collagen lysine and hydroxylysine residues, forming 
deoxypyridinoline (Dpd) or pyridinoline (Pyd) respectively (Knott et al, 1998). These 
cross-links are non-reducible and insoluble and are only released when bone is 
resorbed. Pyd occurs mainly in collagen types I  and II, while Dpd is found mainly in 
collagen type I  (Knott et al, 1998). They thus have different tissue distributions with 
Pyd having its highest concentration in cartilage although it is also present in bone. 
Dpd has its highest concentration in bone where the ratio Pyd: Dpd is approximately 
4:1 (Knott et al, 1998). Dpd is therefore the most bone-specific resorption marker 
available at present (Robins, 1995). Dpd and Pyd are excreted in the urine where 
two-thirds are small peptides and the remainder are free amino acids. As they 
naturally fluoresce, Pyd and Dpd can be measured in urine by high pressure liquid 
chromatography (HPLC) after hydrolysis and pre-fractionation over cellulose, using 
an ion-paired reversed-phase method developed by Black (Black et al, 1988) as 
discussed in Section 2.9.1. Alternatively, the cross-links can be measured by an 
enzyme-linked immunosorbent assay (ELISA) utilising a monoclonal antibody 
assay (Robins et al, 1994) described in Section 2.9.2. Urinary excretion of cross­
links has been shown to be increased in conditions with increased collagen 
breakdown such as rheumatoid arthritis (Black et al, 1989) and Paget’s disease of 
bone (Uebelhart et al, 1990).
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1.1.12 Bone Modelling and Remodelling
During growth, the bones need to increase in size and change in shape. This is 
achieved by modelling, where resorption and formation of bone happen at different 
sites in the skeleton. This results in a redistribution of bone in response to changing 
biomechanical demands. The proliferation and differentiation of cartilage cells at the 
growth plates results in the longitudinal modelling or growth of the long bones. The 
bones increase in width by appositional modelling when bone is resorbed from the 
inner (endosteal) surface of the long bone and new bone is laid down on the outer 
(periosteal) surface (Ng et al, 1997).
After growth has ceased the bone tissue is not static as small quanta of bone are 
resorbed and replaced with new bone. In this remodelling cycle, the skeleton 
renews itself without any change in the macroscopic appearance of the bones 
(Monier-Faugere et al, 1998). Remodelling differs from the modelling which occurs 
in growth as there is coupling, or linkage, of the resorption and formation both 
anatomically and quantitatively (Canalis, 1996). The functions of bone remodelling 
are thought to be predominately mechanical in cortical, load-bearing bone and 
metabolic in trabecular bone.
The remodelling cycle consists of sequential events involving different cell types 
and is illustrated in Figure 1.2. The team of cells which undertake the remodelling of 
a quantum of bone is referred to as a bone multicellular unit (BMU).
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The first event in the remodelling cycle is activation of the bone surface with the 
arrival of mononucleated osteoclast precursors and the retraction of the bone lining 
cell layer, exposing the bone matrix. The signalling factors for activation are not fully 
understood but are thought to include both systemic hormones and locally 
produced polypeptide growth factors such as members of the transforming growth 
factor-p family (Canalis, 1996).
After the osteoclast precursors have fused into mature, multinucleated osteoclasts, 
resorption of the bone can proceed. The osteoclasts remove two-thirds of the bone 
in the resorption cavity over a period of about one week. The remaining resorption 
is carried out by mononuclear cells over a longer period of about thirty-six days.
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After resorption ceases, there is a one to two week reversal phase during which the 
reversal or cement line is laid down. Osteoblast precursors are attracted to the 
eroded surface and, after differentiation into mature osteoblasts, they lay down 
osteoid (uncalcified matrix protein) in the bone formation phase of the remodelling 
cycle. Formation is a slower process than resorption. The osteoid seam is 
mineralised, initially at a rate of 1 to 2pm per day but then more slowly. The newly- 
synthesised bone enters a phase of quiescence. During the first three to six months 
of this phase the young bone matures to contain larger hydroxyapatite crystals with 
a corresponding increase in bone mineral density. In normal adult bone 80% of the 
bone surface is in the quiescent phase at any time.
If normal skeletal metabolism is occurring, the complete remodelling cycle takes 
approximately 100 days in cortical bone and 200 days in trabecular bone (Eriksen 
et al, 1994).
Thus, in health, new bone is formed to completely replace the bone resorbed by 
osteoclasts, resulting in loss of neither bone mass nor strength. If coupling of the 
resorption and formation processes is lost, either net bone loss or gain will occur.
1.2 Osteoporosis
1.2.1 Definition
The 1993 Consensus Development Conference statement defined osteoporosis as 
‘a disease characterised by low bone mass and microarchitectural deterioration of 
bone tissue, leading to enhanced bone fragility and a consequence increase in 
fracture risk’ (Christiansen et al, 1993). Subsequently, a working group of the World 
Health Organisation proposed a classification of white women as osteopenic or
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osteoporotic on the basis of their bone mineral density (BMD) measurement 
(Section 1.2.5) (Kanis et al, 1994). The threshold BMD values are shown in Table
1.1 and are illustrated in Figure 1.3. Severe osteoporosis was defined by a BMD 
more than 2.5 standard deviations (SD) below the young adult mean in the 
presence of at least one non-traumatic (fragility) fracture.
Table 1.1 WHO criteria for osteoporosis and low bone mass
Diagnosis T score: BMD expressed in standard 
deviations (SD) relative to mean for young 
adults
normal bone mass no more than 1.0 SD below young adult mean
low bone mass 
(osteopenia)
between 1.0 and 2.5 SD below young adult mean
osteoporosis more than 2.5 SD below mean
severe osteoporosis more than 2.5 SD below mean and fragility 
fractures
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1.2.2 Epidem iology
Women have lower peak bone mass than men and have rapid bone loss related to 
the reduction in circulating oestrogen at the time of the menopause (Heaney, 1996). 
In addition, there is age-related bone loss of approximately 1 to 2% per year in both 
sexes after the age of 50 years (Wasnich, 1996). Studies have shown that 
Caucasians have lower bone mass than do Black or Asian populations (Wasnich,
1996). As a result, the group most at risk of osteoporosis are white postmenopausal 
women, and fracture rates confirm this (Center et al, 1997). However, osteoporosis 
in other groups, including men, is being increasingly recognised (Jackson, 1996).
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It has been estimated that more than 50% of postmenopausal women in the United 
States have low bone mass and another 20 to 30% fulfil the criteria for osteoporosis 
(Center et al, 1997). The prevalence of osteoporosis rises steeply with age, so that 
while less than 15% of women aged 50 to 59 have BMD measurements consistent 
with osteoporosis, this increases to 70% of women over the age of 80 years (Center 
et al, 1997). For England and Wales, Kanis has estimated that 22.5% of women and 
5.8% of men over the age of 50 have osteoporosis (Kanis et al, 1994).
Fracture rates vary with the type of fracture, the population studied and the method 
of data collection. In general, fracture rates for all types of osteoporotic fractures are 
increasing. This is due to demographic changes, with increasing numbers of people 
aged eighty years and older. Lifetime risks of fracture have been estimated and for a 
50 year old white women were 16% to 19% for a hip fracture in her remaining life, 
and approximately 5% for a man of the same age (Center et al, 1997). Prevalence 
rates for vertebral fractures are harder to determine as only about one third come to 
clinical attention, but, as for hip fracture, rates rise exponentially with age in women. 
Below the age of 50 higher prevalence rates in men than women have been found. 
It has been suggested that this is due to the more physical nature of work 
undertaken by many men (O'Neill et al, 1996).
1.2.3 Clinical Features
Low bone mass without fracture causes no symptoms and osteoporosis has been 
called the silent epidemic. The clinical consequences of osteoporosis are all related 
to the fractures which may occur. The three most common fractures are a Colles’ 
fracture of the distal forearm, hip fracture and vertebral body fracture. Apart from the 
pain of the fracture itself, considerable morbidity and even mortality may result.
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Osteoporotic bone does not take longer to heal after fracture than normal bone, but 
the surgeon may have difficulty in finding enough bone stock for successful 
instrumentation (for example, pin and plate fixing of a fractured hip) and bone grafts 
are sometimes necessary. Forearm fractures cause least problems and do not 
necessarily result in admission to hospital. However, if the person lives alone, they 
may need help with activities of daily living.
Vertebral fractures cause pain, loss of height and change in body shape; the so- 
called Dowager’s hump. If multiple vertebral fractures have occurred, the lowest ribs 
may rest on the iliac crest, resulting in abdominal protrusion which may be mistaken 
for obesity. Apart from the discomfort this causes, respiration may be impaired and 
the abdominal contents compressed. Vertebral fractures may be silent (painless) or 
simply attributed to ‘back ache’. It has been estimated that only one third come to 
medical attention (Cooper et al, 1992). In those which are recognised, the patient 
often describes a sudden severe pain over the fracture site which may radiate 
around the thorax to the midline, anteriorly. This pain is worse on taking a deep 
breath or moving, and usually settles after four to six weeks. It is important to 
consider underlying causes of vertebral fracture, such as multiple myeloma and 
metastatic disease. Only 10 to 15% of vertebral fractures occur on falling. The 
remainder are related to lifting or other loading of the spine and may seem to have 
occurred spontaneously (Cooper et al, 1992).
The most serious fragility fracture is that of the hip. These are also the most 
accurately recorded because medical attention is always sought. There is 
significant mortality associated with hip fractures. Several studies have 
demonstrated an excess mortality of between 10 and 40% over the subsequent
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year (Center et al, 1997). The majority of deaths occur in the first six months after the 
fracture, and it has been suggested that at least some of these deaths may be due 
to co-existing serious diseases which may have contributed to the fall. Estimates of 
deaths directly due to the fracture vary from 15 to 40%. Among the survivors of hip 
fracture, many have serious continuing disability and require long-term nursing 
care. Other fractures may occur in osteoporosis and fractures of the humerus, tibia 
and pelvis are not unusual.
1.2.4 Secondary Osteoporosis
Osteoporosis may be age-related, postmenopausal, or secondary to a variety of 
medical conditions and drugs. Common causes of secondary osteoporosis are 
shown in Table 1.2 and include the inflammatory joint disease rheumatoid arthritis 
(Section 1.3).
Table 1.2 Secondary causes of osteoporosis
Underlying Cause Examples
Endocrine Cushing’s syndrome, thyrotoxicosis, 
hypogonadism
Associated with inflammatory 
diseases
rheumatoid arthritis, inflammatory 
bowel disease, ankylosing 
spondylitis
Drug-related corticosteroids, heparin, 
anticonvulsants
Haematopoietic multiple myeloma, lymphoma, 
mastocytosis
Gastrointestinal disease Coeliac disease, inflammatory bowel 
disease
Hepatic disease Primary biliary cirrhosis
Non-weight-bearing Bed-bound, astronauts
Pregnancy Transient osteoporosis of pregnancy
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1.2.5 Bone Mineral Density Measurement
Osteoporosis cannot be diagnosed from plain radiographs unless a typical fracture 
is seen, but the radiologist may comment that the bones are osteopenic, with 
apparent rarefaction of the bony substance and fewer characteristic markings than 
normal. The mainstay of detection is measurement of the BMD (Kanis et al, 1994) 
which is also used to monitor treatment (Kanis et al, 1996). This is usually derived 
from a measure of bone mineral content (BMC) which can be estimated by a variety 
of techniques. BMD is the most important factor in determining bone strength and 
has been shown to be associated strongly with future fracture risk. Each standard 
deviation reduction in BMD is associated with a 1.5 to 3-fold increase in risk of 
future fracture (Melton et al, 1993) and BMD accounts for 75-85% of the variance in 
bone strength. There are several ways to measure BMD with good accuracy and 
excellent precision. Dual-energy x-ray absorptiometry (DXA) is widely used to 
measure BMD as it needs only a low radiation dose, has high reproducibility and 
can measure BMD at both axial (spine and hip) and appendicular (forearm) sites. 
Thus the sites most prone to osteoporotic fracture can be studied directly. This is 
important as Cummings showed that the best predictor of future hip fracture was the 
hip BMD (Cummings et al, 1993).
DXA measures bone mineral content (BMC, g or g/cm), which is then converted into 
an areal (two dimensional) density (BMD, g/cm2) using the size of the bone 
measured.
In assessment of the lumbar spine BMD, degenerative changes (osteophytosis) can 
falsely elevate the BMD without reducing fracture risk (Jones et al, 1996). Lateral 
lumbar spine BMD measurements which exclude the posterior vertebral elements
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are now possible but have been associated with less precision than the traditional 
antero-posterior view due to positioning difficulties (Bjarnason et al, 1996). In 
practice, lumbar spine BMD values in patients with degenerative changes of the 
lumbar vertebrae should be disregarded and treatment decisions made on the 
basis of measurements at other sites.
1.2.6 Clinical Markers of Bone Turnover
It is possible to assess the rate of bone turnover by invasive (bone biopsy) or non- 
invasive methods. Biochemical markers of bone turnover refer to the measurement 
of compounds in either serum or urine which are related to bone resorption and 
formation. Markers of bone turnover are shown in Table 1.3. As osteoporosis occurs 
in the setting of an imbalance (uncoupling) of formation and resorption, these 
markers may have clinical usefulness. Convenient specific immunoassays are 
being developed for these compounds. An advantage of markers over bone density 
measurements is that they change in response to therapy much more quickly.
For a measured change to be significant, it must be at least three times the 
coefficient of variation of the measurement. Depending on the site, typical 
coefficients of variation in BMD are 1 to 2% and there is therefore no advantage in 
repeating BMD estimation before at least a year when looking for a response to 
treatment. However, significant changes in markers of bone turnover can be seen 
within weeks, so in theory, non-responders or those with poor compliance could be 
identified early.
Markers of both formation and resorption are increased in postmenopausal women 
(Lufkin et al, 1992). A prospective study of elderly French women over two years 
found that two urinary markers of bone resorption, carboxyterminal-telopeptide and
32
free deoxypyridinoline, were predictive of hip fracture risk, independent of baseline 
BMD (Garnero et al, 1996). There has been difficulty in translating results from 
population studies to the individual patient. The hope is that a combination of 
baseline BMD measurement together with markers of bone turnover will enable 
treatment of osteoporosis to be better targeted to these at greatest risk of future 
fracture.
1.2.7 Bone Histology
Despite advances in non-invasive assessments of bone such as BMD by DXA and 
serum and urine markers of bone turnover (Section 1.2.6), bone biopsy remains the 
most informative means of assessing the effect of therapies at the tissue level 
(Monier-Faugere et al, 1998). Histological data is required in the development of 
new treatments for osteoporosis and other metabolic bone diseases. Bone biopsy 
is useful in the diagnosis of osteomalacia, especially in the elderly where there may 
be co-existing osteoporosis. In renal bone disease, bone biopsy reveals the extent 
of aluminium accumulation in patients undergoing dialysis. The techniques of bone 
biopsy and histomorphometry are described fully in Chapter 6.
33
Table 1.3 Markers of bone turnover
Tissue of 
orig in




























































































PICP Carboxy-terminal Propeptide of Type I Procollagen; PINP Amino-terminal Propeptide of 
Type I Procollagen; ICTP Carboxy-terminal Cross-linked Telopeptide of Type I Collagen; 
INTP Amino-terminal Cross-linked Telopeptide of Type I Collagen; IRMA Immunoradiometric 
assay; ELISA Enzyme-linked immunosorbent assay; RIA Radio-immuno assay; HPLC High 
Pressure Liquid Chromatography
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1.3 Rheum atoid  A rthritis
1.3.1 Introduction and Definition
Rheumatoid arthritis (RA) is the most common inflammatory joint disease in the 
Western world, with a prevalence estimated at 1 to 2% (Alarcon, 1995). The 
American College of Rheumatology 1987 revised diagnostic criteria (Arnett et al,
1988) are shown in Table 1.4. Of note is that the joint swelling must have been 
present for six weeks but rheumatoid factor does not have to be present in the 
serum. The cause of RA is unknown but the trigger is assumed to be environmental, 
possibly a virus, in a genetically-susceptible person.
Table 1.4 American Rheumatism Association revised diagnostic criteria 
for rheumatoid arthritis. 1987
Early morning stiffness lasting at least one hour___________________________
Synovial swelling of at least 3 joints observed by a physician_______________





Erosions and/or periarticular osteopenia in hand and/or wrist joints on 
radiographs__________________________________________________________
Criteria 1 to 4 must have been present for at least 6 weeks. Rheumatoid arthritis is defined b y 
four or more criteria.
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1.3.2 Clinical Features
RA is characterised by an inflammatory infiltrate in the lining of synovial joints, 
termed synovitis. The symptoms are joint swelling, pain and stiffness, and the 
joints first affected are often the small joints of the hands and feet; the metacarpo- 
phlangeal, proximal inter-phlangeal and metatarso-phlangeal joints. An 
explosive onset is not uncommon, with nearly every synovial joint affected, often 
on waking one morning. Rheumatoid disease is a systemic illness and almost 
every system can be affected. Extra-articular features include nodules, 
pericarditis, pulmonary fibrosis and vasculitis. The result of the joint inflammation 
is usually erosive damage as shown in Figure 1.4, a Larsen standard film.
1.3.3 Therapy of Rheumatoid Arthritis
Prior to referral to a rheumatologist, most patients will have been treated by their 
general practitioner with analgesics and non-steroidal anti-inflammatory drugs 
(NSAIDs). In the past, the introduction of a drug such as intra-muscular gold was 
delayed until there were definite signs of joint damage (marginal erosions) on 
radiographs. Over the last twenty years, however, with the publication of double­
blind, randomised, placebo-controlled trials of such “second-line” agents, 
confirming that they can delay the progression of RA (Felson et al, 1990), there 
has been a trend to start the drugs as soon as the diagnosis is made. The 
terminology has changed so that the drugs are now referred to as disease- 
modifying anti-rheumatic drugs (DMARDs) or disease-controlling anti-rheumatic 
drugs (DCARTs). Table 1.5 lists the DMARDs in clinical use in Britain today. 
Increasingly, combinations of different DMARDs are being used to try and 
achieve better suppression of the inflammatory process (Tugwell et al, 1995; 
O'Dell etal, 1996).
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Figure 1.4 Rheumatoid erosions in a wrist joint
Standard reference films for Larsen score of radiographic damage in rheumatoid arthritis 
(Larsen, 1997)
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1.3.4 The Concept of Disease Activity in Rheumatoid Arthritis
Rheumatoid arthritis is said to be active when synovitis or extra-articular features 
are present, necessitating a change in treatment with the aim of suppressing the 
disease process. This change could be the introduction of a DMARD in a previously 
untreated patient, an increase in the dose of their current DMARD or a change to a 
different DMARD if the maximum dose of the drug has not given sufficient benefit. In. 
combination therapy the new DMARD is added to the current regime, with 
continuation of the other drug.
In the clinic, the rheumatologist considers many pieces of evidence before deciding 
to change a patient’s treatment. The patient may request a change in treatment if 
they have symptoms of joint pain, swelling and stiffness leading to difficulties in 
everyday activities including work. The rheumatologist may decide after examining 
the joints that the level of synovitis detectable clinically merits a change in treatment, 
even if the patient is uncomplaining.
Laboratory investigations may suggest that the disease is inadequately treated. 
Blood tests confirm an inflammatory response when the liver produces excess of
38
certain proteins such as C-reactive protein (CRP). The additional proteins present in 
the plasma result in increased plasma viscosity (PV) and higher erythrocyte 
sedimentation rate (ESR). The CRP, PV and ESR are all used in clinical practice to 
inform treatment decisions. In addition, the patient with inflammation due to any 
cause may have an anaemia of chronic disease, with low haemoglobin (Hb) and an 
elevated platelet count. The anaemia improves or resolves with adequate 
suppression of the inflammatory process.
The importance of identifying and treating active rheumatoid disease is two-fold. In 
the first place, suppressing inflammation will lead to improvement in the patient’s 
symptoms and joint function in the short-term. Perhaps more importantly synovitis is 
associated with joint erosion and damage. The long-term outcome of the disease 
(Section 1.3.7) may be improved by adequate treatment of synovitis in the early 
stages (Emery et al, 1995). Annual radiographs of the hands and feet are used to 
monitor the development of erosions in the affected joints. Joint erosions are strictly 
an outcome measure (Section 1.3.7) but disease progression demonstrated by 
such radiographic changes may be another reason to change medication.
1.3.5 Assessment of Disease Activity in Rheumatoid Arthritis
Rheumatoid disease activity may be assessed in the clinic in many different ways, 
according to physician preference and local practice. In the research setting, it is 
desirable for investigators to use the same parameters to assess disease activity so 
that results from different studies may be compared.
The European League Against Rheumatism (EULAR) has developed a core set of 
measurements of disease activity recommended for use in trials of early RA patients
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(van Gestel etal, 1996). The suggested measurements are listed in Table 1.6 
and include patient-based, physician-based and laboratory assessments.
Table 1.6 EULAR core data set recommended for assessing disease 
activity In rheumatoid arthritis
Number of swollen joints Richie or 28 joint count
Number of tender joints Richie or 28 joint count
Joint pain on a 10cm visual analogue scale
Patient’s global assessment of 
disease activity
on a 10cm visual analogue scale
Assessor’s global assessment of 
disease activity
on 5 point scale
Acute phase response ESR or C-reactive protein
Functional assessment HAQ
Radiological assessment Larsen score of hands and feet
Although not all of the subjects in this study had early RA, it was decided to use 
the EULAR core data set with a 28-joint count (Fuchs et al, 1989) so that all 
subjects had the same measurements made at each visit. This maximised data 
collection efficiency and made analysis between the different groups easier. 
From the measurements of disease activity a modified disease activity score 
(Section 1.3.6) was derived for each patient encounter.
1.3.6 Modified Disease Activity Score
The different measures of disease activity, such as tender joint count or ESR, 
can be studied separately or can be combined into composite scores. A disease 
activity score (DAS) has been developed by the investigators who developed 
the EULAR core data set (van Gestel et al, 1996). A modified version of
40
the score is used if the joint count is of 28 joints (Prevoo et al, 1995) rather than all 
synovial joints.
The modified DAS is given by the formula:
DAS = 0.555V(TJC) + 0.284V(SJC) + 0.7ln(ESR) + 0.0142(VAS PG), 
where TJC is the tender joint count (28 joints), SJC is the swollen joint count (28 
joints), In is the natural logarithm, ESR is the erythrocyte sedimentation rate and 
VAS PG is the patient global activity score marked on a 100mm visual analogue 
scale (VAS) (van Gestel et al, 1996).
The DAS has been validated in 227 patients with RA of duration less than one year 
(van Gestel et al, 1996) and such patients can be divided into those with low 
disease activity (DAS < 2.4), moderate disease activity (DAS > 2.4 to < 3.7) and
high disease activity (DAS >3.7). Response criteria based on the DAS have been 
developed and validated and are shown in Table 1.7 (van Riel et al, 1996). The 
classification of the improvement in DAS depends on the DAS at baseline. A 
subject with a high baseline DAS of more than 3.7 needs to have a reduction in 
DAS of more than 1.2 units for it to be classed as a moderate response. This 
change in someone with low DAS of less than 2.4 at baseline would be termed a 
good response. The precision of the DAS is 0.6 so a change of more than 0.6 units 
is unlikely to have occurred by chance (Stucki, 1996).
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Table 1.7 Response criteria based on the EULAR disease activity score




> 1.2 from 
baseline DAS
Improvement of 




< 0.6 from 
baseline DAS
DAS < 2.4 Good response Moderate response No response
2.4 < DAS < 3.7 Moderate response Moderate response No response
DAS > 3.7 Moderate response No response No response
1.3.7 Outcome Measurements in Rheumatoid Arthritis
The Health Assessment Questionnaire (HAQ) was developed by Fries (Fries et al, 
1980) to evaluate the long-term outcome of RA patients. Kirwan modified the 
questions relating to disability for use in British patients (Kirwan et al, 1986). The 
modified HAQ consists of three questions for each of eight types of activities of daily 
living, such as dressing, washing, reaching and getting out of bed or a chair. The 
respondent indicates for each question whether they can do the relevant activity 
with no difficulty (score 0), some difficulty (score 1), a lot of difficulty (score 2), or find 
it impossible to do (score 3). If aids such as adapted taps or jar opener are usually 
used, or if help from another person is required, this raised the score for the item to 
2, but no higher. The score is added up and can be a maximum of 24 as the highest 
score for each of the eight stem questions was taken. This is then divided by eight, 
giving a score of 0 to 3, with 0 indicating no impairment.
1.3.8 Bone Loss Related to Rheumatoid Arthritis
RA is associated with three sorts of bone disease: erosions, juxta-articular 
osteopenia, and generalised axial and appendicular osteoporosis (Goldring, 1996).
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The bone close to a joint with active RA demonstrates increased bone turnover and 
blood flow, and rapid trabecular bone loss from the distal radius has been shown in 
early RA (Sambrook et al, 1990). Erosions and juxta-articular osteopenia are 
included in the diagnostic criteria for RA (Arnett et al, 1988), but the generalised 
bone loss associated with the disease has only recently been recognised. The site 
most often reported to have reduced BMD in RA is the hip.
In a controlled, cross-sectional study, Shenstone et al found significantly reduced 
femoral neck BMD in premenopausal women with RA of less than five years 
duration (Shenstone et al, 1994). Another cross-sectional study of postmenopausal 
women found reduced hip BMD compared with controls (Hall et al, 1993). The 
reduction was greater and also present at the spine if their therapy included 
corticosteroids. A Dutch study found the mean ESR over the six months prior to 
BMD measurement was negatively associated with hip BMD (Laan et al, 1993). A 
twin study of British and Australian twins where at least one had RA found that the 
BMD was reduced at most skeletal sites in the twin with RA (Sambrook et al, 1995). 
The greatest difference was again at the femoral neck where the mean reduction 
was 9.7%. Gough followed 148 patients with early RA over two years and compared 
them with 730 normal controls (Gough et al, 1994). Some were treated with 
corticosteroids which may have contributed to the observed bone mass losses of up 
to 10%. For subjects with active RA despite treatment (CRP greater than 20 mg/dl), 
the greatest loss in BMD over either one or two years was at the hip, with losses 
double those seen at the spine. In a group of 120 postmenopausal women with RA, 
bone mass measured at the hip and distal forearm was significantly reduced at both 
sites compared to age-matched controls (Lane et al, 1995). Although the reduction
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was greatest in the subgroup who were current users of corticosteroids, it was also 
significant in those who had never used steroids.
It has been suggested that the measurement of hand bone mineral content may be 
useful in early RA as it correlates with disease activity and BMD at other sites (Peel 
et al, 1994b). Deodhar et al found that hand bone mineral content (BMC) was 
inversely correlated in female RA patients with age, disease duration, and two 
radiological assessments of damage (Larsen’s and modified Sharp’s) (Deodhar et 
al, 1994). In this cross-sectional study, disease activity or functional status was not 
correlated with BMC. However, a longitudinal study by the same group, with repeat 
hand BMC estimation after one year in eighty-one patients, found that the rate of 
loss of BMC correlated with baseline disease activity as assessed by C-reactive 
protein levels (Deodhar et al, 1995).
The biochemical assessment of bone turnover in RA patients may be affected by the 
disease process. The ratio of pyridinium collagen cross-links (Section 1.1.10) in 
synovial tissue is 10:1 (Pyd: Dpd) compared with approximately 50:1 in articular 
cartilage and 4:1 in bone (Pearce et al, 1995). In active RA with proliferation of 
synovial tissue, bone resorption could be over-estimated if Pyd alone or the ratio 
were measured. The deoxypyridinoline (Dpd) cross-link is more specific for bone, 





Methotrexate (MTX) is the anti-metabolite drug, 4-amino-N10-methylpteroyl-L- 
glutamic acid, whose structure is close to that of tetrahydrofolate as shown in Figure
1.6 (Jolivet et al, 1983). It is a weak bicarboxylic organic acid with a molecular 
weight of 454, is negatively charged at neutral pH and has limited lipid solubility. 
The main action of MTX is the competitive inhibition of dihydrofolate reductase 
(DHR) shown in Figure 1.7. This enzyme reduces dietary folate (which is 
metabolically inactive) first to dihydrofolate and then tetrahydrofolate which is 
essential in the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA). MTX can thus effectively halt protein synthesis if given in high doses (Jolivet 
et al, 1983) and this action is utilised in chemotherapy. MTX also inhibits other 
enzymes such as thymidylate synthetase, glycinamide ribotide transformylase and 
5-aminoimidazole-4-carboxamide ribotide transformylase, all of which affect protein 
synthesis (Jolivet et al, 1983). In addition, MTX has anti-inflammatory and cytokine- 
modulating effects described in Section 1.4.5 below. MTX enters cells through the 
active transport system used by folate and leucovorin (folinic acid) and is converted 
to polyglutamated forms by the enzyme folyl-y-polyglutamate synthase. The MTX
polyglutamates are retained intracellularly for a long time and are probably even 
more active than the parent compound (Chabner et al, 1985). The importance of 
polyglutamation was demonstrated in studies of a human breast cancer cell line 
when reduced polyglutamation was associated with resistance to MTX (Jolivet et al, 
1983).
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Figure 1.5 The structure of tetrahydrofolate and m ethotrexate
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Figure 1.6 Main actions of m ethotrexate
Cell membrane
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MTX denotes methotrexate, DHFR dihydrofolate reductase, TS thymidylate synthetase, 
FH4 tetrahydrofolate, FH2 dihydrofolate, Glu glutamyl, dTMP thymidylate, and dUMP 
dioxyuridylate. Broken lines indicate enzyme inhibition.
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1.4.2 Indications for Methotrexate
MTX at the high dose of 100 to 1000mg/m2 body surface area per cycle with 
leucovorin rescue is used in combination with other anti-neoplastic drugs to treat 
many solid and haematological malignancies (Jolivet et al, 1983). Tumours 
sensitive to MTX include breast and ovarian carcinomas, acute lymphocytic and 
non-lymphocytic leukaemias and osteosarcoma.
At the lower dose of 2.5 to 25mg per week, MTX is used to treat a variety of chronic 
conditions (Weinblatt, 1995) including rheumatoid arthritis (Section 1.4.3). MTX has 
also been used as a steroid-sparing agent in polymyalgia rheumatica and giant cell 
arteritis (Krall et al, 1989), severe asthma (Yntema et al, 1993) and Crohn’s disease 
(Weinblatt, 1995). It has been used since the 1960’s as a disease-modifying 
treatment in psoriasis (Tung et al, 1990) and improves both the skin and joint 
symptoms. However, radiological damage may progress despite this (Abu-Shakra 
et al, 1995).
The teratogenic effects of MTX have led to its use, in conjunction with the 
prostaglandin E1 analogue misoprostol, as an abortifacient (Hausknecht, 1995).
1.4.3 Low Dose Methotrexate in Rheumatoid Arthritis
The first report of the use of MTX in RA was in 1951 by Gubner and colleagues 
(Gubner et al, 1951). They gave daily MTX in a dose of 1 to 2mg to seven cases of 
inflammatory arthritis. Of these, six probably had RA and one had psoriatic arthritis. 
There was a definite improvement in symptoms after only two to six days but side 
effects limited therapy. Most subjects had an increase in inflammatory joint 
symptoms on stopping MTX.
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The first placebo-controlled trials of MTX in RA were published in 1985 (Williams et 
al, 1985; Weinblatt et al, 1985). Williams found a significant improvement in clinical 
variables in the MTX group compared to placebo after eighteen weeks of therapy, 
but one third of the MTX treated patients withdrew from the trial because of side- 
effects (Williams et al, 1985). Weinblatt used a double-blind, placebo-controlled, 
cross-over design and found significant differences in joint counts, morning stiffness 
and disease activity assessment according to the physician at the end of the twelve 
weeks treatment in the group which had received MTX (Weinblatt et al, 1985). 
Similar improvements were seen in the group originally treated with placebo, after 
cross-over.
A double-blind, randomised trial of twenty-six weeks’ treatment with either intra­
muscular gold sodium thiomalate or MTX (either oral or intra-muscular) 
demonstrated a useful clinical improvement in both groups, with no statistically 
significant difference between the drugs (Morassut et al, 1989). However, the 
numbers studied were small with only fifteen out of the eighteen patients 
randomised to MTX, and twelve out of the seventeen randomised to gold 
completing the trial. A larger study comparing intramuscular MTX with intramuscular 
gold (IMG) had a total of 126 subjects completing one year of follow-up, seventy- 
three on MTX and fifty-three on IMG, with greater than 50% mean improvement in 
clinical variables with no significant differences between groups (Rau et al, 1997). 
There were more adverse drug effects in the IMG group (83.9%) than in the MTX 
group (66.7%), but most were mild. A total of thirty-eight subjects withdrew because 
of side effects, six in the MTX and thirty-two in the IMG group. However, more 
subjects on IMG achieved remission, 25% compared with 14% in the MTX group.
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Double-blind trials of MTX against azathioprine have failed to show a significant 
difference in effectiveness between the two agents (Hamdy et al, 1987; Willkens 
et al, 1992). However, a meta-analysis published in 1992 of radiographic 
progression in DMARD-treated RA found that MTX was superior to azathioprine 
and equally effective as gold salts in reducing disease progression as assessed 
by new erosions (Alarcdn et al, 1992). Further evidence that MTX may be 
classified as a DMARD came from a study by Rau who prospectively evaluated 
the radiographs of twenty-four RA patients commencing MTX (Rau et al, 1991). 
All the subjects had failed intramuscular gold treatment previously and had 
radiographs of hands and feet taken every one or two years. The follow-up 
period varied from one to five years. There was a significant reduction in the 
percentage of joints developing erosions in the patients once they had been 
started on MTX compared to when they were on gold. However, there have also 
been studies which found MTX to have no effect on radiographic progression 
(Bologna et al, 1997), leading some commentators to suggest the beneficial 
effect on symptoms is due solely to its anti-inflammatory actions (Section 1.4.5).
There have been open observational studies of MTX therapy in RA published 
with follow-up for up to seven years (Weinblatt et al, 1988; Fehlauer et al, 1989; 
Weinblatt et al, 1994; Kremer et al, 1992; Weinblatt et al, 1992; Bologna et al, 
1997). Drug survival rates have been estimated as 50% at five years (Alarcon et 
al, 1989), and 46% at seven years (Weinblatt et al, 1992), although this included 
all dropouts, including administrative ones. Some authors have reported more 
than 70% of subjects remaining on MTX after a five year retrospective study 
(Bologna et al, 1997) or a prospective study for a mean of seven
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and a half years (Kremer et al, 1992). As the experience of prescribing MTX 
increased, the main reason for discontinuation was adverse events (60%), rather 
than lack of efficacy (7.7%) (Alarcon et al, 1989). Many adverse events are minor 
and do not require cessation of MTX, but some are potentially life-threatening 
(Section 1.4.6).
Low dose, weekly MTX is now the DMARD most likely to be prescribed first for RA in 
the United States (Weinblatt, 1996). In the United Kingdom, MTX vies with 
sulphasalazine (SPZ) as the first-line DMARD of choice in RA as it is better 
tolerated, has a longer drug survival and faster onset of action, but does need 
careful monitoring (Anonymous, 1995). Recently, MTX has been used in 
combination with other DMARDs with reportedly superior disease suppression and 
no increase in side effects (O'Dell et al, 1996; Tugwell et al, 1995).
1.4.4 Pharmacology of Low-Dose, Pulse Oral Methotrexate
When MTX is taken in low-dose by mouth, the resulting serum levels of the drug 
vary greatly from subject to subject. One study comparing the bioavailability of intra­
muscular or sub-cutaneous routes with the oral route, found a range of 0.54 to 0.99 
(mean 0.85) of the parental dose (Jundt et al, 1993). Peak serum levels after oral 
tablet treatment occurred at approximately three hours post dose (0.06 ± 0.02 
pmol/l) and MTX was undetectable (<0.01pmol/l) between sixteen and twenty-four 
hours post-dose (Jundt et al, 1993). In contrast, Sinnett et al could still detect MTX in 
the serum at twenty-four hours in all ten RA patients they studied despite having a 
less sensitive detection system (minimum 0.03pmol/l) (Sinnett et al, 1989). They 
also found rapid absorption after a single oral dose, with peak serum concentrations 
at one and a quarter hours. MTX elimination (either by renal excretion of the
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unmetabolised drug, or by cellular uptake) was consistent between subjects, with a 
mean serum half life of nearly five hours (Sinnett et al, 1989). Differing 
bioavailability is probably due to factors such as age, renal and hepatic function, 
and gastrointestinal features such as differing ability of gastrointestinal flora to 
metabolise MTX (Jundt et al, 1993). Food has not been shown to affect absorption 
or bioavailability (Oguey et al, 1992).
A study of tissue levels of the drug following intra-venous MTX in RA patients found 
that at twenty-four hours after administration, synovial fluid levels were greater than 
serum, but levels were undetectable in both compartments by seventy-two hours 
(Tishler et al, 1989). Bologna and colleagues assayed the concentrations of MTX in 
the synovial membrane, and in cortical and trabecular bone of ten RA patients 
treated with the drug for a mean of twenty-six months (Bologna et al, 1994). They 
were able to do this as the patients came to surgery; five were having wrist 
synovectomy, two each having shoulder and knee arthroplasty and one having a 
hip arthroplasty. The day prior to surgery, each patient had an intra-muscular 
injection of 10mg MTX. They were found to have similar high mean levels of MTX in 
the synovial membrane (0.285 nmoles/g) and in both trabecular (0.292 nmoles/g) 
and cortical (0.286 nmoles/g) bone whilst the plasma concentration was ten-fold 
less (0.0252 nmoles/ml).
1.4.5 Actions of Methotrexate in Rheumatoid Arthritis
MTX has been shown to have multiple anti-inflammatory and cytokine modulating 
effects at low dose and they are summarised in the text below and in Table 1.8. The 
precise action of MTX, as for all DMARDs, remains unclear, but some authors have 
proposed it is primarily an anti-inflammatory agent, rather than an
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immunosuppressive, at the doses used in RA (Bologna et al, 1997; Furst, 1997; 
Klippel et al, 1985).
In the clinic, MTX reduces symptoms in the RA patient much more rapidly than do 
other DMARDs, in keeping with an anti-inflammatory effect. Within one week of an 
intra-venous injection of MTX in eighteen RA patients, there was a significant fall in 
two markers of the acute phase response, the erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP) (Segal et al, 1989a). Cronstein and colleagues used a 
murine model to study the effect of MTX on inflammation (Cronstein et al, 1993). 
They found that, through the intracellular accumulation of 5-aminoimidazole-4- 
carboxamide ribonucleotide (AICAR), MTX could increase adenosine release and 
inhibit leukocyte accumulation at sites of cell injury. Previously, an Australian group 
had shown a specific inhibition of polymorphonuclear chemotaxis in vitro when RA 
patients had received MTX (O'Callaghan et al, 1988). Other in vitro studies have 
concentrated on the metabolism of arachidonic acid because many pro- 
inflammatory molecules are generated from this precursor. Both acute (twenty-four 
hours after the first ever dose of MTX) and chronic (after six to eight weeks of 
treatment) suppression of leukotriene-B4 synthesis by neutrophils from RA patients 
was found (Sperling et al, 1992), suggesting reduced activity of the 5- 
liopoxygenase enzyme. Further evidence of an anti-inflammatory effect comes from 
studies of polymorphonuclear leukocytes from patients with RA who are treated with 
MTX, which have reduced production of superoxide anions (Laurindo et al, 1995). 
Also, in a rat model, MTX reduced adherence of leukocytes in mesenteric venules 
(Asako et al, 1993).
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Many of the cytokines which are deranged in RA have been studied with regard to 
MTX. MTX has inhibitory actions on IgM-rheumatoid factor synthesis (Olsen et al,
1987), macrophage activation (Johnson et al, 1988; Hu et al, 1988), actions of 
interleukin-1 (IL-1) (Segal et al, 1989b) and production of interleukin-1p (IL-1 (3) by
peripheral blood mononuclear cells (Barrera et al, 1994) and by synovial fluid 
mononuclear cells (Thomas et a!, 1993). The production of interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-1-receptor-antagonist (IL-1Ra), tumour necrosis 
factor-a (TNFa) and soluble tumour necrosis factor receptor (sTNFR) have all been
shown to be affected by MTX (Kremer, 1994). Soluble interleukin-2 receptor (sIL- 
2R) and p55 levels are reduced by MTX in RA (Barrera et al, 1993). MTX therapy 
increases the expression of the anti-inflammatory cytokines interleukin-4 (IL-4) and 
interleukin-10 (IL-10) and decreases the expression of the pro-inflammatory 
cytokines interleukin-2 (IL-2) and interferon-y (IFNy) (Constantin et al, 1998).
It has been suggested that the pre-treatment ratio of serum IL-1Ra to interleukin-1 p
(IL-1 P) predicts the clinical response to MTX (Seitz et al, 1995). However, serum IL-
2R levels did not predict a response to treatment with MTX in refractory RA 
(Polisson et al, 1994). A study following subjects for thirty-six months after starting 
MTX measured interleukin-2 (IL-2), IL-6, TNF-a and IL-1Ra serially (Straub et al,
1997). The best predictor for the outcome at three years was baseline IL-6. 
Specifically, a decrease in IL-6 during the first six months of treatment with either 
intramuscular MTX or intramuscular gold was predictive of a good outcome (Straub 
etal, 1997).
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Table 1.8 Actions of methotrexate in rheumatoid arthritis







Reduced CRP and ESR
Neutrophils Inhibition of chemotaxis
Inhibition of neutrophil 
adherence due to 
increased adenosine 
release secondary to 
intracellular 
accumulation of AICAR
Suppression of LT-B4 
synthesis












Cytokine effects Macrophages Inhibition of activation
Pro-inflammatory
cytokines
Inhibition of IL-1 
production from 
macrophages
Inhibition of IL-1 activity
Inhibition of synthesis of 
IL-2, IFN-y, TNF-oc, 
sTNF-aR and SIL-2R
Inhibition of IL-6, IL-8
Anti-inflammatory
cytokines







1.4.6 Side Effects of Methotrexate
Table 1.9 shows the main adverse effects associated with low dose, weekly MTX 
therapy (Furst, 1997). The most common reason for discontinuation of MTX is 
toxicity rather than lack of effect (Weinblatt et al, 1994) and the gastrointestinal 
system is most often adversely affected, with mouth ulcers, nausea and vomiting 
(Weinblatt, 1996). Mouth ulcers occurred in up to 30% of patients in one survey 
(Anonymous, 1995), but can often be avoided or alleviated by the concurrent 
administration of low dose folic acid (Section 1.4.7).
Bone marrow suppression with pancytopenia can be an idiosyncratic reaction and 
may occur at any time during treatment so regular full blood count monitoring every 
four to six weeks is mandatory (Gutierrez-Ureha et al, 1996). More often though, a 
predisposing cause for the pancytopenia exists such as untreated folate deficiency, 
hypoalbuminaemia, impaired renal function, concurrent infection, or treatment with 
either probencid, which impairs the renal excretion of MTX, or the anti-folate 
antibiotics trimethoprim or sulphamethoxazole (Weinblatt, 1996; Steuer et al, 1998). 
Impaired renal function has been shown to increase the risk of serious side effects 
by approximately four times (Rheumatoid arthritis clinical trial archive group, 1995). 
Long-term MTX therapy is associated with hepatic fibrosis and cirrhosis when used 
in psoriasis patients, but the risk of hepatotoxicity appears less in RA (Schnabel et 
al, 1994). Up to 70% of RA patients may develop elevated transaminases during 
five years of MTX therapy (Scully et al, 1991) but these are not reflected by 
abnormalities on liver biopsy and the blood tests usually return to within normal 
levels if the MTX is withdrawn for a few weeks. It has been suggested that the
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changes seen on liver biopsy are due to the rheumatoid process rather than MTX 
(Rau et al, 1989).
Pulmonary toxicity in the form of acute interstitial pneumonitis is a rare but 
potentially fatal complication of treatment with MTX. In one series, the fatality rate 
was 17.2% (Kremer et al, 1997). Lung function tests do not enable identification 
prior to the clinical symptoms of pneumonitis (unproductive cough and dyspnoea) 
and many asymptomatic RA patients have slightly abnormal pulmonary function 
tests (Cottin et al, 1996). As pre-existing lung disease may be a predisposing factor 
for the development of this side effect, some authors have recommended that a 
chest radiograph be taken prior to commencing treatment, which may also be useful 
for comparison if symptoms develop (Kremer et al, 1997).
MTX is teratogenic (Bermas et al, 1995) and should not be prescribed to 
premenopausal women unless adequate contraception is practised. In both sexes 
impaired fertility has been reported and, in women, menstrual dysfunction and 
amennorrhoea may occur (Anonymous, 1994).
Concern that MTX may increase the risk of post-operative infections and delay 
wound healing leads approximately 20% of British orthopaedic surgeons to stop 
MTX for two weeks before and two weeks after an arthroplasty (Steuer et al, 1997), 
although the manufacturers (Lederle, UK) do not recommend this.
Although MTX is thought to have low oncogenic potential, there are case reports of 
Epstein-Barr associated non-Hodgkin’s lymphoma developing in MTX-treated RA 
patients (Bachman et al, 1996). The malignancies resolved completely on stopping 
the MTX and no chemotherapy was necessary.
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Opportunistic infections such as Herpes zoster encephalomyelitis (Lyon et al, 1997) 
and Pneumocystis carinii pneumonia (Wallis et al, 1989) have been reported in 
patients on low dose MTX for RA or psoriatic arthritis.
Other unwanted effects secondary to MTX treatment include hair loss, accelerated 
nodulosis, cardiac nodules, photosensitivity and dermatitis (Anonymous, 1995; 
Scully et al, 1991).
Table 1.9 Adverse effects associated with methotrexate
System involved Adverse effect % affected







Haem atological Anaemia 1-2
Leucopenia 2-21
Thrombocytopenia 1-5





Osteopathy Bone pain, fracture Case reports only
Pulmonary Pneumonitis 1-7
Pseudolymphoma Case reports only
Teratogenicity Definite
1.4.7 Use of Folic Acid and Folinic Acid in Methotrexate Therapy
Following high dose MTX as a chemotherapeutic treatment, folinic acid (leucovorin) 
rescue must be given within forty-eight hours to prevent necrosis of the bone
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marrow and gut epithelium (Rosen et al, 1974). If this is not done, severe toxic 
reactions occur with cytopenia and diarrhoea.
Both folic acid (1 to 27.5mg per week) and folinic acid (a synthetic tetrahydrofolate, 
1 to 20mg per week) have been used to try and reduce the incidence of side effects 
from low-dose MTX (Anonymous, 1995).
A systematic review was published in 1997 of the seven double-blind, controlled 
trials of folate or folinic acid supplementation in RA patients treated with low dose 
MTX (20mg per week or less) (Ortiz et al, 1998). It showed that folic acid (either low 
or high dose) reduced mucosal and gastrointestinal side effects by 79% which was 
statistically significant, but folinic acid only reduced such side effects by 42% (not 
significant). At higher doses, folinic acid was associated with higher tender and 
swollen joint counts, suggesting antagonism of the treatment effect of MTX. This was 
not seen with folic acid. It was concluded that low dose folic acid (5mg per week) 
was the most effective and cheapest way to reduce gastrointestinal side effects from 
MTX.
1.4.8 Evidence that High Dose Methotrexate Causes Osteoporosis
MTX osteopathy has been described in children receiving high dose MTX as 
chemotherapy for haematological malignancies and osteosarcomas. The syndrome 
of bone pain, radiographic osteopenia and fractures has been reported in both short 
term (Ecklund et al, 1997) and long term use up to five years (Schwartz et al, 1984). 
A recent retrospective survey found that 9% of children receiving high dose MTX 
(12g/m2 for an average of nine cycles) as therapy for osteosarcoma had developed 
radiographic changes consistent with osteopathy (Ecklund et al, 1997).
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1.4.9 Animal Studies of the Effect of Methotrexate on Bone
The effects of MTX are different depending on whether high or low dose MTX is 
used and whether or not the animals have experimental arthritis.
In a rat heterotopic bone model using high doses, the timing of the dose of MTX 
affected the result (Nilsson et al, 1987). Thus, if MTX was administered at the same 
time as the heterotopic bone (from another animal) was implanted, new bone 
formation in the implant was reduced by 40%. When MTX was given ten days after 
implantation, it had less effect as heterotopic bone formation was reduced by only 
22%. However, if the MTX was given ten days before the bone was transplanted, it 
was associated with increased bone formation of 33% (Nilsson et al, 1987). In a 
subsequent paper, the same group reported the findings from studies of MTX and 
another chemotherapeutic drug, adriamycin (ADR), on the formation of both 
heterotopic and orthotopic (native) bone in rats (Nilsson et al, 1990). MTX and ADR 
are often used in combination to treat bone malignancies. Both drugs inhibited new 
(heterotopic) bone formation but had relatively little effect on orthotopic bone. The 
drugs did not seem to affect bone turnover as much as new bone formation. Unlike 
ADR, MTX inhibited the overall growth of these young rats.
May and co-workers administered low-dose MTX (corresponding to doses used in 
RA in humans) to rats over a sixteen week period (May et al, 1994). 
Histomorphometry of the long bones demonstrated suppressed osteoblast activity 
and increased osteoclastic recruitment in the treated animals compared with 
controls.
In a study of the short and long-term effects of MTX on the rat skeleton, Wheeler 
and colleagues gave MTX daily for five days on two occasions and then harvested
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the bones after 30, 80 or 170 days (Wheeler et al, 1995). They performed 
histomorphometric and biomechanical studies and found the MTX-treated groups 
had significantly lower trabecular bone volume at the 80 and 170 day time points. 
The mineral appositional rate was only reduced at 170 days but the trabecular 
mineralising surface and longitudinal bone growth was significantly depressed in all 
three MTX-treated groups. In contrast to the suppressed bone formation indices, 
bone resorption was enhanced as trabecular osteoclast surface was increased at 
all time points compared with controls. The cortical cross-sectional area and 
periosteal mineral appositional rate were lower in the femur and the tibia at all time 
points but the periosteal mineralising surface was lower in the MTX treated group 
only in the femur. MTX had minimal effects on the biomechanical properties of the 
bones studied. In summary, in normal rat bone, MTX decreased bone volume, bone 
formation and osteoblast activity and increased osteoclast activity and these effects 
were still detectable long after the treatment period (Wheeler et al, 1995).
In a study of rats with adjuvant-induced arthritis, low-dose MTX maintained bone 
mass and prevented the bone loss seen in untreated arthritic animals (Segawa et 
al, 1997). This suggested that the suppression of the arthritis by MTX was more 
important than any adverse effect of the drug on bone formation or turnover.
1.4.10 In Vitro Studies of the Effect of Methotrexate on Bone
A group from Utrecht have studied the effect of MTX in cultures of human 
osteoblasts (Scheven et al, 1995) and articular cartilage (van der Veen et al, 1996). 
They found that MTX inhibited proliferation of human trabecular-derived osteoblast­
like cells in a dose-dependent fashion over the range 1 to 100nM, with little 
additional suppression occurring above this dose (Scheven et al, 1995). The
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addition of 1,25(OH)2 Vitamin D3 caused further suppression of proliferation but 
enabled differentiation to a mature osteoblast-like phenotype, with associated 
alkaline phosphatase and osteocalcin expression. In a second paper MTX had no 
effect on proteoglycan synthesis in cultures of human articular cartilage (van der 
Veen et al, 1996). As before, MTX inhibited proliferation of osteoblasts but did not 
affect either the number of cells expressing alkaline phosphatase nor the activity of 
this enzyme.
May and colleagues studied the effect of MTX on mouse bone cells in vitro (May et 
al, 1996). Neonatal mouse calvariae-derived bone cells were cultured with either 
10% (for osteoblast-like cells) or 2% (for osteoclast-like cells) fetal calf serum. MTX 
at a range of doses from 0.5nM to 600nM was added after one week in culture. No 
effect on osteoblast or osteoclast cell number was observed, but MTX did cause a 
reduction in the level of osteocalcin in the supernatant and in the calcification of the 
matrix produced by the cells. This suggested, in contrast to the human studies of 
Scheven et al described above, that in the mouse, MTX affected cell differentiation 
rather than proliferation.
In a study comparing the two anti-rheumatic drugs MTX and sulphasalazine (SPZ), 
a dose-dependent toxic effect of MTX on the rat osteosarcoma cell line UMR 106 at 
doses greater than 10nM after only twenty-four hours was found (Preston et al, 
1997). These concentrations are similar to those found in the serum of RA patients 
during the first twenty-four hours after taking their weekly dose (Section 1.4.4). MTX 
did not inhibit proliferation or viability of human umbilical endothelial cells and only 
caused reduced viability to 34% after four days in culture of peripheral blood 
mononuclear cells. The bone cell line thus seemed more sensitive than the other
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cell lines tested to the toxic effects of MTX. Interestingly, SPZ at a dose of 100pg/ml 
inhibited UMR 106 proliferation significantly after forty-eight hours or longer in 
culture. SPZ is not thought to have any affect on bone in humans, although this has 
not been studied.
1.4.11 Reports of the Effect of Low Dose, Weekly Methotrexate on 
Bone in Humans
The first case report of osteoporosis associated with low dose MTX use was in 1993 
when Preston reported two patients (one with psoriatic arthritis and one with RA), 
each of whom had stress fractures of tibia after five and six years respectively of 
MTX therapy (Preston et al, 1993). Neither had ever taken oral corticosteroids. Bone 
biopsies were performed which excluded osteomalacia but showed reduced 
osteoid surfaces and osteoid thickness and a low bone formation rate.
A further case report in 1995 was of a 75 year old man with a fifteen year history of 
RA who had been taking MTX 7.5mg/day for five years (Schapira et al, 1995). He 
developed an insufficiency fracture of the tibia but had been taking prednisolone 
10mg/day for at least five years and may thus have had corticosteroid-associated 
osteoporosis.
MTX-associated fragility fractures were reported in two postmenopausal women 
with RA in 1996 (Maenaut et al, 1996). The first had previously been treated with 
oral corticosteroids (mean dose 15mg/day for 1.5 years) prior to starting MTX, and 
had already sustained a fragility fracture of the malleolus in the past. She had taken 
MTX for eight months when multiple metatarsal fractures occurred. The second had 
never been treated with corticosteroids and after three years of MTX treatment 
suffered two stress fractures of the distal tibia, separated by six months. In each
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case, BMD measurements were available for before and after MTX therapy. Both 
women had lost bone mass at the radius whilst the lumbar bone mass was stable. 
The difference in the Z score expressed as percentage of age-matched control 
values for BMD of the distal 8cm of the radius was 35% and 29% respectively.
It was reported in an abstract in 1992 that the serum osteocalcin was reduced in 
nine patients after starting MTX for RA (Ward et al, 1992). Samples had been taken 
before and at up to eighty-one months after starting MTX.
During the first year of this study, several abstracts were presented and they are 
summarised in Table 1.10. All found no effect of MTX on the bone density or fracture 
rates in RA (West et al, 1995; Buckley et al, 1995; Ide et al, 1995; Stainbrook et al, 
1995).




















34 no yes yes yes






BMD: LS and 
FN
Stainbrook, 
D. et al 343 yes yes no no
fragility
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In 1996, a group which had presented their findings the previous year (Ide et al,
1995) reported follow-up BMD data on their cohort. Serial scans of the forearm 
suggested that MTX may protect against appendicular bone loss in RA as the loss of
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bone in the distal forearm was less in the group treated with MTX alone compared 
to those treated either with MTX and corticosteroids, or other DMARDs (Ide et al,
1996).
Also in 1996, a group from Mount Sinai, New York reported a significant reduction 
in the BMD of the proximal third of the forearm in eleven postmenopausal women 
receiving the drug for primary biliary cirrhosis (Blum et al, 1996). They were 
compared with eleven patients who had received MTX for less than one month. 
Bone turnover was assessed by serum osteocalcin, serum bone-specific alkaline 
phosphatase and urinary N-telopeptide and was not significantly different between 
the two groups. However, both osteocalcin and alkaline phosphatase were 
correlated negatively with bone mass and contributed to the impact of MTX on 
forearm BMD.
A three year follow-up study of the subjects presented after two years as an abstract 
in 1995 (Buckley et al, 1995) was published in 1997 (Buckley et al, 1997). At three 
years, low dose MTX was not associated with lower BMD of the femoral neck or 
lumbar spine compared with subjects on low dose prednisolone in a group of 
ninety-five subjects who completed the study. However, the combination of MTX 
and prednisolone did result in greater bone loss from the lumber spine.
A two year prospective but uncontrolled study of nineteen non-steroid treated RA 
patients from Angiers, France found no difference in BMD of the lumbar spine, hip, 
femoral neck, radial ultra-distal or proximal third region (Pascaretti et al, 1997). The 
only marker of bone turnover assessed was osteocalcin. There was no difference 
between the groups. The lack of a control group, failure to measure bone resorption
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or assess RA disease activity are criticisms of this study, as is the small number of 
subjects.
The only full paper published on the effect of MTX on BMD in RA was in 1997 
(Buckley et al, 1995). RA subjects who were taking part in a randomised, placebo- 
controlled study of calcium and vitamin D3 supplementation on BMD of the lumbar 
spine and femoral neck were included. After three years, lumbar spine and femoral 
neck BMD was not affected by low dose MTX but those patients who were on 
prednisolone greater than 5mg per day in addition to MTX had more loss in the 
lumbar spine than those who were on MTX alone. Forearm BMD measurements 
were not made.
1.4.12 Summary of the Evidence of an Effect of Methotrexate on Bone
MTX impairs bone formation in vitro. The adverse effect is less in animal models of 
inflammatory arthritis than in normal animals. Methotrexate osteopathy is not 
uncommon in children treated with high dose MTX for malignancies and maintained 
on it to prevent remission. However, in adults with inflammatory conditions, 
osteopathy is rare in patients who are not taking long-term oral corticosteroids. 
Cortical bone in the forearm was adversely affected in MTX-treated primary biliary 
cirrhosis (Blum et al, 1996). In the few case-controlled studies of long-term, low- 
dose MTX therapy for RA in adults, it does not appear to cause a deleterious effect 
on bone mineral density or bone turnover. However, there have been no studies 
where an attempt has been made to control for factors which may affect bone 
mineral density such as disease duration, activity and joint damage.
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2. METHODS: CLINICAL STUDY
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2.1 Introduction
The aim of the clinical study was to investigate the effect of methotrexate (MTX, 
Section 1.4) on bone density and bone turnover when used to treat rheumatoid 
arthritis (RA, Section 1.3). The study was designed to test the hypothesis that MTX 
had an adverse effect on bone turnover, based on evidence from animal and in vitro 
studies, chemotherapy experience and case reports (sections 1.4.8 to 1.4.12). The 
study included patients who had been exposed to MTX for both a short and long 
time, as adverse drug effects may become apparent only with prolonged use, 
especially in a tissue such as bone with a slow turnover.
As bone mineral density is currently the best available method for predicting future 
fracture risk (Melton et al, 1993), the primary outcome measure was the bone 
mineral density measured by dual x-ray absorptiometry of the lumbar spine, hip and 
forearm.
Bone turnover was measured by formation markers in the serum (bone specific 
alkaline phosphatase and osteocalcin) and by resorption markers in the urine 
(pyridinoline and deoxypyridinoline collagen cross-links). Together these 
measurements constituted the secondary outcome measures.
In addition, histomorphometric analysis of dual-labelled iliac crest bone biopsies 
was performed on a subgroup of subjects to study the effects of MTX at the tissue 
level in vivo.
2.2 Study Design
The study was a pragmatic, open and non-randomised study of RA patients. Those 
treated with MTX were compared with those who had not received MTX.
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It was planned to recruit patients into the four groups described below. No group 
included normal subjects; all had RA.
Starting MTX Group (Starting MTX)
Patients who had developed RA within the previous two years, who had not been 
treated with a disease-modifying drug (DMARD) before (section 1.3.3), who had 
active RA (section 1.3.4) and were starting MTX for the first time.
Control Group for Group Starting MTX (Starting SPZ1
Patients who had developed RA within the previous two years, who had not been 
treated with a disease-modifying drug before, who had active RA and were starting 
sulphasalazine (SPZ) for the first time. As they had never had a DMARD before, by 
definition they had not had MTX in the past.
Established on MTX Group (Continuing MTX1
RA patients who had been taking low dose weekly MTX continuously for at least five 
years.
Control Group for Group Continuing MTX (Continuing Other DMARD)
RA patients who had been taking a disease-modifying anti-rheumatic drug 
(DMARD) other than MTX continuously for at least five years, and who had never 
taken MTX.
The conditions of entry to the study are set out in Table 2.1.
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Table 2.1 Entry criteria to study
(aroup Disease duration Drug therapy
Start MTX Preferably less than 2 yrs
No previous treatment with 
MTX and needed to start or 
change to MTX
Start SPZ Preferably less than 2 yrs
No previous treatment with 
MTX and to start SPZ
Continue MTX At least 5 years
MTX tor at least 5 yrs. No 
limit on previous DMARDs
Continue Other DMARD At least 5 years
Present bMAHD tor at 
least 5 yrs, and no MTX 
ever. No limit on previous 
DMARDs
MTX, Methotrexate; SPZ, Sulphasalazine; DMARD, disease-modifying anti-rheumatic drug.
Men and women between the ages of 18 and 80 who fulfilled the American College 
of Rheumatology 1987 revised diagnostic criteria for RA (Table 1.3) (Arnett et al,
1988) were eligible for inclusion. Ethical approval for the study was granted by the 
local ethics committee and each participant gave signed, informed consent. 
Exclusion criteria are shown in Table 2.2. Postmenopausal women using hormone 
replacement therapy (HRT) were not excluded but a record was kept of the use of 
such drugs throughout the study. It had been hoped to avoid recruiting women who 
were perimenopausal as they are in a state of increased bone turnover (Lufkin et al, 
1992), but many women presenting with RA fell into this category and the exclusion 
was relaxed.
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Table 2.2 Exclusion criteria for recruitment to study
Current treatment with corticosteroids, apart from inhaled steroids tor airways disease 
Previous maintenance treatment with corticosteroids tor any disease, apart from short 
reducing courses for reversible airways disease (not permitted within the previous 6 
months)
Intra-venous pulse treatment with corticosteroids tor flare ot HA within the previous 3 
months
Previous or current treatment with bisphosphonates, calcitonin or Cyclosporin A 
Previous or current illness known to effect bone mass such as hyperparathyroidism, 
multiple myeloma, Cushing’s syndrome
Current untreated hyperthyroidism. Replacement therapy with thyroxine following 
previous hyperthyroidism was permitted provided the dose of thyroxine had been 
stable for at least 6 months
Hypogonadal men receiving testosterone replacement therapy 
Serious illness such as malignancy, heart failure or vasculitis 
Unable or unwilling to give informed consent
2.2.1 Subject Recruitment
The study subjects were patients attending the Royal National Hospital for 
Rheumatic Diseases NHS Trust, Bath.
Subjects were recruited during the first year of the study. The medical notes of all 
out-patients attending the hospital were scrutinised and potential subjects identified. 
The doctor who saw the individual in clinic was asked to seek the patient’s 
permission for an initial telephone contact by the author and two hundred and thirty- 
one patients agreed to be telephoned. The telephone conversation enabled
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subjects to be further screened and the study protocol was discussed briefly. At this 
point one hundred and thirty-nine patients were excluded, most commonly due to 
refusal to attend study visits. The reason most often given was unwillingness to 
have additional hospital visits, particularly when others were relied on for transport. 
Those who did agree to be seen were sent an appointment card, a container to 
bring the urine sample in and instructions on how to collect the fasting, second void 
morning urine sample. Additional patients were seen in person during their clinic 
visits and study appointments arranged then.
By these means, one hundred and thirty-eight subjects attended for first interview, 
when twenty-two were excluded, leaving one hundred and sixteen recruited to the 
study (Figure 2.1). The pattern of recruitment throughout the year is shown in Table 
2.3.
Figure 2.1 Recruitment to the study
All out-patient notes reviewed and 
potential subjects approached in clinic
231 patients telephoned ---------- i 139 excluded
-----------------------------------------------S L _  . ...
138 patients seen in person -------- 122 excluded
116 subjects recruited
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Table 2.3 Recruitment of subjects
^/lonth Potential 
subjects seen
Number recruited Cumulative number 
recruited
May 95 13 9 9
June 95 13 12 21
July 95 19 16 37
August 95 18 17 54
September 95 17 15 69
October 95 9 9 78
November 95 16 11 89
December 95 7 b 95
January 96 11 8 "103
February 96 11 9 "112
March 9b 4 4 116
Total 138 116 116
There were several reasons for exclusion at the first visit. One patient had long­
standing RA treated with D-Penicillamine who was in a flare of RA requiring a pulse 
of steroids. Another had been placed on oral prednisolone by the General 
Practitioner, again for a flare. Two patients had already started taking the study 
DMARD (MTX and SPZ) in error. Several patients with mild disease had decided 
not to start taking the recommended DMARD and several decided they were not 
willing to wait the two weeks until the second baseline assessment before starting 
therapy. One patient had abnormal baseline liver function tests and could not start 
MTX or SPZ. Another had secondary fibromyalgia and all the joints were tender 
despite his RA being under good control. Both physician and patient assessment of 
disease activity could have been inaccurate and he was therefore excluded.
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2.2.2 Study Visits
The main determinants of bone mineral density at any site are age and, in women, 
menopausal age (years since the menopause). In patients with RA, disease activity 
and duration of RA may also affect bone density and are potential confounders. 
Study visits were therefore planned to detect changes in both bone turnover and RA 
disease activity. It was assumed that the rheumatoid disease activity and bone 
turnover would change rapidly in the groups starting either MTX or SPZ as their 
active RA was treated. Therefore these subjects were seen more frequently than 
those on stable RA therapy in whom the disease could be expected to be under 
better control.
Subjects Starting MTX or SPZ
These patients were seen five times over one year. As the day-to-day variation in 
crosslink excretion has been shown to be as high as 26% (Colwell et al, 1993), two 
baseline visits were performed approximately two weeks apart to obtain two sets of 
baseline data for bone turnover and disease activity. The subjects were then seen 
at three months, six months and a year after starting the DMARD (either MTX or 
SPZ). The subgroup with RA of duration less than two years at study entry were 
invited to attend a sixth visit two years after starting the DMARD.
Continuing MTX or Other DMARD
These patients were seen three times over one year. They were seen on two 
occasions, a fortnight apart at study entry to provide baseline data (similar to the 
prospective groups). The third and final visit was a year later.
The timing and number of visits is shown for each group in Table 2.4.
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Table 2.4 Number of study visits for the different groups





Start MTX Yes Yes Yes Yes Yes
Yes (if 
early RA)*








Yes Yes No No Yes No
* Early RA was arbitrarily defined as RA duration of less than 2 years at study entry.
A morning research clinic was set up. Serum osteocalcin has a diurnal rhythm, 
with the peak between 04.00 and 08.00 and the nadir between noon and 14.00 
(Gundberg et al, 1985). It is therefore recommended that blood samples for 
osteocalcin estimation are taken at the same time and preferably before 10.00. 
However, patients with active RA do not like attending early morning clinics due 
to their morning stiffness and some patients had a long way to travel (from South 
Wales, for example). The latest clinic appointment time was 12.30, with blood 
samples taken at 13.00. This was not ideal, but was necessary to maximise 
recruitment because many patients who were used to afternoon appointments 
refused to come if they could not be seen at 12.00 or 12.30. The appointment 
time for a subject was the same throughout the study, so that if they came at
11.00 the first time, all subsequent visits would be at 11.00. This meant that the 
diurnal variation in osteocalcin was less important when percentage change in 
osteocalcin in a single subject was considered but it has implications for mean 
group values. Although the clinic was on a Thursday, during the first year 
potential subjects were seen on any suitable morning to maximise the number 
recruited.
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The study visits were used to collect baseline demographic data (first visit) and 
information about the bone turnover and rheumatoid activity (all visits). The 
measurements obtained at the different study visits are shown in Table 2.5. The 
same data was collected in all groups of subjects to enable four-way statistical 
analysis. All the joint assessments were by one observer (the author) which 
eliminated inter-observer variation.
Intra-articular corticosteroid injections were performed as clinically necessary, but 
not at the first visit as it has been shown that the serum osteocalcin level is reduced 
one day after such an injection and takes two weeks to return to normal (Emkey et 
al, 1996). The osteocalcin could still have been suppressed at the second baseline 
visit two weeks later.
Table 2.5 Measurements at study visits













BMD Yes Yes Yes
Bone
turnover Yes Yes Yes Yes Yes Yes
Ra  activity Yes Yes Yes Yes Yes Yes
HAQ Yes Yes Yes Yes Yes Yes
Radiographs Yes Yes Yes
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The First Visit
At the first visit, for which an hour was available, a detailed patient information sheet 
was read through with the patient and any questions about the study protocol 
answered. If the patient agreed to take part in the study, they were asked to sign a 
consent form. All female patients with early RA who were starting MTX were asked if 
they would agree to have a transiliac crest bone biopsy before starting MTX, with 
the biopsy repeated after one year. If the patient was commencing a DMARD (MTX 
or SPZ), the implications and possible side effects of the drug were discussed.
A proforma was completed which was designed to identify osteoporotic risk factors 
and, in women, menopausal status. A full medical history and examination were 
performed. The history included details of previous DMARD use. If a thyroid 
stimulating hormone had not been estimated in the last year, this was done. Serum 
calcium and Vitamin D measurements were not performed.
The assessments of RA activity and bone turnover were completed (see sections 
2.5 and 2.4).
Subsequent Visits
For the second and later visits, half an hour of clinic time was available. At each visit 
a proforma was completed and the assessments of RA activity and bone turnover 
were made.
2.3 Measurement of Bone Mineral Density
The bone mineral density (BMD) of the lumbar spine, hip and forearm was 
measured by dual x-ray absorptiometry (DXA) on a Hologic QDR 4500 machine 
(Hologic, USA) in the Clinical Measurements Department at the RNHRD. The BMD 
was done at entry to the study and then after one year. All the scans were done on
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the same device which is calibrated every day using a lumbar vertebra phantom. 
The coefficient of variation of the phantom measurement throughout the study 
period was 0.51%. Typical precision errors for the sites scanned have been 
reported as 1.0% for the lumbar spine, 1.6% for the femoral neck (Laskey et al, 
1991) and 1.0% for the forearm (Hologic Inc datasheet).
The areas scanned and measurements made are shown in Tables 2.6 and 2.7 
and an example of the printout is shown in Figures 2.2 to 2.4.
Table 2.6 Bone mineral density measurements
Anatomical Area Regions scanned
Lumbar spine lumbar vertebrae 1 to 4 and result 
averaged






























Spine Yes Yes Yes Yes Yes Yes Yes
Neck of 




Yes Yes Yes Yes Yes Yes Yes
Trochant­
eric Yes Yes Yes Yes Yes Yes Yes
Ward’s
area Yes Yes Yes Yes Yes Yes Yes




Third Yes Yes Yes Yes Yes Yes No
Mid-
portion Yes Yes Yes Yes Yes Yes No
Ultra-
Distal Yes Yes Yes Yes Yes Yes No
Total




Third No Yes Yes Yes Yes Yes No
Mid­
portion No Yes Yes Yes Yes Yes No
Ultra-
Distal No Yes Yes Yes Yes Yes No
Total
Forearm No Yes Yes Yes Yes Yes Yes
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Figure 2.2 Printout of bone mineral density measurement estimation of
lumbar spine
B0728950C Fri 28.Jul. 1995 11:23 
Name: OBM
Comment: R .A . R26
I. D . : Sex: F
S . S . tt : - - Ethn i c : CJ
ZIPCode: Height: 164.50 cm
Operator: JBS Weight: 88.70 kg
BirthDate: 14.Aug.58 Age: 36
Physician: DR BHALLA
Image not for diagnostic use
TOTAL BMD CO FOR LI - L4 1.0v.
C.F. 1.022 0.992 1.000
teg ion Est.Area Est.BMC BMD
(cm2) (grams) (gms/cm*
LI 13.91 13.83 0.994
L2 14.67 16.89 1.151
L3 16.38 20.04 1.223
L4 17.65 20.15 1.142
TOTAL 62.61 70.91 1.133
1.129 d0 = 42.9(1.000H) 8.449
C l i n i c a l  M e a s u re m e n t ,  RNHRD, B ath
a Lumbar Spine 
Reference Database
Age












Fri 28.Jul.1995 11:23 
OBN 
R .A . R26 
Sex: F
- - Ethnic: U
Height: 164.50 cm 
JBS Weight: 88.70 kg
14. Aug.58 Age: 36
DR BHALLA
Region BMD T (3 0 .0 ) Z
L I 0 .9 9 4 + 0 .6 3  107v + 0 .73 109v
L2 1 .1 5 1 + 1 .1 2  112v. + 1 .2 3 113v
L3 1 .2 2 3 + 1 .2 7  113v + 1 .3 9 114x
L4 1 .1 4 2 + 0 .2 4  102v +0 .35 104v
L1-L4 1 .1 3 3 + 0 .7 8  108v + 0 .89 109v
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Figure 2.3 Printout of bone mineral density measurement estimation of
hip
k = 1.131 d0 = 46.4(1.000H) 6.675 I . V . ■ Sex: F
S.S.#: - - Ethnic: U
ZIPCode: Height: 164.50 cm
Operator: JBS Weight: 88.70 kg
BirthDate: 14.Aug.58 Age: 36
Physician: DR BHALLA
Image not for diagnostic use 
TOTAL BMD CO 1.0X
C.F. 1.022 0.992 1.000
Region Est.Area Est.BMC BMD
(cm2) (grams) (gms/cm2)
Neck 4.74 3.99 07842
Troch 11.08 7.73 0.697
Inter 20.47 22.44 1.096
TOTAL 36.30 34.16 0.941
Ward's 1.11 0.74 0.671
Midline ( 98,124)-( 22, 58)
Neck 49 x 15 at [-20, 11]
Troch -12 x 44 at [ 0, 0]
Ward's 11 x 11 at C -7, 7]
HOLOGIC















Fri 28.Jul.1995 11:30 
OBM 
R .A . R26 
Sex: F
- - Ethnic: W
Height: 164.50 cm 




Reg ion BMD T Z
Neck 0.842 -0.53 94x -0.21 98x
(22 .0)
Troch 0.697 -0.27 97x -0.19 98x
(30 .0)
Inter 1.096 -0.37 96x -0.29 96x
(29 .0)
TOTAL 0.941 -0.28 97x l h* CO 98x
(28 .0)
Ward's 0.671 -1.14 84x -0.39 94x
(20 .0)
•28.Jul.1995 11:59 [95 x 108]
Hologic QDR-4500A (S/N 45023) 
Right Hip U8.10a:3
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Forearm Length: 26.7 cm 
Image not for diagnostic use
k = 1.229 d0 = 62.6(1.000)14]
•17.Feb.1997 15:39 [184 x 98]
Hologic QDR-4500A (S/N 45023) 
Right Forearm 08.18a:3
TOTAL BMD CO IS LESS THAN 1.0X
C.F. 1.022 0.992 1.000
RADIUS Area BMC BMD
+ ULNA (cm2) (grams) (gms/cm2)
1/3 4.87 3.64 0.748
MID 12.17 8.15 0.669
UD 5.43 2.48 0.457
TOTAL 22.47 14.27 0.635













RNHRD, B a t h .
Fri 28.Jul.1995 11:37 
OBM 
R .A . R26 
Sex: F
- - Ethnic: U
Height: 164.50 cm 
JBS Weight: 88.70 kg
14.Aug.58 Age: 36
DR BHALLA
20 30 40 50 60 70 80
Age
BMD(Radius+Ulna[R] TOTAL) = 0.635 g/cm2
Region BMD T Z
1 /3 0 .7 4 8 +1 .1 0  109x 
( 2 0 . 0 )
+1 .38 112x
MID 0 .6 6 9 +1 .54  114x 
( 2 0 . 0 )
+ 1 .83 117x
UD 0 .4 5 7 + 0 .89  l l i x  
( 2 0 . 0 )
+ 1 .09 114x
TOTAL 0 .6 3 5 +1 .3 9  113x 
( 2 0 . 0 )
+ 1 .68 116x
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Bone mineral content (BMC), from which the BMD was derived, was recorded for 
the following: lumbar spine, neck of femur, trochanteric, intertrochanteric, total hip, 
Ward’s region, radius and ulna proximal third, mid-portion, ultra-distal and total 
forearm.
Estimates of BMD were available for all the regions where the BMC was measured 
and for the proximal third, mid-portion, ultra-distal and total forearm of the radius 
alone as well as the radius and ulna combined.
For subjects with early RA (arbitrarily defined as less than two years’ duration), they 
were invited to have a third BMD measurement of the lumbar spine, hip and forearm 
at two years. If they consented, a lateral lumbar spine BMD was also obtained as 
the software became available during the course of the study. A total of twenty-nine 
subjects with early RA had this measurement at twelve and twenty-four months after 
entry to the study.
The annual change in BMD was recorded for each region and expressed both as 
absolute change and percentage. For those areas where the change in BMD was 
not provided from the printout, annual changes were calculated from the BMD 
values.
The lumbar spine BMDs were reviewed at the end of the first year by Dr A.K. Bhalla, 
Consultant Rheumatologist, who was not aware of the clinical details of the 
subjects. He identified any vertebrae which had morphological changes, which 
would lead to inaccurate BMD values. The scans were re-analysed excluding such 
vertebrae.
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2.4  M easurem ent of Bone T u rn o v e r
At each visit, samples were collected for markers of bone formation (serum) and 
resorption (urine).
2.4.1 Markers of Bone Formation
Serum was stored at -70°C in four aliquots for later estimation of osteocalcin and 
bone-specific alkaline phosphatase and only thawed on the day of analysis.
2.4.2 Markers of Bone Resorption
Fasting, second void urine samples were brought to each visit in two containers. 
Samples were collected according to instructions previously sent to the subject. 
One urine sample was sent to the Biochemistry Department at the Royal United 
Hospital NHS Trust, Bath for urinary creatinine measurement by automatic analyser 
(Roche Cobas Mira and Integra), whilst the other was stored at -20°C in two aliquots 
for later estimation of the collagen cross-links, pyridinoline and deoxypyridinoline. 
Samples were only thawed on the day of analysis.
2.5 Measurement of Rheumatoid Arthritis Disease Activity
The following measures of disease activity in RA (section 1.3.5) were made at each 
visit:
length of early morning stiffness of the joints in minutes;
a twenty-eight joint count was performed in which swelling and tenderness were 
scored separately (Fuchs et al, 1989);
the subject indicated on two separate 100mm visual analogue scales the level of 
the pain they were experiencing and a measure of overall disease activity;
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blood was taken for haemoglobin (Hb), C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) estimation.
From these measures, a modified Disease Activity Score (DAS, Section 1.3.6) (van 
Gestel et al, 1996) was derived.
2.6 Measurement of Rheumatoid Arthritis Disease Impact
Each subject completed the modified Health Assessment Questionnaire (HAQ, 
Section 1.3.7) (Kirwan et al, 1986) at each visit.
Radiographs of hands and wrists were taken on entry and then annually. The 
radiographs were scored using Larsen standard plates (Larsen et al, 1977) at the 
end of the study by Dr Gordon Evison, Consultant Radiologist. He had no 
knowledge of the patient clinical details, other than the diagnosis of RA. In subjects 
who agreed, elbow radiographs were taken at one year follow-up. These were 
taken because preliminary analysis during the first year of the study indicated that 
the forearm BMD of the long-term MTX group was significantly lower than in their 
control subjects (those continuing DMARDs other than MTX). The elbow films were 
also scored according to the Larsen plates.
2.7 Other Data Collected
During the course of the study, any changes in therapy were noted. Changes in 
treatment were initiated by the General Practitioner, at other RNHRD clinics or by 
the patient.
Appropriate monitoring and baseline blood tests for the DMARD were performed as 
for a usual outpatient appointment and the General Practitioner asked to continue 
monitoring according to hospital guidelines.
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2.7.1 Physical Activity
Weight-bearing exercise is essential for bone health and completely bed-bound 
individuals may loose as much as 40% of their bone mass over a year (Marcus, 
1996). Peak bone mass attained is partly determined by the length of time spent 
walking outdoors (Cooper et al, 1995). Patients with RA often have reduced 
physical activity due to lower limb joint disease. The EVOS study used a validated 
questionnaire and spinal radiographs to determine the impact of factors such as 
physical activity and diet on the prevalence of vertebral osteoporosis in nineteen 
European countries (O'Neill et al, 1995; Silman et al, 1997). Part of the EVOS 
questionnaire was administered to the study patients. The subject filled in the 
questionnaire alone but the responses were checked to ensure comprehension. 
The questions related to physical activity, both current and previous, and also to diet 
(Section 2.7.2). In the analysis, a score derived from the length of time spent 
walking outdoors at the present time was used and is shown in Table 2.8.
Table 2.8 Score for outdoor walking from questionnaire




some, but less than halt an hour 2
between halt an hour and one hour 3
more than one hour 4
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2.7.2 Calcium Intake
The dietary components of the questionnaire asked about current and previous milk 
intake, current intake of various calcium-containing foods and intake of tea, coffee 
and alcohol. Dietary calcium during childhood affects the peak bone mass attained 
(Cadogan et al, 1997). In postmenopausal women there is reduced calcium 
absorption from the gut and calcium supplements (with or without Vitamin D3) may 
reduce bone loss and fractures (Dawson-Hughes et al, 1990; Reid et al, 1993; 
Chapuy et al, 1992). A score shown in Table 2.9 was developed for the current 
calcium intake and used in the analysis.
Table 2.9 Score for calcium intake from questionnaire
Foodstuff Score is the average 
numbers of days per week 
each foodstuff is eaten
Hard cheese o to  7
Soft cheese oto  7
Yoghurt Oto 7
Milk OtO 7
Other e.g. ice cream Oto 7
Total 0 to 35
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2.8 Analysis of Bone Formation Markers
2.8.1 Osteocalcin
Osteocalcin was estimated by a competitive immunoassay (Novocalcin, Metra 
Biosystems, UK) using osteocalcin-coated strips in a ninety-six well plate. 
Standard, control or sample (25/vl) were added to wells in duplicate and 
incubated with an anti-osteocalcin antibody at room temperature for two hours. 
After three washes, an anti-mouse alkaline phosphatase conjugate was 
incubated for another hour at room temperature before another three washes. 
Finally, a p-Nitrophenyl Phosphate (p-NPP) substrate was added for thirty 
minutes at room temperature before the reaction was stopped by 50/yl of 3M 
NaOH. The resulting optical densities were read at 405nm. In addition, six 
standards and a high and low control were supplied, allowing forty patient 
samples to be processed per assay as each was done in duplicate with a 
standard curve performed with each assay. A four-parameter calibration curve 
fitting equation was used to construct a standard curve and to determine the 
concentrations of the controls and samples. The software to calculate this was 
provided by Metra Biosystems. Interassay variation in this study was 6.9%.
2.8 .2  Bone-Specific A lkaline Phosphatase
This was estimated by an immunoassay (Alkphase-B, Metra Biosystems) using 
monoclonal anti-bone-specific alkaline phosphatase (BALP) antibody-coated 
strips which capture serum BALP. Initially, 125>l/I of assay buffer were added to 
each well, then 2(ty/l of standard, control or patient sample in duplicate. The plate 
was incubated at room temperature for three hours. After four washes, incubation 
for thirty minutes with p-NPP was done which detects the enzyme activity of the
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BALP and the reaction stopped with 100//I of 3M NaOH. A quadratic calibration 
curve was used to construct the standard curve and then generate BALP serum 
values from the optical densities obtained at 405 nm, again using software 
supplied by Metra Biosystems. Interassay variation in this study was 4.8%.
2.9 Analysis of Bone Resorption Markers
2.9.1 High Pressure Liquid Chromatography Method
High Pressure Liquid Chromatography (HPLC) is a powerful technique for 
separating the different components in a chemical mixture (Schram, 1980). The 
compounds of interest (solutes) are dissolved in a liquid solvent (the mobile 
phase) and then passed at high pressure through a chromatographic column 
(the stationary phase). The principle of the HPLC technique is shown 
schematically in Figure 2.5.











By altering the solvent composition and flow rate and column characteristics, the 
compounds can be made to come off the column at different times. The collagen 
cross links, Pyd and Dpd (Section 1.1.10), naturally fluoresce and can be quantified 
in a urine sample which has been passed over a HPLC column by a fluorescence 
detector set to the appropriate excitation (295nm) and emission (395nm) 
wavelengths (Colwell et al, 1993). An analysing computer integrates the area under
i
the curve for each peak and by comparison with a standard, the concentration of 
Pyd and Dpd can be determined. The usual ratio of urinary Pyd to Dpd is 4:1 
(Robins et al, 1991), although this may be increased in RA, when turnover of tissues 
such as cartilage and synovium have a larger contribution of Pyd than normal 
(Pearce et al, 1995). However, there are many contaminating compounds in urine 
and the samples need to be purified by fractionation over cellulose columns before 
analysis. In addition, the collagen cross links are hydrolysed by heating for eighteen 
hours with concentrated hydrochloric acid prior to fractionation. The technique for 
preparing and purifying the urine samples before passing them over the column is 
illustrated in Figure 2.6.
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Figure 2.6 Flow diagram of the method for preparing urjne_sa_mples for 
collagen cross-link estimation
250|il urine + 
250ul cone HCi
Heated at 118°C for 18 hours
500|il acetic acid 
500pl CF-1 cellulose slurry 
2mls butan-1-ol
added to urine and HCI
Passed over cellulose columns and 
washed five times with 5mls butanol eluent
Crosslinks eluted off with 4ml 
HPLC-grade water_________
Centrifuged at 1000g for 15 minutes
Butanol phase removed and 
lyophilised at 145g, 55°C for 10 
hours
Reconstituted in 150u.l 0.01 M 
HFBA
All chemicals used in the estimation of Pyd and Dpd by HPLC were of HPLC-grade 
and were obtained from BDH Laboratory Supplies, Poole, Dorset, unless otherwise
stated.
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Preparation of urine samples for collagen crosslink estimation (Figure 2 .5)
Overnight hydrolysis with hydrochloric acid
In the fume hood, 250pl of thawed urine was placed with 250pl of concentrated 
hydrochloric acid in a 100mm long pyrex tube with a teflon-lined screw cap (Aldrich 
Chemical Company Inc., Milwaukee, Wisconsin, USA) and heated at 118°C in a
heating block (Stuart Scientific, UK) overnight for eighteen hours. The heating block 
held twenty-four tubes (twelve samples in duplicate) and all samples from a single 
patient (three or five visits) underwent prefractionation in parallel on the same day to 
reduce variability.
Pre-fractiona tion
The pre-fractionation was done over cellulose columns which were washed with a 
butan-1-ol eluent. In the fume hood, the butanolic eluent was prepared from butan- 
1 -ol, glacial acetic acid and HPLC-grade water in the ratio 4:1:1 by volume. The 5% 
CF1 cellulose slurry was made using 25g fibrous cellulose powder CF1 (Whatman 
Laboratory Division, Maidstone, Kent, UK) suspended in 500mls butanolic eluent. 
The cellulose was kept suspended in solution by magnetic stirring. In the fume 
hood, the hydrolysed urine samples had 500jil glacial acetic acid, 500pl 5% CF1 
cellulose slurry and then 2mls butan-1-ol added to each tube. During this stage the 
cross-links bound to the cellulose. Working in the fume hood, the cellulose columns 
were made by pipetting 5mls of the cellulose slurry into polyprep columns (Biorad 
Labs Inc., Hemel Hempstead, UK) suspended over a container to catch the butanol 
eluent washes. Each column was washed once with 5mls of butanol eluent prior to 
the urine sample being poured onto the relevant column. To ensure maximum 
retrieval of the cellulose (and thus cross-links) from the pyrex tubes, the tubes were
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washed three times with 5mls butanolic eluent and shaken vigorously prior to 
tipping the contents onto the correct column. Finally, the columns were washed 
twice with 5mls butanolic eluent.
Elution of the crosslinks and lyophilization
The Biorad columns were then transferred to a rack where correspondingly 
labelled LP4 tubes (Luckham, UK) were suspended underneath. The crosslinks 
were eluted off the columns by 4mls of HPLC grade water. The samples were 
then centrifuged at 10OOg for fifteen minutes to separate the aqueous from the 
butanolic phase. The butanol phase was aspirated off and the tubes transferred 
to the centrifuge evaporator (RC10, Jouan Ltd, UK) with a cold trap (RCT90, 
Jouan Ltd, UK) cooled to -90°C to collect the evaporated solvent for
lyophilization overnight. Spinning at 145g for ten hours with heating to 55°C and
a pulsed vacuum was sufficient to dry forty-eight tubes completely.
Reconstitution
The following day, the residue was reconstituted with “ISOpl of 0.01 M HFBA, 
placed in a 200p\ conical insert (02-MTV, Chromacol Ltd, London, UK) and then 
in a 2ml HPLC vial (2-CV, Chromacol Ltd, London, UK), with the top crimped. 
Prepared samples were stored in the dark at 4-8°C until they were run on the 
HPLC column.
Separation of .crosslinks by reverse-phase, .ion-pa ired ..HPLC.
The method followed was that described by Colwell et al (Colwell et al, 1993) 
and is shown schematically in Figure 2.5. This is an isocratic method: that is, the 
same ratio of mobile phase components is maintained throughout the run.
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The column was 33 x 4.6mm long, packed with 3pm octadecyldimethylsilane (ODS) 
(LC-18-DB, Supelco Inc., Bellefonte, PA, USA), used in conjunction with a sampler 
(Marathon, Spark Holland), flurometer (JASCO 820-FP Intelligent 
Spectrofluorometer, Japan Spectroscopic Co. Ltd, Japan), solvent delivery system 
(Milton Roy CM400 multiple solvent delivery system, LDC Analytical, Thermo 
Instrument Systems, Stone, Staffs, UK), LDC Analytical CI-4100 data acquisition 
system (LDC Analytical, Stone Staffs, UK) and pump (Bambi Air, UK).
The mobile phase was 90% solution A and 10% solution B, where solution A was 
10mM HFBA (2.64mls in 1 litre HPLC-grade water), pH adjusted to 2.5 with 10M 
NaOH, made fresh every day. Solution B was 75% acetonitrile (HPLC grade, BDH 
Laboratory Supplies, Poole, Dorset, UK), 25% solution A by volume.
A 20pl loop was used to inject the sample onto the column and fluorescence was 
measured with excitation at 295nm and emission at 395nm.
The Pyd usually came off the column at four to five minutes and the Dpd at seven to 
eight minutes, with good separation of the peaks. The analysis took ten minutes, 
with two minutes for calculation. An example of the printout obtained is shown in 
Figure 2.7 with the peaks of interest labelled. An internal standard was not used. 
External standards from Dr D Black (Glaxo Ltd, Greenford, UK) were run every 
twenty samples to ensure stability of the system and to allow calculation of the 
conversion factors for Dpd and Pyd. A printout from the standards is shown in Figure 
2.8.
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Figure 2.7 HPLC output of collagen cross-links
D E U iU b  S A M P L E  m e t h o d  t i m e
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Pyridinoline peak at 4.51 minutes; deoxypyridinoline peak at 5.90 minutes.
Figure 2.8 HPLC output of the deoxvpvridinoline and 
standards
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From the area under the peaks, the concentrations of Dpd and Pyd for each sample 
were calculated using the formulae:
Dpd (nmol/ml) = area(Dpd) x (150/250) x 1000 x rf(Dpd) and 
Pyd (nmol/ml) = area(Pyd) x (150/250) x 1000 x rf(Dpd),
where area (Dpd) and area (Pyd) are the areas under the two peaks printed out 
(integrated automatically);
150/250 is the correction factor for the starting volume of urine (250pl) and the final 
volume of the purified crosslinks (150pl);
1000 converts the concentration from nmol/l to nmol/ml;
rf is the response factor, established from the external controls. For Dpd the 
concentration of the external control was 0.518 and for Pyd it was 0.76. The 
response factor for each was given by the following formulae: 
rf(Dpd) = 0.518 /  (area of Dpd external control peak) 
rf(Pyd) = 0.76 / (area of Pyd external control peak).
The drug sulphasalazine has a metabolite which is excreted renally and which 
interferes with the quantification of the LP and HLP peaks by HPLC. The interfering 
peak can be delayed on the column by changing the proportion of the mobile phase 
from 90(A): 10(B) to 96(A):4(B) (Peel et al, 1994a). The samples from patients on 
sulphasalazine were processed at the same time as ones from other patients, but 
they were stored in the dark at 4-8°C and would have been run together at the end.
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HPLC was initially used for analysis of the urine samples in this study and the in- 
house protocol was followed. The ion-paired, reversed-phase method of Black 
(Black etal, 1988) had been modified by previous investigators so that the starting 
volume of urine had been increased from 250p.l to 1ml. This was on the (incorrect) 
assumption that a greater starting volume would result in greater recovery of the 
crosslinks of interest: pyridinoline (Pyd) and deoxypyridinoline (Dpd). Although it 
had been planned that two aliquots of urine of at least 2mls were to be stored from 
each sample, a smaller volume had often been saved. As samples were prepared 
in duplicate, frequently there was not enough urine to process two 1ml volumes and 
thus two different volumes of 1ml and 500pl or even 1ml and 250pl were used, with 
appropriate correction of the final results for the starting volume. When the first 
results were obtained, it became apparent that the smaller starting volume (250pl) 
yielded a greater final concentration of Dpd and Pyd than did 500pl or 1ml of urine, 
inversely proportional to the starting volume.
An experiment was done using urine from a Pagetic patient with varying starting 
volumes of urine and varying volumes of cellulose slurry packing the pre­
fractionation columns. The results are shown in Figure 2.9 and it can be seen that 
the optimum starting volume of urine is 250pl, with 5ml cellulose slurry in the 
columns, as in the method of Colwell et al (Colwell et al, 1993).
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Figure 2,9 Recovery of deoxvpvridinoline and pyridinoline from Paqetic
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Results shown as the mean and the 95% confidence level, n = 4
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The urine samples were prepared again in duplicate, using 250pl of urine. 
However, recurrent technical difficulties with the HPLC sampler and pump meant 
that after eight months’ work and processing of 624 samples in duplicate, results 
for Dpd were only available on 163 samples and only 17 out of the 116 subjects 
had complete Dpd and Pyd results for all samples. At this time, it was decided to 
process all the samples for free Dpd alone by ELISA (Pyrilinks-D, Metra, UK). 
This kit was chosen as Dpd is more specific than Pyd for bone (Section 1.3.8) 
and is the only ELISA commercially available which measures the cross-linked 
collagen rather than the C- or N-terminal peptides. All the remaining urine 
samples were then analysed again by ELISA.
2.9 .2  ELISA Method
This was a competitive enzyme immuno-assay using monoclonal anti-Dpd 
antibody coated on the well (Pyrilinks-D, Metra Biosystems, UK). The Dpd in the 
sample competed with conjugated Dpd-alkaline phosphatase for the antibody 
and the reaction was detected with a p-NPP substrate. The samples, standards 
and control solutions were diluted 1 in 10 with assay buffer in a microtitre plate 
and 50fj\ of the diluted samples added to the anti-Dpd coated wells in duplicate. 
Enzyme conjugate (100pl) was then added to each well and the plate incubated 
in the dark at 2-8°C for two hours. The plate was then washed three times with
wash buffer and 150/l/I of the working substrate (p-NPP) added to the wells prior 
to a one hour incubation at room temperature. The reaction was stopped with 
100pl of 1M NaOH and the optical densities read at 405nm on a plate reader. A 
4-parameter curve-fitting equation was used to construct the standard curve and 
determine the concentrations of the controls and samples. Metra provided the 
software for use with the ELISA. Inter-assay variation in this study was 5.5%.
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3. RESULTS: CLINICAL STUDY
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3.1 Introduction
In this chapter the results from the clinical study are presented. First, the methods of 
analysis are discussed and the characteristics of the subjects are detailed. The 
adverse events, drop outs and protocol violations are addressed. The results of the 
primary outcome measure (bone mineral density) and the secondary outcome 
measures (markers of bone turnover) are described for all subjects. Then the 
subgroups of postmenopausal women, subjects with early rheumatoid arthritis (RA), 
and men are discussed in turn.
3.2 Analysis of Results
The analyses were performed by the author using the Statview 4.5 for Macintosh 
statistical package. For the four-way comparisons between groups, analysis of 
variance (ANOVA) with Fisher's Protected Least Significant Difference (PLSD) post 
hoc testing was performed. Confidence levels were set at 95% and the p values for 
significant differences determined. For two-way comparisons between groups either 
a paired or an unpaired t-test was used as appropriate. All possible inter-group 
comparisons were performed but for clarity only those where differences were 
significant are illustrated.
The regression analysis on the subgroup of postmenopausal women (Section 3.6) 
was performed by Dr Daphne Kounali, School of Mathematical Sciences, Bath 
University. She studied the whole data set and gave advice on the appropriate 
statistical tests to apply. Due to the small number of subjects and the strong 
influence of menopausal status on bone mineral density, regression and 
discriminant analyses were limited to the subgroup of postmenopausal women. The
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statistical models she developed and applied to the postmenopausal data set are 
discussed in Section 3.6.
3,3 Characteristics of Subjects Included in the Study
There were one hundred and sixteen subjects recruited to the study by the methods 
described in Chapter 2. All were Caucasian. The number of subjects recruited into 
each study group, their sex distribution, age, body mass index, rheumatoid factor 
status and rheumatoid arthritis (RA) duration in months or years are shown in Table
3.1.



































































*MTX, Methotrexate; SPZ, Sulphasalazine; DMARD, disease-modifying anti-rheumatic drug; 
RA, rheumatoid arthritis.
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The group continuing Methotrexate (MTX) was well-matched with the group 
continuing other disease-modifying anti-rheumatic drugs (DMARDs) for age, body 
mass index and duration of RA. There were no differences between the two groups 
for these three parameters by unpaired t-testing.
Subjects starting either MTX or Sulphasalazine (SPZ) were less well-matched for 
disease duration and there was a significant difference between them by unpaired t- 
test (p = 0.0102, Table 3.1). This was due to the twenty-one subjects included who 
had failed a previous DMARD, sixteen subjects in the group starting MTX, but only 
five subjects in the group starting SPZ. These subjects did not fulfil the entry criteria 
as defined in Section 2.2 but were recruited to increase numbers.
Overall, twenty subjects in the group starting MTX and eighteen in the group starting 
SPZ had early RA (arbitrarily defined as RA duration less than twenty-four months) 
and the results for this subgroup are presented in Section 3.7.
3.3.1 Osteoporotic Risk Factors
The distribution of various risk factors for osteoporosis by group is shown in Table
3.2. Except for smoking-related risk factors, the number of subjects affected in each 
group was five or less and the distribution between groups was approximately 
equal.
No subjects had taken oral corticosteroids for any condition within eight years of the 
study apart from those with chest disease where short reducing courses more than 
six months prior to study entry were permitted. No subjects with early RA had been 
treated with intra-venous or intra-muscular steroids. Oral steroids for up to eighteen 
months had been taken by three subjects, between eight and thirteen years prior to 
study entry.
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Pack years is a useful way of expressing both the duration and intensity of smoking 
cigarettes in an individual. A person who had smoked twenty cigarettes a day (one 
pack) for five years was scored as five pack years, as was someone who had 
smoked five cigarettes a day for twenty years, or ten a day for ten years. In the 
groups continuing on their therapy, those on MTX had a higher mean smoking pack 
years score than those on other DMARDs. The number of subjects still smoking in 
each of these groups however was the same.
The group starting SPZ had higher mean weekly alcohol intake than the group 
starting MTX. This was due to one individual who had a heavy alcohol intake.
3.3.2 Menopausal Status
The menopausal status and hormone replacement therapy (HRT) use for all the 
women recruited is shown in Table 3.3. Postmenopausal women were the majority 
in each group but only a minority were taking HRT, although more had tried it in the 
past. Overall, HRT had been discussed with 40% of postmenopausal subjects by 
either their General Practitioner or Hospital Consultant.
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Hyperthyroid 0 0 2 taking T / 0
Steroid
therapy6
4 IV pulse 
1c(see below)








osteoporosis6 4 2 4 1
Previous
fracture' 4 1 3 2
Current smoker 7 9 4 4
Pack years, 
mean 7.0 10.8 15.1 10.5
Alcohol u/wk, 
median 0 1.5 0 0
Late menarche9 2 0 3 3
Early
menopause6 0 2 5 (1 surgical) 2
Nulliparous1 4 4 5 2
• Dose of thyroxine replacement was appropriate as checked by serum thyroid stimulating 
hormone (TSH) levels.
b Intra-venous (IV) or intra-muscular (IM) pulses of steroid were for RA flare and had been 
given at least six months before study entry. Steroids given for chest disease (chest dis), 
either asthma or chronic obstructive pulmonary disease, were short, rapidly reducing 
courses of oral steroids given infrequently, and at least six months before study entry.
cThis patient had less than 10mg prednisolone daily for one year for sarcoidosis, thirteen 
years prior to study entry.
d One subject had oral prednisolone between 5 and 10mg daily for RA for one year and the 
other had between 5 to 15mg prednisolone daily for eighteen months for pemphigus, 
twelve and eight years prior to study entry respectively.
e Family history of osteoporosis was taken to be present if there was a dear history of 
osteoporotic fractures in a first or second degree relative.
' Previous fracture refers to previous fragility fractures, not traumatic ones.
fl Late menarche was taken as older than fifteen years of age.
h Early menopause was taken as younger than forty-five years of age, whether natural or 
surgical.
1 Nulliparity refers to not having given birth to any live children.
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3.3.3 Rheumatoid Arthritis Therapy
The mean length of time subjects had been using their current DMARD for each 
group and the mean number of different DMARDs taken by each subject prior to 
their current drug is shown in Table 3.4. None of the group continuing MTX had 
been prescribed it as their first DMARD. Prior to 1991 when these patients started 
MTX, it was reserved for those who had failed other DMARDs. Of note are the 
seventeen subjects in the group continuing other DMARDs who were still using their 
first ever prescribed DMARD. This group were taking a variety of drugs and this is 
illustrated in Table 3.5. None of these drugs is thought to have a direct effect on 
bone.
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Table 3.4 DMARD therapy of subjects

















Starting MTX 26.0 0.5 0 - 3 25 (36)
Starting SPZ 7.8 0.1 0 -1 21 (23)
Continue




121.7 0.6 0 - 2 17(29)















IM Gold 2 1 2 3 8
D-Penicill-
amine 3 1 0 4 8
Sulpha-
salazine 1 1 1 1 4
Oral Gold 1 0 0 3 4
Hydroxy­
chloro­
quine 0 1 0 3 4
Azathio-
prine 0 0 0 1 1
Total 7 4 3 1 5 29
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3.3.4 Rheumatoid Arthritis Disease Activity
The assessment of disease activity in RA is discussed in Section 1.3.5 and the 
disease activity score (DAS) which was used in this study in Section 1.3.6.
The mean number of swollen and tender joints, mean erythrocyte sedimentation 
rate (ESR) and mean DAS for each group at baseline is shown in Table 3.6. The 
number of subjects in each group who had a normal C-reactive protein (CRP, less 
than 0.001 units/ml) and the mean CRP value for each group are also shown. 
Although the group starting SPZ contained a greater percentage of individuals with 
normal CRP (59%) than did any of the other groups, the combined DAS for this 
group was the highest. The DAS was calculated from the ESR, the tender and 
swollen 28-joint counts and the patient’s global assessment of disease activity. The 
number of subjects in each group with a low (^ 2.4), moderate (2.4 to  ^ 3.7) or high
(> 3.7) DAS at baseline and at one year is shown in Table 3.7. The majority of 
subjects had moderate or high DAS throughout the study.
108

















































































14 (48) 5.314 
± 0.889
The measurements from the two baseline visits were averaged.
* ESR: erythrocyte sedimentation rate by Westergren’s method (mm per hour). Normal values 
for up to 50 years old: male less than 10, female less than 12; for age 51 to 60: male less than 
12, female, less than 19; for over 60 years old: male less than 14, female less than 20.
** CRP: C-reactive protein. A CRP of < 0.001 was taken as zero to enable a mean value to 
be calculated.
Table 3.7 Disease Activity Score (DAS) at baseline and at one year
Group, time point / number 
of subjects
Tow  DAS (< 2.4) Moderate dAS 
(2.4 to < 3.7)
High DAS (> 
3.7)
Starting MtX  
Baseline 0 0 36
Starting MTX 
One year 0 7 28
Starting SPZ 
Baseline 0 1 21
Starting SPz 
One year 1 8 8
Continue MTX 
Baseline 0 2 27
Continue MTX 
One year 0 3 26
Continue other DMARD 
Baseline 0 2 25
Continue other DMARD 
One year 0 3 25
dropouts and failure to complete DAS in some cases
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Analysis of variance of the four groups showed that there was no difference in the 
measures of disease activity at baseline between the two groups continuing on their 
DMARD. However, those starting a DMARD had significantly higher DAS than those 
continuing on their therapy (Table 3.6). This is unsurprising as the decision to 
change or start a DMARD was related to disease activity.
When the two groups starting a DMARD were compared, only the tender joint count 
was significantly higher in those starting SPZ than in those starting MTX (Table 3.6). 
The changes in disease activity (DAS) over the twelve months of the study are 
shown in Figure 3.1 for those continuing their DMARD. The mean change in DAS 
was an increase of 0.175 units for those continuing MTX and a reduction of 0.351 
units for those continuing another DMARD. These changes were not significantly 
different from baseline (by paired t-test), nor were the differences between the 
groups (by unpaired t-test). As a difference in DAS of less than 0.6 units may have 
occurred by chance alone (Stucki, 1996), these groups were stable with regard to 
disease activity over the course of the study.
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Results are shown as the mean ±95% confidence interval
Continue MTX 
Continue other DMARD
Figure 3.2 p jsease activity score XPA.S) in subjects starting a 
DMARD















Time on DMARD in months
Results shown as mean ± 95% confidence interval. There was no difference between the 
two groups when compared by repeated measures ANOVA. There was a reduction in 
disease activity score at later time points compared to baseline (p < 0.0001).
I l l
Figure 3.2 shows the change in disease activity over two years for those starting 
MTX or SPZ. In both groups there was a significant reduction in the DAS 
compared to baseline values at each later time point (by repeated measures 
ANOVA). The mean reduction in the DAS was 1.046 for the group starting MTX 
and 1.469 units for those starting SPZ. However, there was no significant 
difference at any time point between the two groups point (by repeated 
measures ANOVA).
3.3 .5  Functional Status
The mean Health Assessment Questionnaire (HAQ) score (Section 1.3.7) and 
the mean outdoor walking score (Section 2.7.1) for the four groups at study entry 
are shown in Table 3.8. The outdoor walking score was defined according to the 
length of time spent walking outside on an average day. The responses: more 
than one hour, half to one hour, less than one hour and none, scored 4, 3, 2 and 
1 respectively. There were no significant differences between the four groups by 
ANOVA testing for either functional measurement at baseline (Table 3.8).
Table 3.8 Functional status at baseline by group




Outdoor walking score** 
(1 to 4)
Starting MTX 1.156 2.806
±0.753 ± 0.786
Starting SPZ 1.105 2.714
±0.557 ±0.784
Continue MTX 1.420 2.857
±0.829 ±0.848
Continue Other DMARD 1.244 2.714
±0.704 ±0.937
* Health Assessment Questionnaire score (Kirwan, 1986, Section 1.3.7)
** Derived from EVOS Questionnaire (O’Neill, 1995, Section 2.7.1)
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The changes in HAQ over one year are shown in Figure 3.3 for those continuing 
their DMARD and there was a mean increase in HAQ score of 0.602 in the group 
continuing MTX and 0.055 in the group continuing other DMARDs. These 
changes were not significant compared to baseline (by paired t-test) and there 
was no significant difference between the two groups at one year (by unpaired t- 
test).
Figure 3.3 Health assessment questionnaire (HAQ) in subjects  











Results shown as mean ±95% confidence interval
The serial HAQ scores over the two years for those for those starting either MTX 
or SPZ is shown in Figure 3.4 (mean reduction of 0.166 and 0.397 respectively). 
There was a significant difference between the two groups when they were 
compared by repeated measures ANOVA (p = 0.0165).
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Figure 3.4  Health assessment questionnaire (HAQ ) in subjects  
starting a DMARD
Time on DMARD in months
Results shown as mean ± 95% confidence interval. There was a significant difference 
between the two groups by repeated measures ANOVA, p = 0.0165.
Radiographic Score of Dam age
The mean Larsen scores of joint damage of the hands and wrists for the different 
groups at baseline and one year, and for elbows at one year is shown in Table 
3.9. Significant differences by analysis of variance for radiographic damage at 
baseline are shown in Table 3.10. As expected, there were significantly more 
erosions in the hands and wrists of subjects with long-standing RA (those 
continuing MTX or other DMARDs) when compared with the propesctive 
subjects. In addition, there were significantly more hand and elbow erosions in
1.6
Baseline 3
- A -  Starting MTX 
Starting SPZ
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the group continuing MTX compared to those continuing other DMARDs. This could 
reflect the fact that the MTX group had been on more DMARDs in the past and had 
all failed at least one drug, whereas the continuing other DMARD group were more 
likely to have continued on their first ever DMARD (Table 3.4). Alternatively, MTX 
may be less effective at suppressing disease progression. However, Larsen scores 
of wrist radiographs at baseline were similar in the two groups continuing their 
DMARD.
The Larsen scores for wrist and hand radiographs at one year are also shown in 
Table 3.9 and the analysis of the change over one year is shown in Table 3.11. The 
group starting MTX had a significant increase in Larsen score of the wrists 
compared with each of the other three groups, whilst the Larsen score of the hands 
significantly increased compared with the two long-term groups, but not those 
starting SPZ. Thus, MTX was less effective than SPZ in this cohort of subjects in 
preventing disease progression as measured by radiographic erosions of the wrist. 
The two groups continuing either MTX or another DMARD did not have a significant 
difference in change of Larsen score over the year of the study.
Table 3.9 Radiographic damage of hands and wrist joints at baseline 














Starting 1.65 3.03 "2.11 2.66 1.00
MTX ±1.45 ±1.56 ±1.45 ±1.47 ±1.26
Starting 1.29 TC3"".... 1.39 T.50 0.56
SPZ ±1.31 ±1.40 ±1.20 ±1.20 ±0.51
Continue "4736 3.9'6 4.39 4.07 4.39
MTX ±1.03 ±1.11 ±1.03 ±1.09 ±1.03
Continue 3.35 "3731"....... 3.57 3.50 3.57
Other
DMARD
±1.67 ±1.56 ±1.64 ±1.53 ±1.64
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Table 3.1 0 Statistical analysis of the variance of radiographic damage
(Larsen score) of the entire study group at baseline between the four
groups







































0.0143 < 0.0001 < 0.0001 < 0.0001 < 0.0001
*NS is no significant difference by analysis of variance with Fisher's Protected Least 
Significant Difference Post Hoc Testing
Table 3.1 1 Statistical analysis of the variance of the change in Larsen 
Score over one year of the entire study group







Start MTX versus 
Start SPZ
Change Larsen 
score of hands over 
first year
0.0006 0.0204 NS*
Change in Larsen 
score of wrists 
over first year
0.0004 0.0022 0.0057
*NS is no significant difference by analysis of variance with Fisher's Protected Least 
Significant Difference Post Hoc Testing
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The change in mean Larsen score of the hands and wrists and the analysis 
between the groups starting either MTX or SPZ by unpaired t-test is shown in Table
3.12. There was a mean increase in Larsen score for both groups at both sites each 
year. The greatest change was at the wrists during the first year of treatment in the 
group starting MTX (0.842) which was significantly higher than the corresponding 
change in the group starting SPZ (0.200, p = 0.0215). By the second year, however, 
the mean annual increase in the Larsen score of the wrists had fallen to 0.200 in the 
MTX group, whilst it was 0.231 in the SPZ group. The overall change from baseline 
to two years was less in the MTX group than in the group starting SPZ (0.308 
compared with 0.500, p = 0.0097). This may represent regression to the mean.
Table 3.1 2 Change in radiographic score during the study in subjects 
starting a DMARD








P value at the 95% 
confidence level by 
unpaired t-test
Hands: change from 






Hands: change from 1 






Hands: change from 






Wrists: change from 






Wrists: change from 1 






Wrists: change from 






Results shown as mean change in Larsen score ± standard deviation (n).
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3.3.7 Summary of Demographic and Rheumatoid Arthritis 
Characteristics of the Subjects
The groups of patients starting either MTX or SPZ were well-matched, especially 
when only those with RA of less than two years’ duration were considered.
The subjects continuing on MTX were different from those continuing on other 
DMARDs as in general they had RA which had been more difficult to treat, reflected 
by the greater number of erosions in the hands and elbows (though not the wrists) 
and the number of different DMARDs they had been on prior to MTX. The difference 
in erosions at the elbow was important as significant differences in some 
measurements of forearm BMD were found in the two groups continuing DMARDs 
(Section 3.6).
MTX and SPZ had similar, rapid beneficial effects on rheumatoid disease activity 
which were sustained over the period of follow-up. The reduction in DAS was 
significant compared to baseline at all subsequent time points, although the majority 
of subjects in all four groups had high DAS throughout the study period. SPZ was 
more effective than MTX in improving the functional status (HAQ) over the first year 
of treatment, but this advantage was lost by two years.
The changes in radiographic scores at the wrist and hands over one year were not 
significantly different between the two groups on long-term treatment. The group 
starting MTX did have a significant increase in Larsen score of the wrist over the first 
year of the study compared with the group starting SPZ, suggesting MTX was less 
effective in retarding disease progression at this site. However, over two years, the 
group starting MTX had significantly less progression at the wrist than the group 
starting SPZ.
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3.4  Adverse Events During the S tudy
3.4.1 Incident Fractures During the Study
There were two incident osteoporotic or fragility fractures during the study period, 
both of the humerus.
One woman who had taken MTX for five years, fractured the surgical neck of the 
humerus after a simple fall at home. She was aged sixty-nine, had suffered from RA 
for thirty-four years and was on no treatment for osteoporosis despite having 
fractured her hip in the past.
The second subject was in the group starting MTX. There was no fracture history 
and she slipped on a wet bathroom floor and fractured the distal humerus. She was 
aged fifty-six, was diagnosed with RA six years ago and had previously been 
treated with SPZ. She was taking hormone-replacement therapy having first had 
menopausal symptoms four years earlier.
3.4.2 Adverse Drug-Related Events
There were twenty-six adverse events during the study. The fourteen events which 
were recognised side effects of MTX, SPZ or other DMARDs are shown in Table
3.13, together with the numbers in each group who stopped their DMARD.
3.4.3 Adverse Events Not Related to Drugs
The twelve other adverse events which were probably not related to the DMARD 
therapy are shown in Table 3.14. The only death which occurred during the study 
was a seventy-eight year old woman who had a myocardial infarction within three 
months of starting SPZ.
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Table 3.1 3 Adverse events related to medication
Group Type of adverse event 
(number of subjects)
Number of subjects who 
stopped DMARD due to 
side effects
Starting MTX
mouth ulcers (3) 
nausea (2) 
abnormal LFTs* (1) 
hair loss (2) 
rash (1) 0
Starting SPZ
abnormal LFTs* (1) 
rash (2) 
shingles (1) 2
Continue MTX mouth ulcers (1) 0
Continue Other DMARD none 0
* abnormal LFTs were elevated serum liver function tests (transaminases) which resolved after 
one month off treatment
Table 3.1 4 Adverse events probably unrelated to medication
Group Type of adverse event 
(number of subjects)
Starting MTX
carpal tunnel syndrome (2)
ruptured Achilles tendon (1)






Starting SPZ fatal myocardial infarction (1)
Continue MTX none
Continue Other DMARD none
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3.4.4 Protocol Violations
During the period of the study subjects were followed up in their usual clinic where 
a change in medication was sometimes felt necessary on clinical grounds. A total of 
nine protocol violations occurred and are shown in Table 3.15. The most common 
change in medication was from another DMARD to methotrexate.
Table 3.1 5 Protocol violations during the first year
Group Type of violation (number of subjects)
Startinq MTX intramuscular steroid for flare of RA (1)
Startinq SPZ




changed to MTX (2)
intravenous steroid for flare of RA (1)
3.4.5 Changes in Therapy Which Could Affect Bone
Patients and General Practitioners also made changes in medication which may 
have had an effect on bone. These are shown in Table 3.16. The subject who took a 
Chinese medication was unable to discover the content other than “herbs” but was 
told that it did not contain corticosteroids. She had symptomatic, rapid relief from the 
preparation. There have been reports of Chinese medication containing undeclared 
non-steroidal anti-inflammatory drugs and benzodiazipines (Gertner et al, 1995).
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Table 3.1 6 Change in medication during study which mav affect bone
Group Medication (number of subjects)
Startinq MTX took Chinese medicine for 2 months (1)
Startinq SPZ started hormone replacement therapy (1)
Continue MTX started thiazide for hypertension (2)
Continue Other DMARD none
3.4.6 Dropouts and Failure to Attend Study Visits
There were five dropouts (4.4%) from the study after the baseline visit. Four were in 
the group starting SPZ. A woman died from a myocardial infarct between the first 
two baseline visits and the three month visit. A man failed to attend after the three 
month visit and could not be traced despite phone calls, letters and contacting his 
GP. He had probably moved back to Ireland. Another woman decided that she did 
not want to participate further in the study after the baseline visits, although she was 
happy to continue on SPZ. A woman who had failed to tolerate SPZ due to side 
effects of nausea and vomiting, failed MTX after one month with the same symptoms 
and was treated subsequently with intra-muscular gold did not attend the one year 
visit.
A woman in the group continuing a DMARD other than MTX was unable to attend 
the appointment at one year due to chronic obstructive pulmonary disease requiring 
continuous oxygen therapy.
Finally, a woman in the group starting MTX failed to attend the three month 
appointment but was seen at six months and at one year.
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Data where available on those subjects who dropped out was included in the 
analysis.
3.4.7 Missing Data
A total of sixteen serum samples could not be found to analyse and sixteen urine 
samples were all used up in the HPLC preparation and could not therefore be 
analysed by ELISA.
Three urine samples were not brought for study visits and one patient left before 
having his blood taken.
The radiograph packets for two subjects were lost and thus could not be scored.
Hip BMD measurements could not be obtained in one subject in the continuing MTX 
group as she had had bilateral hip replacements.
It was not possible to position the forearm for bone densitometry in some patients 
with severe rheumatoid elbow or shoulder disease. Forearm BMDs could not be 
obtained in one subject in the continuing MTX group and two subjects in the 
continuing Other DMARD group.
3.5 Resuits of the Whole Cohort
3.5.1 Bone Mineral Content, Bone Mineral Density and Bone Mineral 
Density Z Score of All Subjects at Baseline
The mean bone mineral content (BMC, g) of the four groups for each of the regions 
scanned is shown in Table 3.17. The bone mineral density (bone mineral content 
expressed as areal density, BMD, g/cm2) and BMD expressed as standard
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deviations from the age- and sex-matched normal reference data (Z scores) are 
shown in Tables 3.18 and 3.19 respectively.
















n = 29 #
63.47* (a) 61.31 54.85* (a) 60.45
Lumbar spine ± 15.83 ± 13.74 ± 16.81 ± 15.65
Neck of 4.01* (b) 3.91 3.53* (b) 3.77
femur ± 0.89 ± 0.77 ± 1.12 ± 0.75
7.97 7.85 7.14 7.84
Trochanteric ± 2.46 ± 2.68 ± 2.10 ± 2.49
Inter­ 20.16 20.29 19.49 20.34
trochanteric ± 6.27 ± 5.68 ± 8.95 ± 6.45
0.71** (c) 0.72** (d) 0.55** (c, d) 0.63
Ward’s region ± 0.23 ± 0.19 ± 0.24 ± 0.19
32.14 32.04 30.17 31.94
Total hip + 9.31 ± 8.77 ± 11.09 ± 9.29
Proximal third 3.50* (e) 3.54* (f) 2.97* (e, f) 3.48
forearm ± 0.83 ± 0.89 ± 1.26 ± 1.02
Mid-portion 6.72 7.18* (g) 5.51* (g) 6.88
forearm ± 2.10 ± 2.61 ± 2.97 ± 2.70
Ultra-distal 2.24 2.28 1.93 2.23
forearm ± 0.68 ± 0.65 ± 0.79 ± 0.69
12.46 13.01* (h) 10.40* (h) 12.59
Total forearm ± 3.54 ± 4.07 ± 4.94 ± 4.33
Analysis by ANOVA with Fisher's Protected Least Significant Difference post hoc testing
* p < 0.05, ** p < 0.01, a, b, c etc. identify the groups with significant differences.
# There was no hip or forearm scan available for one subject in the continue MTX group and 
two subjects in the group continuing other DMARDs group (Section 3.8.7).
There were no significant differences in BMC at any site between the two groups 
continuing on their DMARD (either MTX or other DMARD, Table 3.17) or the two 
groups starting either MTX or SPZ (result not shown). However, the BMC was
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significantly lower in the group continuing MTX than in those starting MTX at the 
lumbar spine, neck of femur, Ward’s area of the hip and the proximal third of the 
forearm (radius and ulna combined). The BMC of the long-term MTX group was also 
lower than the group starting SPZ at Ward’s area of the hip, and the proximal third, 
mid-portion and total forearm measurements (radius and ulna combined).













































































































































0.458* (ac) / ** 
(aa.ab) f  0.139
0.522* (ac) 
± 0.103
Analysis by ANOVA with Fisher's PLSD post hoc testing.
* p < 0.05, ** p < 0.01, *** p < 0.001; a, b, c etc. identify the groups with significant differences.
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Table 3.19 Bone mineral density expressed as the Z score of the













































































































































Analysis by ANOVA with Fisher's PLSD post hoc testing
Z score is the bone mineral density expressed as standard deviations above (positive 
vaiues) or below (negative values) the mean value of an age- and sex-matched reference 
population (Section 1.2.5).
* p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.0001. a, b, c etc. identify the groups with 
significant differences.
BMD estimates for the group continuing MTX were significantly lower than the 
group starting MTX at all sites except the ultra-distal portion of the forearm (for
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the radius and ulna combined, and the radius alone). The values in the long-term 
MTX group were also significantly lower than in the group starting SPZ for many 
sites (Table 3.18). This may reflect the longer duration of RA and the older age of 
the cohort on long-term MTX compared to subjects starting a DMARD. However, 
there were also significant differences between the group continuing MTX when 
compared to those subjects who were continuing a different DMARD from MTX 
although these groups were well-matched for age and disease duration (Section 
3.3). The BMD of the forearm (except for the ultra-distal portion) was significantly 
lower in the group on MTX compared to those taking other DMARDs and the 
differences became highly significant (p < 0.0001) in the proximal third portion when 
BMD was corrected for age and sex (Z score, Table 3.19). These differences may be 
partially explained by the increased Larsen scores of the elbows in the group 
continuing MTX (Section 3.3.6), but was an unexpected finding.
Many of the significant differences in BMD measurements between the long-term 
MTX group and those starting MTX or SPZ were no longer significant when the Z 
score was considered, confirming that they were due to age differences between 
the groups (Table 3.19).
3.5.2 Change in Bone Mineral Density of All Subjects Over One Year
The percentage changes in bone mineral density (BMD) over the first year of the 
study are shown in Table 3.20. The percentage changes in BMD are shown in 
Figures 3.5 to Figures 3.10 for the regions where the differences by group reached 
significance at the 95% confidence level.
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Table 3.2 0 Percentage change in bone mineral density of all subjects
over one year.
% change in BMD 
Mean ± standard 
deviation




























































































































Analysis by ANOVA with Fisher’s Protected Least Significant Difference post hoc testing
* p < 0.05, ** p < 0.01, *** p < 0.001, a, b and c etc. identify the groups with significant
differences
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Figure 3.8 Change in proximal third forearm bone m ineral density over 
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Starting MTX 
Starting SPZ
Results shown as mean percentage change ± 95% confidence interval
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Figure 3.9 C hange in ultra-distal forearm bone m ineral density over 
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Results shown as mean percentage change ±95%  confidence interval
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The mean bone mineral density of the lumbar spine increased in the group 
continuing on MTX whilst it decreased in the other three groups (Table 3.20). The 
greatest loss was in the group starting MTX where the mean loss was 1.5%. There 
were significant differences between the group continuing MTX and each of the 
groups starting a DMARD but not between the two groups continuing on their 
DMARD (Table 3.20 and Figure 3.5). The loss of bone mass in the lumbar spine in 
early RA has been described previously (Shenstone et al, 1994; Gough et al, 1994). 
The increase in lumbar spine BMD seen in the group continuing MTX may be due to 
degenerative changes.
There were no significant inter-group differences in the rate of annual change of 
BMD for the trochanteric, inter-trochanteric or total hip measurements (Table 3.20). 
The group starting MTX had significantly more bone loss at the neck of femur site 
than each of the two groups continuing on their DMARD and the mean BMD actually 
increased in both these groups. However there was no difference in the rate of 
change between the group starting MTX and the group starting SPZ (Table 3.20 
and Figure 3.6). Similarly, the group starting MTX had more bone loss from Ward’s 
area and this reached significance only when compared with the two long-term 
groups (Table 3.20 and Figure 3.7).
The only significant difference in bone loss between the group starting MTX and the 
group starting SPZ was found in the proximal third of the forearm (for the radius and 
ulna combined, Table 3.20 and Figure 3.8). This is the same site where highly 
significant differences had been found at baseline between the two groups which 
had been on long-term DMARD treatment. In addition, compared to the group 
continuing MTX, the group starting MTX had sustained significantly more bone loss
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from the ultra-distal (Figure 3.9) and total forearm (Figure 3.10) regions, again for 
the ulna and radius combined.
These results, taken together with the baseline Z score analysis (Table 3.19), 
suggested that MTX therapy was associated with increased bone loss from the 
forearm, particularly the proximal third region. The increased loss occurred early 
rather than later in treatment with MTX, as subjects continuing on MTX no longer 
had excess bone loss from this site.
3.5.3 Markers of Bone Turnover of All Subjects at Baseline
The mean baseline levels of serum osteocalcin (OC), bone specific alkaline 
phosphatase (AP) and urinary deoxypyridinoline corrected for urinary creatinine 
(Dpd) for the four groups are shown in Table 3.21. The mean results from the two 
baseline visits a fortnight apart are given. There were significantly higher mean 
values of the markers of bone formation (OC and AP) in the group which had been 
on MTX for at least five years when compared with the other three groups. There 
were no significant differences between groups for the marker of resorption (Dpd).
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Analysis by ANOVA with Fisher's PLSD post hoc testing
* p < 0.05, ** p < 0.01, *** p < 0.001, a, b, c etc. identify the groups with significant differences.
3.5.4 Change in Markers of Bone Turnover of All Subjects Over One 
Year
The percentage change in the markers of bone turnover from mean baseline values 
over the year of the study for the subjects continuing their DMARD are shown in 
Figure 3.11 for OC, Figure 3.12 for AP and Figure 3.13 for Dpd. The changes were 
compared by unpaired t-test and the only significant difference was in mean AP. 
The group continuing MTX mean AP value decreased by 11% whilst it increased by 
5% in the group continuing other DMARDs (p = 0.0198).
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Results shown as mean percentage change from baseline ±95% confidence interval


































Results shown as mean percentage change from baseline ±95%  confidence interval
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Results shown as mean percentage change from baseline ±95% confidence interval
For the subjects starting MTX or SPZ, the percentage change from baseline over 
the first two years of treatment are shown in Figure 3.14 for OC, Figure 3.15 for 
AP and Figure 3.16 for Dpd.
The two groups were compared by repeated measures ANOVA, with the different 
time point measures included as a compact variable. There were no significant 
differences between the two groups by this analysis for any of the bone turnover 
measures, suggesting MTX has no effect on OC, AP or Dpd in these subjects.
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Figure 3.14 Serum osteocalcin in subjects starting a DMARD









Results are shown as mean percentage change from baseline ± 95% confidence interval. 
The groups were compared by repeated measures ANOVA.
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Time on treatment in months. Groups were compared by repeated measures ANOVA.






Time on treatment in months. Groups were compared by repeated measures ANOVA.
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3.6  Results of P ostm enopausal W om en
Postmenopausal women are at greatest risk of osteoporosis and so, if MTX has an 
adverse effect on bone, this is the group in which it could be expected to be seen. 
The BMD at any given time and site is influenced by many factors which are often 
not truly independent. In RA, disease duration and disease activity interact to 
produce damage (erosive changes on radiographs) but the nature of the 
relationship between these factors is not known. In a postmenopausal woman, the 
BMD will depend on both how much bone mass was lost in the immediate 
postmenopausal period but also on what peak bone mass she had attained in her 
youth. The peak bone mass is influenced by genetic and environmental factors, 
such as diet and exercise.
Due to the numbers in each group (only nine subjects starting SPZ), it was not 
possible (or desirable) to enter every variable on which data had been collected 
into the model. A much larger, multi-centre study design would be required for such 
an analysis. The factors which are known to have the greatest impact on BMD, both 
from population studies and a survey of the data in this study, were chosen and 
included in the multiple regression model.
Dr Daphne Kounali (School of Maths, University of Bath) undertook the statistical 
analysis of this group. The BMD for the different regions was expressed as the Z 
score (standard deviations from the age-appropriate mean) and the change in BMD 
as percentage change in Z score which removed the requirement for age as an 
independent variable. In the analysis of the markers of bone turnover, however, age 
was a covariate.
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3.6.1 Statistical Methods Applied to the Dataset of Postmenopausal 
Women
The many different variables on which data had been collected were studied and 
plotted out for the different groups. There were no differences found between the 
groups in many of the life-style variables such as diet, exercise, smoking and other 
features such as family history. Trends were noted such as smokers tended to have 
lower BMD and subjects who were more physically active, both now and in the past, 
tended to have higher BMDs. The variables which were studied and not included in 
the regression analysis are shown in Table 3.22.
Table 3.2 2 Variables studied and not included in the regression  
analysis
Family history ot osteoporosis 





Use ot thiazide diuretics




The variables found to strongly influence BMD were: the duration of rheumatoid 
arthritis (disease duration), the menopausal age (number of years since the onset of 
the menopause), the body mass index (BMI), and the disease activity at baseline 
(DAS, Section 1.3.6). The Larsen x-ray score of the hand, wrist and elbow and the 
changes in hand and wrist x-ray scores over the year were also used in the model 
as covariates. Due to the small number of subjects, the Larsen scores were 
dichotomised into ‘low’ and ‘high’ scores, where ‘high’ was any score greater than 
zero. This enabled the Larsen score to be used as a nominal variable. Similarly, the 
change in Larsen score over the year was coded as ‘O’ for no change (increase) 
and as ‘1’ for any increase. In practice, no subject had an increase of more than one 
in Larsen score at any site, and no subjects had an improvement (reduction) in 
Larsen score.
The confounding factors which were used as the covariates in the analysis are 
shown in Table 3.23.
Table 3.2 3 Confounding factors (covariates) used in the analysis
Duration of RA (months)
Disease activity (DAS)
Body mass index (kg/m2)
Menopausal age (years)
Baseline hand x-ray score 
Change in hand x-ray score 
Baseline wrist x-ray score 
Change in wrist x-ray score 
Baseline elbow x-ray score
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Factorial analysis of variance (ANOVA) and repeated measures analysis of 
variance was performed. Duncan’s multiple range test was used to examine 
multiple comparisons between the four groups (Barnett, 1982). When the 
assumptions needed for analysis of variance were violated, such as normality and 
homogeneity of variance, either Friedman’s non-parametric test was used, or the 
data were log-transformed prior to ANOVA (Conover, 1980).
Multiple regression analysis was used to examine apparent effects of MTX on BMD 
(Section 3.6.4). The potentially confounding covariates above in Table 3.23 were 
entered into the model (McCullagh et al, 1984).
To test the strength of association between nominal variables Mantel-Haenszel chi- 
square test was used and Fisher’s exact test was employed when relatively small 
cell sizes were found (Everitt, 1984).
Finally, discriminant analysis was used to identify which measurements were 
important for distinguishing among treatment groups using a multivariate approach 
(Tatsuoka, 1971).
3.6.2 Unadjusted Results of Postmenopausal Women
The primary outcome measures were the BMD Z score and the change in BMD Z 
score over one year and the results of the analysis of these unadjusted 
measurements by ANOVA are shown in Table 3.24 and Table 3.25.
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Table 3 .24 Baseline unadjusted BMD Z score
Starting MTX Starting
SPZ




Spine BMD Z 
score














Baseline Neck of 


































































































Results are shown as the mean ± standard deviation of the mean, [95% confidence interval for 
the mean], (n). ‘Significant differences between the groups, p < 0.05. a, b, c etc. identify the 
groups with significant differences.
Of note, although the mean values of BMD at all sites were lower in the group 
continuing MTX compared to the group on other DMARDs, these differences were 
not significant. This is despite the significant differences observed in the data for all 
subjects (Table 3.19). There were no differences between the two groups starting a 
DMARD. The group continuing MTX did have significantly lower Z scores than one
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or other, or both, the groups starting a DMARD for each region except the total hip 
and ultra-distal forearm regions.
The unadjusted percentage change in BMD expressed as Z score over the first year 
of the study is shown in Table 3.25.
Table 3.2 5 Unadjusted percentage change in BMD Z score of 
postmenopausal women
Starting MTX Starting SPZ Continuing M ix Continuing Other 
DMARD

























































































































Results are shown as the mean ± the standard deviation of the mean, [95% confidence interval 
for the mean], (n). * Significant differences between the groups, p < 0.05 (*). (a) and (b) 
identify groups with significant differences.
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There were significant inter-group differences identified only for the change in total 
forearm BMD Z score (Table 3.25). Those continuing MTX therapy had significantly 
greater bone loss at this site (23%) than each of the groups starting treatment. The 
mean percentage loss was greatest in those continuing other DMARDs (a reduction 
of 184.82% in Z score), but the confidence interval was very wide reflecting 
heterogeneity in the group.
The results of the markers of bone turnover (secondary outcome measures) by 
group are presented in Table 3.26.
Table 3.2 6 Unadjusted markers of bone turnover





























































































Results are shown as the mean ± standard deviation of the mean, [95% confidence interval for 
the mean], (n). Analysis by ANOVA. Significant differences are described in the text below.
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There were significant decreases in all groups between the mean baseline and one 
year values for both markers of bone formation, serum osteocalcin and bone 
specific alkaline phosphatase. The group continuing MTX had significantly higher 
mean values of the bone formation markers than either the group starting SPZ or 
the group continuing on other DMARDs.
3.6.3 Association of Confounding Factors Between Groups
Due to the study design, the groups differed in some factors such as disease 
duration and the distribution of the confounding factors between the groups is 
shown in Table 3.27.
Table 3.2 7 The difference between groups with regard to confounding 
factors




‘Duration of RA 
(years) 6.18 ±5.8 1.37 ±1.14 15.3 ±5.89 17.07 ±6.85
‘Disease activity 
(DAS) 5.7 ±0.9 5.9± 0.8 5.5 ±0.77 5.7 ±0.73
‘Body mass 
index (kg/m2) 24.56 ±5.48 23.92 ± 3.57 25.3 ±4.18 23.89 ±3.89
‘ Menopausal age 
(years) 14.83 ±9.57 21.77 ±11.5 19 ± 10.2 13.7 ±6.01
ABaseline hand x- 
ray score 1 / 14 1 / 7 0 / 1 9 0 / 1 5
#Change in hand 
x-ray score 10/ 5 5 / 1 18/1 12 / 2
ABaseline wrist x- 
ray score 2 / 1 3 0 / 1 9 0 / 1 9 0 / 1 5
#Change in wrist 
x-ray score 7 /8 5 /1 18/1 12 / 2
ABaseline elbow 
x-ray score 4 /8 1 / 5 3 / 16 1 / 13
‘ Mean ± standard deviation of the mean shown. AThe number with low / high (> 0) Larsen 
scores are given for the baseline x-ray scores, and # the number with ‘no change in x-ray 
score’ / ‘increase in x-ray score’ are given.
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The relationship between the two confounding factors ‘disease duration’ and ‘x-ray 
score’ was examined and the results shown in Table 3.28. Unsurprisingly, those 
subjects who have had RA for a longer time had been treated with a DMARD for 
longer. However, when the x-ray score of the groups was controlled for, differences 
emerged in the duration of RA between those subjects who had been treated with 
MTX or other DMARDs. Disease severity (as judged by x-ray score) interacted with 
duration of treatment. In the groups continuing on their DMARD (having been 
treated for a minimum of five years with either MTX or Other DMARDs), if the x-ray 
score was high, those on MTX had been treated for less time than those on other 
DMARDs. However, if the x-ray score was low, the MTX group had been treated for 
longer than those on other DMARDs. This suggests that MTX does indeed have a 
DMARD rather than purely anti-inflammatory role, as longer treatment was 
associated with lower x-ray scores. In the groups starting treatment with MTX, they 
had been treated for a longer time for RA than had those starting SPZ (reflecting the 
smaller proportion of ‘early RA’ subjects in the group starting MTX). When subjects 
with high x-rays scores were studied, they had been treated for a longer time in the 
group starting MTX than in the group starting SPZ. Thus, in Table 3.28, those on 
other DMARDs have higher x-ray scores (departure from the mean, 4.39) than those 
continuing on MTX (departure from the mean, 3.33). However, in subjects starting 
MTX, they are more likely to have a higher mean x-ray score than those starting 
SPZ (departure from the mean -4.70 versus -11.41). This is in keeping with the 
results of Larsen scores and the change in Larsen scores described for the cohort 
as a whole (Section 3.3.6).
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Table 3.2 8 In teraction of disease duration and disease severity 
(radiographic score)













Baseline hand x-ray score 4.39 0
-0.20 1
Change in hand x-ray score -0.12
0.76 1
Baseline wrist x-ray score -0.92 0
0.04 1
Change in wrist x-ray score 0.52 0
-1.89 1
Baseline elbow x-ray score -5.20 0
1.11 1
* due to treatment effect adjusted for disease severity.
3.6.4 Multiple Regression Analysis
This statistical method was used to re-appraise the potential treatment effect of MTX 
on the presence of the covariates. The differences in the magnitude of the log- 
transformed baseline BMD Z scores after adjustment for significant covariates is 
shown in Table 3.29 and the change in BMD Z score presented in the same way in 
Table 3.30. Significant differences were found after adjustment in the baseline neck 
of femur BMD Z score (p = 0.0027) and marginally significant differences in the 
proximal third and mid-portion forearm Z scores (p = 0.06 and 0.07 respectively, 
Table 3.29). There were also significant differences at these three sites and the total 
forearm site in the percentage change in Z score over one year (Table 3.30).
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Table 3.29 Baseline differences in BMD Z scores accounting for significant covariates
BMD Z score 
magnitude (log- 
transformed)






C3rand mean -0.5 -0.41 -0.41 -0.05 0.11 -0.12 -0.48
Main effect 

















































Sign of score 0.15 -0.0b 0.19 0.03 *0.094 0.03 0.02
Body mass index -0.03 -0.03 -0.05 -0.02 -0.14 -0.03
Disease duration -0.01 0.03 0.03 *-0.007 0.02 *-0.06 0.03
Menopausal age 0 -0.01 -0.02 0.04 0.01 0.03 0.03
Disease activity 0.12 -0.03 0 *0.204 1.03 0.16 -0.27
Baseline hand x-ray 
score
1.15 ’'0.196 -0.22 -1.24 -0.69 -1.17 0.64
Baseline wrist x-ray 
score
0.16 2.57 0.45 -0.32 -0.05 -0.46 -0.71
Baseline elbow x- 
ray score
-0.35 0.7 0.23 -0.38 0.69 -0.15 -0.34
* Significant covariates which contribute to the significant differences
Table 3.30 Change in BMD Z scores accounting for significant covariates











Grand mean 1.22 3.14 3.14 "3!19 2.8b 3.04 3.19
Main effect 
















































Sign of score -01)3 ' DV23 -0.03 0.3b 0.35 -0.28 -0.05
baseline value *-0.339 *-0.96l *-0.77'/ "*-'1.042 *-1.255 *0.942 --0.73b
Body mass index U.U2 0.05 *0.083 "*0.117 -0.091 -0.252 0.08
Menopausal age --0.0O5 *-0.012 *0.002 ^0.030 "*0.026 --0.O47 --0.O57
Disease duration -0T01 -O.Ob -0.01 "TJ.06 -0.03 -0.0O7 *0.006
Baseline osteocalcin O.Ob *0.0b 0.04 *0.059 -0.03 -0.02 0
Baseline alkaline 
phosphatase
*0.006 0 0.01 *0.017 0.01 -0.02 -0.02
Baseline hand x-ray 
score
-0.32 -0.77 0.47 1.5 1.34 1.96 -0.66
Baseline elbow x-ray 
score
0.432 .239 0.3b -O.Ob *-1.7588 -0.59 -0.02
* Significant covariates which contribute to the significant differences
Table 3.31 Baseline differences in bone turnover markers accounting
for significant covariates






Grand mean 12.1 26.96 9.32
Main ettect
(departure from the mean) 





















Age 0.16 -0.17 *-0.034
Body mass index 0.06 0.5 0.25
Disease duration 0.05 0.03 *0.052
Menopausal age 0.03 -0.37 0.15
Disease activity 0.08 3.79 0.87
Baseline hand x-ray score -2.77 " 17.81 *-7.64
Baseline wrist x-ray score 0.14 -8.75 5.19
Baseline elbow x-ray score -1.1 -7.31 *4.66
Table 3.3 2 Change in markers of bone turnover accounting for 
significant covariates






Grand mean 10.3 22.77 9.51
Main ettect
(departure from the mean) 





















Baseline value *0.648 *0.487 *0.089
Age *0.053 *-0.021 *-0.045
Body mass index ^ o :r...... -0.41 0.32
Disease duration -0.07 *0.099 -0.04
Menopausal age -0.07 -0.3 *0.015
Disease activity 0.11 0.46 *1.368
Baseline hand x-ray score -0.60 *11.678 *-7.309
Baseline wrist x-ray score 3.35 *4.148 *6.816
Baseline elbow x-ray score 1747 1.24 *-5.553
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The difference in the magnitude of the log-transformed baseline bone turnover 
markers and change in bone turnover markers after similar adjustment are shown in 
Tables 3.31 and 3.32 respectively. The baseline OC and percentage change in AP 
were significantly associated with MTX treatment. For the changes in markers of 
bone turnover baseline values and age were significant covariates for all three 
markers.
3.6.5 Discriminant Analysis
In the discriminant analysis, variables were analysed at the same time, not 
sequentially, as in multiple regression analysis. The relationships between 
variables could then be included in the model. This was important as the factors 
contributing to the bone loss associated with RA were not independent. For 
example, a subject who has had the disease for longer is more likely to have a 
higher Larsen score. In discriminant analysis, a linear combination of the 
independent variables is developed, using group membership (in this situation, 
treatment group) as the dependent factor. The information contained in multiple 
independent variables is summarised by a single index, by finding a weighted sum 
of the dependent variables. The weights are estimated so as to result in the ‘best’ 
(or furthest) separation of the different treatment groups.
In Table 3.33, the variables were ranked depending on their relative importance in 
correctly predicting the group membership of any particular Z score. When the 
model was applied back to the data set, it correctly categorised 97.56% of cases 
(only one case was incorrectly categorised).
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Table 3.34 depicts the correlation between the values of the discriminant functions 
and the original variables to enable an assessment of the contribution each makes 
to the discriminant function.
Table 3.3 3 Standardised canonical discriminant function coefficients 
(with baseline values)
Function 1 Function 2 Cumulative 
percentage of 
variance explained
Baseline hand x-ray score 0.53 -0.85
Baseline wrist x-ray score 1.01 0.94
Baseline prox 1/3 FA BMD -1.62 -2.01 77.64%
Baseline mid-portion FA BMD 0.58 1.89
Baseline osteocalcin 0.69 0.43
Disease duration 1.02 -0.36
Baseline lumbar spine BMD -0.64 -0.79
Baseline alkaline phosphatase 0.12 0.05
Baseline ultra-distal FA BMD -0.21 -0.34
Change total FA BMD 0.01 0.81 94.23%
Change ultra-distal FA BMD 0.84 0.02
Change mid-portion FA BMD 0.75 0.46
Baseline neck of femur BMD -1.22 -0.37
Change neck of femur BMD -0.1 0.07
Change total hip BMD 0.68 0.61
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Table 3.3 4 C orrelations between discriminating variables and the 
canonical discriminant functions (with baseline values!
Function 1 Function 2
Baseline hand x-ray score 0.34
Baseline wrist x-ray score 0.22
Baseline prox 1/3 FA BMD -0.22
Baseline mid-portion FA BMD -0.19
Baseline osteocalcin 0.18
Disease duration -0.29
Baseline lumbar spine BMD -0.23
Baseline alkaline phosphatase 0.19
Baseline ultra-distal FA BMD -0.18
Change total FA BMD 0.17
Change ultra-distal FA BMD -0.15
Change mid-portion FA BMD 0.15
Baseline neck of femur BMD -0.12
Change neck of femur BMD 0.11
Change total hip BMD 0.08
From the discriminant analysis, the factors which explained most of the observed 
variation were found to be the following: baseline hand and wrist x-ray scores, 
baseline osteocalcin and baseline mid-portion forearm BMD. Elbow scores were 
not discriminatory as they were high in most subjects. Subjects on MTX were more 
likely to have higher hand and wrist x-ray scores, higher baseline osteocalcin and 
lower baseline mid-portion forearm BMD score. This held for the subjects who were 
starting MTX as well as those continuing MTX. After duration of treatment with MTX 
or other DMARDs was controlled for, the baseline proximal third forearm BMD 
emerged as a discriminant factor, suggesting that long-term MTX therapy is
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associated with reduced BMD in this site even after correction for all the 
confounding factors listed above.
Overall, the statistical analysis showed that the best discriminators between 
subjects treated with MTX and those treated with other DMARDs were the baseline 
hand and wrist x-ray scores, the baseline osteocalcin level and baseline BMD, 
especially of the mid-portion of the forearm (Tables 3.33 and 3.34). Analysis of 
covariance suggested that differences between groups existed in BMD of the neck 
of femur and baseline osteocalcin and may be present at the forearm sites of mid­
portion and proximal third in addition (Tables 3.29 and 3.31). The changes in BMD 
or markers of bone turnover were greater in those continuing on MTX than other 
DMARDs, but less in those starting MTX than SPZ (Tables 3.30 and 3.32).
Many of the changes in BMD at skeletal sites which at first appeared significant, 
were explained by baseline differences in BMD between the groups. This held for 
the following sites: lumbar spine, neck of femur, ultra-distal, proximal third and total 
forearm. Both the proximal third and total forearm changes in BMD were strongly 
correlated with the elbow x-ray score, suggesting disease activity rather than a toxic 
effect of MTX is important here.
Thus, the only BMD site where the changes were large enough to overcome the 
baseline differences between groups was the mid-portion of the forearm, where 
MTX treatment was associated with significantly greater loss in BMD.
3.7 Results of Subjects with Early Rheumatoid Arthritis
In this section, the results for subjects with rheumatoid arthritis of less than two 
years’ duration are presented. The distribution of the early RA subjects by sex and
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menopausal status between the groups starting MTX and SPZ is shown in Table 
3.35. By one year, the number in the SPZ group had decreased to sixteen as there 
had been one death and one subject was lost to follow-up (Section 3.4). All subjects 
with early RA were invited for a final visit two years after they started their drug and 
sixteen subjects in the MTX and thirteen in the SPZ group attended. Of these, fifteen 
subjects in the MTX group and twelve subjects in the SPZ group underwent lateral 
lumbar spine estimation at both the one and two year time points.












MTX 3 7 4 6 20
Starting
SPZ 5 2 4 7 18
The mean Larsen scores for the hand, wrist and elbow radiographs of the subjects 
with early RA are shown in Table 3.36 and Figures 3.17 and 3.18 below.
Table 3.3 6 Larsen scores of subjects with earlv rheumatoid arthritis
Mean ± standard deviation (n) Starting MTX Starting SPZ
Baseline Hand Larsen Score 0.79 ±0.42 (19) 1.00 ±1.22 (17)
Baseline Wrist Larsen Score 1.05 ±0.71 (19) 1.18 ± 1.33 (17)
1 Year Hand Larsen Score 1.37 ±0.68 (19) 1.13 ± 1.06 (15)
1 Year Wrist Larsen Score 1.89 ±1.10 (19) 1.20 ±1.01 (15)
2 Year Hand Larsen Score 1.87 ±0.83 (15) 1.50 ±1.17 (12)
2 Year Wrist Larsen Score 1.93 ±1.22 (15) 1.50 ± 1.17 (12)
Elbow Larsen Score 0.59 ±0.62 (17) 0.47 ±0.52 (15)
No significant differences between the two groups at any time point by unpaired t-test.
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Baseline 2 year1 year
Results shown as the mean score ± 95% confidence interval. Analysis by paired t-test: 1 year 
compared with baseline, p = 0.0041 for MTX, p = 0.0406 for SPZ; 2 years compared with 
baseline, p = 0.0001 for MTX, p = 0.0261 for SPZ.













Baseline 2 Year1 Year
MTX
SPZ
Results shown as the mean score ± 95% confidence interval. Analysis by paired t-test: 1 year 
compared with baseline, p = 0.0012 for MTX, not significant for SPZ; 2 years compared with 
baseline, p = 0.0104 for MTX, not significant for SPZ.
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3.7.1 Bone Mineral Density Z Score of Subjects with Early 
Rheumatoid Arthritis at Baseline
The bone mineral density Z score of subjects with early RA at entry to the study is 
shown in Table 3.37. None of the areas scanned was significantly different 
between groups at baseline by repeated measures ANOVA, confirming that the 
two groups were well-matched.
Table 3.37 Bone mineral density expressed as the Z score of 
subjects with early rheumatoid arthritis at baseline







Lumbar spine ±1.350 ±1.067
-0.012 -0.139
Neck of femur ±1.342 ±0.830
0.307 0.130
Trochanteric ±1.492 ±0.976
T).’2 i i' -0.015
Inter-trochanteric ±1.357 ±0.691
0.412 0.396
Ward’s reafon ±1.399 ±0.944
0.132 0.013
Total hip ±1.344 ±0.708
Proximal third forearm "07377............ 0.348
±1.231 ±1.250
Mid-portion forearm -0.029 0.217
±1.319 ±1.275
Ultra-distal forearm -07064 -0.077
±1.220 ±1.143
0.061 0.194
Total forearm ±1.287 ±1.268
Proximal third radius "0295 ........ 0.384
±1.243 ±1.197
Mid-portion radius -0.164 0.157
±1.346 ±1.129
-0.067 ' 0.034
Ultra-distal radius ±1.189 ±1.167
-0.053 0.182
Total radius ±1.291 ±1.191
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3.7 .2  Change In Bone M ineral Density of Subjects with Early 
Rheumatoid Arthritis
The mean changes in percentage of BMD measurements in the subjects with 
early rheumatoid are shown in Table 3.38.
During the first year, the group starting MTX lost a greater percentage of BMD at 
all sites studied than did the group starting SPZ. However, the difference in 
percentage loss between groups was not significant by repeated measures 
analysis of variance (ANOVA). The standard deviations for all the sites were 
large, reflecting the heterogeneity of rates of bone loss within the groups.
The changes in mean percentage of BMD between baseline and two years and 
between the one and two year time points are also shown in Table 3.38. There 
were no significant differences in the changes between the two groups at any of 
the sites measured. Whereas during the first year of treatment the MTX group 
had mean bone loss at all sites (negative values of the percentage change), 
during the second year of treatment there was mean increase at all sites except 
the proximal third (radius and ulna) and all the radius alone measurements. 
From baseline to the two-year time point, the MTX group had a greater loss of 
bone than the group starting SPZ at ail sites except at Ward’s area and the ultra- 
distal regions of the forearm (radius alone, and radius and ulna combined). Of 
note, in the proximal third regions (radius alone, and radius and ulna combined), 
the group starting SPZ had overall gain in BMD whilst the group starting MTX 
had a loss. These differences did not reach significance by repeated measures 
ANOVA.
During the first year, the group starting SPZ had suffered less mean bone loss at 
each site than the group starting MTX. However, over the second year of 
treatment, the mean percentage loss in the SPZ group was greater than in the
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MTX group at the following sites: neck of femur, inter-trochanteric, Ward’s area 
and the total hip, and in the forearm, the ultra-distal and total forearm 
measurements for the radius and ulna combined. At the proximal third forearm 
site, a mean loss of 0.26% in BMD occurred in the MTX group, compared with a 
gain of 0.1% in the SPZ group.
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Table 3.38 Mean percentage change of bone mineral density of

























































































































































































































There was no significant difference between the groups Starting Methotrexate and Starting 
Sulphasalazine by repeated measures ANOVA.
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3.7.3 Markers of Bone Turnover of Subjects with Early Rheumatoid 
Arthritis at Baseline
The pre-treatment values of the bone markers osteocalcin (OC), bone specific 
alkaline phosphatase (AP) and urinary deoxypyridinoline corrected for creatinine 
(Dpd) are given in Table 3.39. The values of OC were similar in the two groups, the 
AP in the group starting MTX was higher than in the group starting SPZ, but the 
difference between the groups was not significant. There was a significantly higher 
mean Dpd value for the group starting MTX, with p = 0.0044 by unpaired t-test. This 
suggests that the group starting MTX had more bone resorption than the group 
starting SPZ, but that formation was similar in the two groups.
Table 3.3 9 Markers of bone turnover in the subjects with early 









mean ± standard 
deviation 
n = 18






















3.7.4 Change in Markers of Bone Turnover of Subjects with Early 
Rheumatoid Arthritis Over One Year and Two Years
The mean percentage change in markers of bone turnover for the first two years of 
treatment are shown in Table 3.40. There were no differences between the groups 
for any of the three markers by unpaired t-test.
Table 3.4 0 Percentage change in markers of bone turnover in the 
subjects with early rheumatoid arthritis
Mean % change from 






Serum osteocalcin at 
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3 .8  R esu lts  o f M a le  S u b je c ts
3.8.1 Bone Mineral Density Z Score of Male Subjects at Baseline
The Z scores of the bone mineral density at entry to the study for the male subjects 
is shown in Table 3.41. Unlike the study group as a whole and the subgroup of 
postmenopausal women, there were no significant differences between the groups 
for any of the forearm measurements. The only significant difference between the 
four groups for age- and sex-adjusted BMD (Z scores) was at the trochanteric region 
of the hip, where the group continuing MTX had a lower mean Z score than the 
group starting MTX. There were no significant differences between the two groups 
continuing on DMARDs.
3.8.2 Change in Bone Mineral Density of Male Subjects Over One 
Year
These are shown in Table 3.42. In general, compared to the female subjects, the 
changes seen were much smaller and were often near to zero. The greatest losses 
in BMD were observed at the ultra-distal portion of the forearm, in all groups except 
those continuing on MTX.
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Table 3 .41  Z score of the bone mineral density of the male subjects at
baseline
Mean ± Start MTX Start SPZ C ontinue C ontinue
standard MTX O ther
deviation n = 8 n = 6 n = 6 DMARD n = 7
Lumbar spine 1.088 -0.110 0.127 0.463
± 1.017 ± 1.277 ± 0.936 ± 1.158
Neck of 0.229 0.254 -0.313 -0.109
femur ± 1.136 + 1.096 ± 1.081 ± 0.804
Trochanteric *0.959 0.760 *0.207 0.647
± 0.920 ± 1.006 ± 1.445 ± 0.594
Inter­ 0.927 0.208 -0.235 0.131
trochanteric ± 0.691 ± 0.618 ± 1.271 ± 0.516
Ward’s region 0.492 0.752 -0.155 -0.104
± 1.511 ± 1.592 ± 1.091 ± 0.961
Total hip 0.774 0.346 -0.175 0.243
± 0.797 ± 0.709 ± 1.294 ± 0.548
Proximal third -0.046 -0.164 -1.256 0.252
forearm ± 0.818 ± 1.823 ± 2.425 ± 1.248
Mid-portion -0.408 -0.296 -0.944 -0.568
forearm ± 0.798 ± 1.853 ± 1.921 ± 0.825
Ultra-distal -0.268 -0.252 0.080 -0.248
forearm ± 1.097 ± 1.525 ± 3.127 ± 0.777
Total forearm -0.301 -0.264 -0.868 -0.290
± 0.863 ± 1.831 ± 1.749 ± 0.829
Proximal third -0.136 -0.196 -0.927 0.434
radius ± 0.869 ± 1.586 ± 2.657 ± 1.386
M id-portion -0.643 -0.379 -0.675 -0.587
radius ± 0.747 ± 1.512 ± 1.667 ± 0.885
Ultra-distal -0.274 -0.121 0.145 -0.154
radius ± 1.301 ± 1.537 ± 2.697 ± 0.722
Total radius -0.468 -0.293 -0.656 -0.268
± 0.906 ± 1.663 ± 1.551 ± 0.927
Analysis by ANOVA with Fisher's PLSD post hoc testing
* Significant difference between the group starting MTX and the group continuing MTX, 
p = 0.0147
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* Significant difference between the groups starting MTX and continuing other DMARDs: p 
0.0149 for the neck of femur (a) and p = 0.0116 for Ward’s area (b)
3.8.3 Markers of Bone Turnover of Male Subjects at Baseline
Subjects on long-term MTX had significantly Increased OC at baseline compared 
with those starting MTX (Table 3.43), but all groups except those starting MTX had
mean OC levels outside the reference value for males. The group continuing MTX 
also had high AP but it was only just above the normal range and was significantly 
higher only when compared with the long term other DMARD group. As for the 
whole study cohort and the postmenopausal women, there was no difference in 
resorption (Dpd) seen.





















































Analysis by ANOVA with Fisher’s protected least significant difference post hoc testing.
* (a and b) Significant differences between groups at the level p < 0.05.
3.8.4 Change in Markers of Bone Turnover of Male Subjects Over One 
Year
The men starting MTX had a mean increase in OC of 11% whilst the other three 
groups had a reduction of between 25 and 32%. These differences were significant 
(Table 3.44).
The group continuing DMARDs other than MTX had a large mean increase in AP of 
24% whilst it reduced in the other three groups. Again, these differences were 
significant.
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The group continuing MTX had a mean decrease in Dpd of 14% whilst the other 
three groups had a mean increase, but this did not reach significance.
Table 3.4 4 Mean percentage change in the markers of bone turnover in 





(n = 7 & 8)
Start SPZ 
(n = 3 & 4)
Continue
MTX
(n = 6 & 6)
Continue Other
DMARD



























The numbers are given of subjects results available for formation and resorption markers for 
each group. AP is serum bone specific alkaline phosphatase; Dpd is urinary deoxypyridinoline 
corrected for urinary creatinine.
Analysis by ANOVA with Fisher's PLSD post hoc testing. * p < 0.05, ** p < 0.01. a, b, c etc. 
identify the groups with significant differences.
3.9 Summary of Results of the Clinical Study and Future Work
When all the subjects were considered together (Section 3.5), the cohort who had 
been on MTX for more than five years had significantly reduced BMD corrected for 
age and sex (Z score) compared with the other three groups of subjects in the 
following areas: forearm proximal third and midportion regions, for both the radius 
alone and the radius and ulna combined. However, the rate of change in BMD for 
the proximal third and midportion forearm areas was no different between the two 
groups continuing their DMARD, suggesting that the loss of bone mass seen in the 
group continuing MTX had occurred in the past.
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There were differences found in the groups starting either MTX or SPZ with regard 
to annual change in forearm BMD. Those subjects starting MTX had significantly 
more reduction in BMD in the proximal third region (radius and ulna) than did those 
starting SPZ.
These results suggest that MTX is associated with early loss of bone from the 
proximal third of the forearm, but that the rate of loss slows with long-term use. The 
bone in this part of the forearm is predominately cortical (Schlenker et al, 1976). 
However, this study does not inform whether the group continuing MTX had lost 
bone before or after starting the drug.
At baseline, the bone formation markers (OC and AP) were within the normal 
reference range apart from in the group continuing MTX, where they were increased 
significantly compared to all the other groups. In the group starting MTX, AP was 
slightly raised, but this was not significant when compared with the other groups. 
The mean percentage change in AP over one year in the group continuing MTX 
(decrease of 11%) was significantly different from the change in the group on other 
DMARDs (increase of 5%).
Bone resorption markers were elevated above the normal reference range in all 
four groups, and there was no significant difference between the groups or over the 
time of the study.
When the subgroup of postmenopausal women were considered (Section 3.6), the 
discriminant analysis results showed that the factors which explained most of the 
observed variation between groups were the following values: baseline osteocalcin 
levels, baseline hand and baseline wrist x-ray scores and the baseline proximal 
third and mid-portion forearm BMD Z scores. These factors explained much of the
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variability between the groups (77.64%). Another 17% of variability was 
explained by the factors in the bottom half of Tables 3.29 and 3.30. The analysis 
found that the only site which had a significant negative annual change 
associated with MTX therapy, after correction for confounding factors, including 
baseline values of BMD, was the mid-portion of the forearm. Sites where 
osteoporotic fractures typically occur, such as the ultra-distal forearm site and 
hip, were not at increased risk of reduction in BMD due to MTX therapy in the 
model. Other factors, such as baseline BMD and disease duration and activity 
were more important at these sites. However, it is not known whether other sites 
would become significant if a larger sample of subjects had been available for 
analysis.
The results for the subgroup with early RA (less than two years) was presented in 
Section 3.7. In this small cohort of subjects there was no significant difference 
between the two groups (Starting MTX and Starting SPZ) when the percentage 
change in bone mineral density at each site was compared by repeated 
measures ANOVA (Table 3.38).
The subgroup of males were discussed in Section 3.8. There were no significant 
differences in baseline BMD or change in BMD between the two groups starting 
or continuing their DMARDs. However, there were significantly greater losses in 
BMD occurring over the year of the study at the neck of femur and Ward’s area of 
the hip in those starting MTX when compared with those continuing other 
DMARDs. As in the group as a whole, MTX treatment was associated with higher 
osteocalcin levels.
Overall, MTX treatment was not associated with adverse effects by either 
markers of bone turnover or BMD measurement. The only site where MTX was
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associated with increased bone loss after correction for confounding factors in the 
sub-group of post-menopausal women was the mid-portion of the forearm. This is a 
predominately cortical bone site and is not prone to insufficiency fractures. These 
results are reassuring for clinicians prescribing MTX.
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4. METHODS: BONE CELL CULTURE
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4.1 Introduction
The following experiments were designed to investigate whether or not 
methotrexate (MTX) had any effect on the behaviour of normal human osteoblast­
like bone cells in vitro.
Osteoblast-like cells which proliferate from trabecular bone chips and normal 
human bone marrow cells were studied in a series of experiments and the results 
are presented in Chapter 5. The culture techniques outlined below (Sections 4.3 
and 4.5) have been developed over several years by Dr JN Beresford and others 
(Gallagher et al, 1996).
All chemicals and reagents were obtained from BDH Ltd, UK or Sigma Ltd, UK and 
all plastics from Falcon,UK unless otherwise stated.
4.2 Preparation of Marrow Stromal Cells for Culture
Cells were prepared from portions of rib from elective thoracic surgery at Frenchay 
Hospital NHS Trust, Bristol. The most frequent diagnosis was lung tumour but some 
patients were undergoing pleurodesis for recurrent pneumothorax. Several 
samples were from exploratory thoracotomies, where the diagnosis was unknown. 
Characteristics of patients whose bone was used in this series of experiments are 
discussed in Chapter 5 (Section 5.2 and Table 5.1).
The sample was placed in serum-free medium until preparation, which was usually 
the same afternoon following a morning operation.
The portions of rib varied in length from 3cm to 10cm. Working in a laminar flow 
hood, the connective tissue and periosteum were carefully stripped away from the 
bone surface using sterile instruments such as locking forceps and scalpel
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(Richardsons, UK). This minimised contamination of the cell suspension with 
fibroblasts. In a clean square petri dish with a small volume of serum-free 
Dulbecco’s Modified Essential Medium (DMEM, Gibco, see Tissue Culture 
appendix), the rib was cracked open along its length using bone cutters and the 
marrow washed out by repeated vortexing of rib fragments. The marrow was 
transferred to a 50ml polypropylene tube with a screw cap with 30ml serum-free 
DMEM and washed by centrifugation at 350g for five minutes. The remaining rib 
was reserved for preparation of the trabecular bone (Section 4.4).
Following the wash, many of the adipocytes could be aspirated off with the DMEM 
as they were at the top of the liquid layer. The cell pellet was resuspended in 25ml 
serum-free DMEM, layered on top of 20ml Lymphoprep (Nycomed) in a clean 50ml 
polypropylene tube and centrifuged at 630g for thirty minutes, with the brake off. 
This separated the mononuclear cells from erythrocytes and other marrow 
components. The mononuclear cells, which included the marrow stromal cells of 
interest, were removed by carefully drawing up the interface into a 25ml pipette and 
transferring it to a clean 50ml polypropylene tube. Following the addition of 20ml 
serum-free DMEM, the cells were centrifuged at 980g for ten minutes to separate 
the Lymphoprep. The cell pellet was resuspended in 15ml serum-free DMEM and 
filtered through a 70pm cell filter (Becton Dickinson, UK) before counting. Cells
were counted by either Coulter counter (Section 4.6.4) or haematocytometer 
(Section 4.6.5) with Trypan Blue staining to identify viable cells. Total cell counts 
were typically 60 to 120 million cells per sample, depending on the length of rib and 
age of the patient.
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4.3 Primary Culture of Marrow Cells
The prepared mononuclear cells were established in primary culture in petri dishes 
for colony formation experiments (Section 4.7), or in 25cm2 or 75cm2 flasks. The 
cells were plated out at a density of 2 x 104 cells/cm2. The medium was DMEM (with 
the supplements listed in the Tissue Culture appendix) supplemented additionally 
with 100pM L-Ascorbate-2-phosphate magnesium salt n-hydrate (Asc-2-P, Wako
Pure Chemical Industries Ltd, Japan) and heat-inactivated fetal calf serum (FCS, 
Sigma-Aldrich Co Ltd, Poole, UK), either 10% or 15% by volume. During the course 
of this work, the preferred concentration for growing marrow-derived stromal cells 
changed from 10% to 15% FCS, based on work by other members of the Bath Bone 
Research Group. Similarly, the length of time to the first change of medium and 
wash with PBS, was reduced from seven to three or four days, as this was found to 
accelerate growth (reduce time to confluence) and increase the yield of colonies. In 
contrast, trabecular-derived bone cells were cultured throughout in DMEM with 10% 
FCS by volume and fed first after seven days with no wash step (Section 4.5). 
Cultures were routinely set up with and without 10nM Dexamethasone (DX). Cells 
were fed twice a week and cultured at 37°C in an humidified atmosphere of 95% air 
and 5% C 0 2.
4.4 Preparation of Trabecular Bone Chips
Trabecular (cancellous) bone cells were grown in flasks as outgrowths from chips of 
bone after the method of Beresford et al (Gallagher et al, 1996). The source of the 
bone was either rib from Frenchay Hospital, Bristol or bone fragments from 
orthopaedic operations at the Royal United Hospital NHS Trust, Bath. The origin of
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the bone was usually the femur (reamings from the shaft to make space for the 
femoral stem of a total hip replacement) but samples from the iliac crest (donor site 
of bone graft for spinal fusion surgery) or tibia (total knee replacement) were also 
received.
The trabecular bone was carefully separated from the cortical bone and any 
connective tissue or cartilage elements were discarded. Trabecular bone was 
distinguished as it was white and could be cut into small fragments with a sharp pair 
of scissors. In contrast, the cortical bone was yellow, tended to splinter and could 
only be cut with bone cutters. The preparation was done in the hood, using a small 
amount of serum-free DMEM to keep the bone moist. The trabecular chips were 
suspended in calcium- and magnesium-free phosphate buffered saline (PBS) in a 
50ml polypropylene tube and washed by vortexing three times, allowing settling 
each time. The PBS was aspirated off, the bone chips were resuspended in clean 
PBS and the wash step repeated twice more. The chips were then placed in a clean 
square petri dish and any remaining haematopoietic elements (red tissue) were 
discarded. Further wash steps were performed as necessary to obtain clean, white 
trabecular chips.
4.5 Primary Culture of Trabecular Bone
The trabecular chips were placed in 25cm2 or 75cm2 flasks, with DMEM 
supplemented with 10% FCS, 100pM Asc-2-P and with and without 10nM DX. The 
cultures were left to settle for seven days and thereafter were fed twice a week and, 
as for the marrow cultures, grown at 37°C in an humidified atmosphere of 95% air
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and 5% C 02. No wash step was performed at the time of the first feed, unlike the 
marrow cultures.
4.6 Redistribution and Passaging of Marrow-Derived and 
Trabecular Bone Cells
The technique is the same for both types of cell cultures and consists of treatment 
with collagenase followed by trypsin EDTA (Gallagher et al, 1996).
Redistribution of the cells within the flask was carried out at four weeks of culture. By 
disaggregating the cells, contact inhibition of proliferation was reduced and the cells 
reached confluence more quickly.
Passaging was done when the cell layer was confluent over the bottom of the flask. 
The cells were counted and further experiments done in secondary culture.
4.6.1 Collagenase Incubation
The medium was discarded and the cell layer washed gently with serum-free 
DMEM or PBS twice. The cells were incubated at 37°C for 60 to 90 minutes with 4ml
(for a 75cm2 flask) of collagenase VII solution containing 2mM CaCI2 (1 in 500 
dilution of sterile 1M stock) and 25 units/ml collagenase VII in serum-free DMEM. 
The CaCI2 is needed for optimal activity of the enzyme .
4.6.2  Trypsin Incubation
At the end of the first incubation, the cells could be seen rounding up under the 
microscope. The medium was aspirated off and the cell layer washed gently twice 
with PBS. Trypsin EDTA (Gibco, UK), 4ml for a 75 cm2 flask, was added to the cell 
layer and further incubation at 37°C for fifteen minutes carried out. As the trypsin
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acted, the cell layer could be seen lifting off the bottom of the flask in a sheet. The 
trypsin activity was halted by the addition of 0.5ml FCS and the cells pipetted up 
and down vigorously, to dislodge the cells from the dense matrix. The cell 
suspension was transferred to a 50ml polypropylene tube and the flask washed out 
with 10ml serum-free DMEM to obtain the maximum yield of cells.
4.6.3 DNA-ase Step
The cell suspension was centrifuged at 350g for five minutes with the brake off. The 
cell pellet was resuspended in 1ml of serum-free DMEM containing 10pg/ml DNA­
ase and pipetted vigorously to further disaggregate the cells. The cell suspension 
was filtered through a 70pm cell strainer (Becton Dickinson, UK), spun again for five
minutes at 350g and resuspended in 1 or 2ml serum-free DMEM. The cells were 
then counted and plated out for experiments in secondary culture.
4.6.4 Cell Counts by Coulter counter
A Coulter Electronics Multisizer Counter (Coulter, UK) was used and a known 
volume of cell suspension (usually 100pl) was placed in a counting cup with a
known volume of filtered isoton (usually 8ml). The cell count for two 500pl aliquots
were obtained and summed, giving a count per ml. The cell concentration was then 
given by the following equation:
(count x isoton volume/ sample volume) x 10 = cell count per ml
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4.6.5 Cell Counts by Haematocytometer
A 50pl aliquot of the cell suspension was mixed with 50|il of Trypan Blue. A small 
volume (approximately 20pl) of the mixture was introduced into one half of the
haematocytometer. Under high power magnification (x 400, Wilovert microscope) 
viable cells which had not taken up the Trypan Blue were counted in at least four 
squares of the grid to give a count of at least one hundred. The suspension was 
diluted if necessary, if the cells were too dense to count, or clumped. Non-viable 
cells, identified by a blue halo, were then counted. The cell concentration was given 
by the following equation:
(count/number of squares counted in) x 100/50 x 104 = cell count per ml 
The percentage of viable cells was given by:
Cell viability (%) = ________Viable cell count_______ x 100%
(Viable + non-viable cell counts)
4.7 The Effect of Methotrexate on Colony Forming Units- 
Fibroblastic Formation from Normal Human Bone Marrow 
Stromal Cells.
Bone marrow stromal cells include clonogenic adherent precursors which under 
appropriate conditions can form colonies and which have been termed colony- 
forming units fibroblastic (CFU-F) (Friedenstein et al, 1970; Friedenstein et al, 
1987). Although they have the appearance of fibroblasts, the cells from a proportion 
of the colonies can form bone and cartilage if transplanted into diffusion chambers 
in allogeneic recipient animals demonstrating that they retain their osteogenic
179
potential (Friedenstein et al, 1987). In addition they express alkaline phosphatase 
(Section 4.7.1), suggesting that they have acquired osteoblast-like characteristics.
A series of experiments was performed to investigate the effect of methotrexate on 
the formation of colonies and on their differentiation into osteoblast-like cells, and 
the results are presented in Chapter 5 (Section 5.3). All these experiments were 
done in 60mm diameter (28cm2) petri dishes, with four replicates for each condition. 
Freshly prepared marrow cells were plated out at 4x105 cells per dish (1.5 x 104 
cells per cm2) and washed with PBS before the first feed. The medium used was 
DMEM supplemented with 100pM Asc-2-P and either 10% or 15% FCS. Following
the first feed, cells were fed every three or four days. If used, methotrexate (MTX, 
Wyeth-Lederle, Gosport, Hants, UK), folate and folinic acid was added to the 
medium from the outset in all experiments.
After eighteen to twenty-one days in culture, the dishes were washed once with 
PBS and the colonies fixed with methanol for five minutes. The methanol was 
aspirated off and the cultures air dried. The colonies were then stained with Fast 
Red (Section 4.7.1) for alkaline phosphatase-positive colonies containing 
osteoblast-like cells. These were counted under low power microscopy (Olympus, 
magnification x 5).
The same dishes were then restained with 1% methylene blue (Section 4.7.2) in 
10mM Borate buffer (appendix bone cell culture) and the colonies counted. This 
stained all colonies, whether fibroblastic or osteogenic.
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4.7.1 Fast Red Stain for Alkaline Phosphatase-Positive Osteogenic 
Colonies
To make 30ml of stain, 6mg of Naphthol AS-MX was dissolved in 600pl dimethyl 
formamide in a glass container. This was diluted to 30ml with 0.1M Tris buffer, pH 
9.2. Just before use, 30mg Fast Red TR salt was dissolved in the solution and 2mI 
placed in each petri dish of fixed cells. After ten minutes at room temperature, the 
stain was washed off with tap water and the dishes air dried. Colonies containing 
cells expressing alkaline phosphatase had been stained red and could be counted 
at low magnification (x 5). A colony was counted if it contained at least fifty cells: 
clusters of fewer than fifty cells were not included.
4.7.2 Methylene Blue Stain for All Colonies
The stain for total colony counts used was 1% Methylene Blue in 10mM Borate 
buffer and 2mIs was placed in each petri dish and left for thirty minutes at room 
temperature. The stain was washed off with tap water and the dishes air dried. 
Colonies were stained blue and could be counted at low magnification, as above. 
Clusters of less than fifty cells were not counted.
4.8 Experiments with Passaged Bone Cells
Following collagenase and trypsin passaging, the cells were plated out in twenty- 
four well plates at 1 x 104 cells per cm2, unless stated otherwise.
4.9 Protein Assay
The Bio-Rad DC Protein Assay is a calorimetric assay for protein concentration 
following detergent solubilisation and is similar to the well-documented Lowry
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Assay (Hartree, 1972). The protein to be quantified reacts with an alkaline copper 
tartrate solution and Folin reagent. There are two steps which lead to the blue 
colour development: the reaction between protein and copper in an alkaline 
medium, and the subsequent reduction of Folin reagent by the copper-treated 
protein.
Reagents used Reagent A an alkaline copper tartrate solution
Reagent B a dilute Folin reagent 
Reagent S SDS (detergent)
Protein standards were made from 4mg/ml stock bovine serum albumin (BSA) by 
doubling dilutions to the following concentrations:
0, 62.5, 125, 250, 500, 1000, 2000 and 4000pg/ml 
Method
The protein was dissolved by the addition of 4M NaOH at 50°C prior to the assay.
Reagent A’ was prepared by adding 20jllI of Reagent S to every 1mI of Reagent A to 
be used.
In a 96 well plate, 5pl of samples and standards were added in triplicate. 25pl of 
Reagent A’ was added followed by 200pl of Reagent B. The plate was gently 
agitated to mix solutions. After fifteen minutes at room temperature the plate was 
read at 750nm on a plate reader (Dynatech MR5000).
4.10 Alkaline Phosphatase Assay
The mature osteoblast expresses the enzyme alkaline phosphatase (AP), which has 
an essential role in matrix mineralisation, both on the cell surface and in the 
cytoplasm (Raisz et al, 1998).
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Principle of the Assay
Colourless p-Nitrophenyl Phosphate (pNPP) was used as a substrate for alkaline 
phosphatase and formed yellow p-Nitrophenol on hydrolysis by the enzyme. The 
assay was done in a ninety-six well plate which was read at 410nm.
Method
Reaction Buffer was made from adding 0.5% Triton-X to 221 Alkaline Phosphatase 
Buffer (2-amino-2-methyl-1-propanol, 1.5M, pH 10.3). The Triton-X lysed the cells, 
enabling quantification of total AP, both cytoplasmic and cell surface.
Standards were made from stock p-Nitrophenol (p-NP 10pM) diluted in Reaction 
Buffer as in Table 4.1.
Table 4.1 Preparation of standards for alkaline phosphatase assay
Standard
Number
P-NP (pi) Reaction 
Buffer (pi)
[p-NP] (pg/ml)
1 2.5 2497.5 10
2 12.5 2487.5 50
3 25 2475 100
4 50 2450 200
5 20 480 400
6 40 460 800
7 50 450 1000
8 60 440 1200
9 70 430 1400
10 90 410 1800
11 100 400 2000
Aliquots of 50pl of the standards were placed in a ninety-six microtitre well plate in 
triplicate. The plate was stored at -20°C until use.
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Assay
150|il of Reaction Buffer was added to each standard well to make the volume up to 
200pJ.
Controls
The control solution was the Substrate Buffer which was made by dissolving 4.6mg 
of p-NPP in 10ml Reaction Buffer and 200jil was placed in the nine control wells. 
Samples
The samples were thawed, vortexed and 50pl placed in the sample wells in 
duplicate. Substrate Buffer (150pl) was then added to each sample well and the 
plate was incubated at 37°C for ten minutes. At this time, the colour production was
checked and if necessary, the plate was incubated for a further ten minutes before 
reading at 410nm on a plate reader. The duration of the incubation was noted as 
the enzyme activity is expressed as unit per cell per minute i.e. [n-NPP produced 
(pg/ml)] /1  x 105 cells /  minute.
4.11 Flow Cytometry of Human Bone Marrow Stromal Cells
4.11.1 Principle of Flow Cytometry
Flow cytometry (also known as fluorescent activated cell sorting, FACS) is a 
powerful way of studying the expression of cell surface markers, such as receptors 
or cell-associated molecules (Carter et al, 1990). Other applications of flow 
cytometry include the study of cell kinetics, membrane potential and chromosomal 
analysis (Ormerod et al, 1990).
In flow cytometry, rapid measurements are made on cells (or particles) as a fluid 
stream containing the cells passes a sensor. Laser-based flow cytometers measure
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the scattered and fluorescent light generated by cells as they pass through the 
illuminating laser beam. The cells are labelled with fluorochromes attached to 
antibodies bound to the molecule of interest (Ormerod, 1990). These compounds 
release energy when they are excited by the laser beam and the photons are 
collected by photodetectors and converted into electronic signals. The signals are 
computed into a graphical display of the events. A powerful feature of the technique 
is that each measurement, or event, is made on a single cell rather than pooled 
(Carter et al, 1990).
Suitable antibodies against the molecules of interest must be available and be 
appropriately specific. Monoclonal antibodies are therefore preferable. In the 
experiments described below, indirect staining by a secondary, directly conjugated 
goat anti-mouse antibody against the primary (mouse) antibody was used. An 
advantage of using secondary staining is that more than one secondary antibody 
can bind to the primary antibody, increasing the fluorescence intensity of the cell. 
Single, dual or triple labelling with one, two or three different primary antibodies is 
possible, resulting in two, four or eight subpopulations. The cells are sorted into 
populations depending on the binding of the antibodies and results are given as the 
percentage of the total cells in each population. Population shifts according to 
different experimental conditions can be studied. Sorted subpopulations of cells can 
be further cultured but this was not undertaken in this project.
4.11.2  Monoclonal Antibodies Used in Flow Cytometry of Bone Cells
The monoclonal antibody B4-78 recognises the bone/liver/kidney isoform of 
alkaline phosphatase (Lawson et al, 1985).
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Osteoblasts develop from multipotential bone marrow stromal cells and the 
characteristics of the intermediary cell types is unknown. Simmons and Torok Strob 
have developed a monoclonal antibody against a subpopulation of bone marrow 
stromal cells which they have called Stro-1 (Simmons et al, 1991). It has been 
shown that this antibody identifies all the cells which can produce colonies (CFU-F) 
in vitro, and it is thought that Stro-1 may be a marker of the stem cell for osteoblasts 
(Gronthos et al, 1994). The expression of Stro-1 is lost as the cell becomes more 
mature and committed to the osteoblast phenotype.
Hybridomas for the monoclonal mouse anti-human antibodies Stro-1 and AP (B4- 
78) were supplied by the Development Studies Hybridoma Bank, University of Iowa. 
The B4-78 antibody was purified by Dr Carolyn Jefferis by passage over a protein G 
column and Dr Susan Walsh prepared the Stro-1 antibody from the hybridoma 
supernatant.
4.11.3  Model of Osteoblast Differentiation
Osteoblasts differentiate from multipotential stem cells which give rise to other 
mesenchymal lineages such as chondrocytes and adipocytes. Dr JN Beresford and 
colleagues have developed a model of osteoblast differentiation based on the four 
populations of cells obtained by FACS analysis of cells labelled with B4-78 and 
Stro-1 (Stewart et al, 1996). The model is shown in Figure 4.1 and Table 4.2.
It is possible that the least well-characterised (double negative) population includes 
both early and late stage cells of the osteoblast lineage, osteoblasts or osteocytes.
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Figure 4.1 Model of osteoblast differentiation using Stro-1 and alkaline 
phosphatase (AP) expression determined bv flow cytometry
Stro-1-negative Stro-1-positive
AP-positive Stro-1 negative and AP 
positive cells: mature
~  r
Stro-1 and AP positive 
cells: pre-osteoblastss
AP-negative V
Stro-1 and AP negative 
cells: uncommitted 




Stro-1 positive and AP 
negative cells: committed 
osteoprogenitor cells
Table 4.2 Cell populations by flow cvtometry after dual labelling
Stro-1 AP (B4-78)
Least differentiated negative negative
Progenitor osteoblast positive negative
Committed osteoblast positive positive
Mature osteoblast negative positive
4.11.4  Experimental Design
Bone marrow-derived cells were grown under standard culture conditions in DMEM 
(with additions, see appendix ) with 100pM Ascorbate-2-phosphate and 15% fetal 
calf serum by volume (Section 4.3). Additional conditions were Methotrexate (0, 1, 
10, 100 or 1000nM MTX) and Dexamethasone 0 or 10nM. At the end of primary 
culture, cells were passaged, dual-labelled with the monoclonal antibodies B4-78
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and Stro-1 and subjected to fluorescence-activated cell sorting. The number of days 
the cells were in culture is shown in Table 4.3.
Table 4.3 Culture time for marrow-derived osteoblast-like cells prior to 
flow cytometry
Results shown in: Days in primary culture 
before redistribution
Days in culture 
after redistribution
Figures 5.19 and 5.20 23 48
Figures 5.21 and 5.22 44 24
Figures 5.23 and 5.24 44 29
4.11.5 Dual-Labelling of Human Bone Marrow Derived Cells
Cells were passaged as described above (Section 4.6), and counted.
In brief, the cells were blocked, incubated with the primary monoclonal antibodies 
(B4-78 and Stro-1, or controls), washed and incubated with the secondary 
(fluorescent) antibodies. After two further washes, the cells were fixed in 
paraformaldehyde and stored overnight at 4°C before flow cytometry the following 
day.
Protocol in detail
For each experimental condition, the following FACS tubes were prepared:
B4-78 monoclonal antibody only (O/A)
Stro-1 monoclonal antibody only (S/I)
B4-78 & Stro-1 monoclonal antibodies (S/A) (2 tubes),
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where O was a non-specific monoclonal antibody (OBL) developed in-house by Dr 
Susan Walsh , A was B4-78, S was Stro-1 and I was mouse monoclonal Ig Gr  
OBL was used as the IgM isotype control for Stro-1 and I was used as the IgG 
isotype control for B4-78. In addition, cells which were blocked and fixed, but not 
incubated with any antibody, were used to align the FACS laser beam (negative 
cells). Negative control tubes were: cells incubated with the secondary (fluorescent) 
antibody only (2nd ab only), and cells incubated with the two non-specific 
antibodies, OBL and I (O/l).
Cells were blocked by placing on ice with blocking buffer for 20 minutes, where 
blocking buffer was Hanks Buffered Saline Solution (HBSS, Gibco, UK) with 10mM 
HEPES and 5% FCS and 10% human AB serum by volume. The serum blocked 
non-specific binding in human cells.
After blocking, 105 cells were placed in each tube, and all tubes, except the negative 
cells, were centrifuged at 350g for five minutes at 4°C. The block was aspirated off
and the primary antibody was added to each tube, except the 2nd ab only cells, 
which had 500pl of wash buffer instead.
Primary antibodies
Freshly thawed 0,l,S  and A antibodies were used. The volumes needed for each 
tube were:
0  and S 500pl (hybridoma supernatant)
A 3jil (15pg/ml)
1 10pl (15pg/ml)
Thus for an experiment with four conditions, the following solutions of antibodies 
were prepared:
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S/A 500pl /  3pl for eight tubes = 4 mis (S) + 24pl (A)
S/I 500pl /  10|jil for two tubes = 1 ml (S) + 20pl (I)
O/A 500|il /  3pl for two tubes = 1 mis (O) + 6pl (A)
O/l 500(0.1 /  10pl for one tube = 500pl (O) + 10(ol (I)
The appropriate volume (503pl or 51 Opil) was added to each tube, the pellet was 
resuspended by gentle shaking and they were incubated on ice for one hour. 
Following this, each tube (including 2nd ab only tube) was filled to the top with cold 
washing buffer and spun at 350g for five minutes at 4°C with a low brake. The wash
was aspirated off, and the second antibody added.
Secondary antibody
These were two fluorescent antibodies which bound to the primary antibody and 
allowed identification of differentially-labelled cells. The goat anti-mouse human- 
adsorbed secondary conjugates anti-lgG^rhodamine-phycoerythrin (R-PE) and 
anti-lgM-fluorescein isothiocyanate (FITC) were supplied by Southern 
Biotechnology Associates. R-PE absorbs light at 488nm and emits light in the 
orange spectrum whilst FITC absorbs light at 495nm and emits a green light 
(Ormerod, 1990). One laser can excite both compounds and thus differential 
detection can be made.
A 1.5ml secondary antibody suspension was made using the following volumes: 
150pl human AB serum 
1.35 mis HBSS with 5% FCS 
7.5 pi R-PE 
60 pi FITC,
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and 100pl of the suspension was added to each tube. The cell pellet was 
resuspended and incubated on ice for forty-five minutes, in the dark to prevent 
fading of the fluorescent labels.
Fixing step
Following the second incubation, the cells were washed using cold washing buffer 
and centrifuged as before. After the wash was aspirated, 500pl of cold PBS with 1 % 
paraformaldehyde was added to each tube and the pellet resuspended. Lids were 
placed on the tubes and they were kept at 4°C overnight.
4.11.6  Flow Cytometry Analysis of Dual-Labelled Passaged Human 
Bone Marrow-Derived Cells
Analysis of the dual-labelled cells was done on a Becton Dickinson FACstar Plus 
flow cytometer with a 488nm Argon laser. The machine was calibrated daily using 
standard beads provided by the manufacturer. The FACS laser beam was aligned 
using the negative control sample and the lower threshold set for the recording of 
events. The single positive controls were used to set the machine compensation for 
the spectral overlap of FITC and RPE, and the four cell populations defined. The 
positive controls also confirmed the effectiveness of the secondary antibody 
binding. The double-labelled samples were then analysed and distributions in the 
four quadrants recorded for each sample. Results are presented in Section 5.7 and 
Figures 5.18 to 5.24.
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4.12 Appendix For Bone Cell Culture
Stock solutions for tissue culture were obtained from Gibco BRL, UK unless 
otherwise stated.
Dulbecco’s Modified Essential Medium (DMEM) (with NEAA, without glutamine, 
pyruvate and bicarbonate), with the following additions:
Sodium Bicarbonate (7.5%) 11.4ml/l
HEPES buffer (1M) 20ml/l
Glutamine (200mM) 10ml/l
Sodium pyruvate (100mM) 10ml/l
Penicillin/Streptomycin (25 IU) 2.5ml/l
Amino acids Alanine (35.6mg/l), Asparagine (60.0mg/l),
Aspartic acid (53.0mg/l), Glutamic acid (59.0mg/l), Proline (46.0mg/l)
This was made up to 1 litre with Milli-Q water, adjusted to pH 7.2 with sodium 




Na Bicarbonate 7.5% 5.7ml
Amino acids (as above) 5mI
Penicillin/Streptomycin (as above) 1.25ml 
HEPES 2.38g
Glutamine 15ml
Folate-free DMEM 10x stock 50ml
Prepared in hood, buffered with 10 M NaOH to pH 7.2 and filter sterilised.
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Phosphate buffered saline (PBS)
10 PBS tablets were dissolved in 1 litre of Milli-Q water and autoclaved. It was 
allowed to cool to room temperature before use.
Collagenase IV
This was made up in sterile water or serum-free medium and stored in 1 ml 
aliquots at -20°C. It was used at 25 U/ml final concentration.
Deoxyribonuclease I (Dnase I)
This was made up in 150mM sodium chloride to 2000 units/ml. It was used at 20 
units/ml final concentration.
1 a. 25 - dihydroxyvitamin P2 (calcitriol)
This was made up in absolute ethanol and stored in sealed evacuated tubes 
under gaseous nitrogen in 250 /yl aliquots of 3.44 x 104 M at -20°C.
Ascorbate - .2- phosphateIa3.C--.&P-).
This was supplied as a desiccate and stored at -20°C in a box containing 
desiccant. It was made up in serum-free DMEM to a stock strength of 10mM and 
filter-sterilised before being stored at -20°C as 5 ml aliquots. It was used at a
final concentration of 100 j;M.
Dexamethasone (DX)
This was made up in serum-free DMEM to a stock concentration of 5 x 10'5 M 
and filter-sterilised before being stored at -20°C as 1ml aliquots. It was used at a 
final concentration of 10'8 M.
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Methotrexate
This was obtained from Wyeth-Lederle in 2ml vials of 25mg/ml. The molecular 
weight of Methotrexate in the hydrous form is 454.5. Therefore 1000nM 
Methotrexate is 0.45mg in 1ml. As 1ml contained 25mg, 18/yl contained 0.45mg 
and concentrations of 10OnM to 1 nM were made by serial dilutions, 
folic-acid
Normal DMEM contains 4mg/l. Folic acid and normal human serum levels are 4 
to 18//g/l. Folic acid is concentrated in red blood corpuscles at a concentration of 
160 to 180/yg/l. Folic acid was added back to folate-free medium in some 
experiments. The stock was kept sterile and 19.4mg was measured out in the 
hood, weighed in a sealed container and dissolved in 1.94ml PBS or folate-free 
DMEM to give 10mg/ml. A dilution was made by adding 10/71 of this to 10ml PBS 
or folate-free DMEM gave 10/yg/ml. This was used in experiments either 1 in 100 
or 1 in 1000 to give final concentrations of 10/yg/l or 100/7g/l.
Folinic acid
Folinic acid stock was kept sterile. The molecular weight is 511.5, thus 1M is 
511.5g/l and 1 mM is 511.5mg/l. A working stock solution of concentration 1 mM 
was made by diluting 14.5mg in 28.35ml PBS or folate-free DMEM and was 
used at 1 in 1000 in experiments, at a final concentration of 1pM.
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5. BONE CELL CULTURE RESULTS
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5.1 Introduction
The results from the series of experiments performed on human bone cells in 
culture to explore any direct effect of the drug methotrexate (MTX) are presented in 
this chapter. The experimental methods were described in Chapter 4.
5.2 Characteristics of Donors
The available features of donors are shown in Table 5.1. They include age, sex, 
diagnosis and drug treatment where known.
Table 5.1 Characteristics of donors of bone
Sex Age (years) Diagnosis Medication




Female 57 Lung cancer HRT
Male 62 Lung cancer None
Female 72







5.3 Analysis of Results
When possible, experiments were set up in quadriplicates to enable analysis of 
variance to be performed. An exception was the flow cytometry experiments where 
only duplicates were available. Results were analysed by the author using Statview 
4.5 for Macintosh. Statistical tests used included paired t-test and analysis of 
variance (ANOVA) with post-hoc testing with Fisher’s Protected Least Significant
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Difference (PLSD). Levels of significance were set at 95% and standard errors or 
standard deviation of the means are illustrated.
5.4 Effect of Methotrexate on the Proliferation and Migration of 
Cells from Trabecular Bone Chips in Vitro
Trabecular bone chips were prepared as described in Section 4.4 and cultured in a 
twenty-four well plate with 1ml of medium per well. The medium was Dulbecco’s 
Modified Essential Medium (DMEM) with the supplements listed in the appendix to 
Chapter 4 and additionally 100|iM L-ascorbate-2-phosphate and fetal calf serum 
(FCS) 10% by volume. Experimental conditions were with or without 10nM 
Dexamethasone (DX) and 0, 1, 10, 100 or 1000nM Methotrexate (MTX, Wyeth- 
Lederle, Gosport, Hants, UK). The wells were assessed for proliferation of cells on 
the surface of the bone chips and migration of the cells out onto the surface of the 
plastic by light microscopy on the ninth, fourteenth and eighteenth day of culture. An 
arbitrary scoring system of ‘V for cell proliferation (as seen in Figure 5.1) and ‘2’ for 
migration (as seen in Figure 5.2) was used. The mean scores at the three time 
points are shown in Table 5.2. The results demonstrated the permissive effect of DX 
on bone cell proliferation and migration, with the highest scores on day eighteen 
being in the group treated with 10nM DX but no MTX. MTX delayed rather than 
abolished proliferation and migration, as shown by the scores on day nine. By day 
eighteen, there was evidence of proliferation even at the highest dose of MTX 
(1000nM), both in the presence and absence of DX. On day twenty-five, the well 
contents were stained with Fast Red (Section 4.7.1) to demonstrate the expression 
of alkaline phosphatase. Staining was heaviest over the chips, but was also present
197
over the cell layer which had migrated onto the well surface, confirming an 
osteoblast-like phenotype.
In summary, MTX inhibited and delayed, but did not abolish, the proliferation and 
migration of osteoblast-like cells from normal human trabecular bone.





Figure 5.2 Migration of cells from a trabecular bone chip out onto the 
surface of the culture flask
Magnification x 200














0(3) 1.67 "T~t>T 1.33 1.67 X B T 2
1 (2) 0 0 0.5 0 2 2
10(2) 0 1 2 0 0.5 1
100(2) 0 0 1 0 0 0.5
1000 (3) 0 0.6V 0.67 0 0 1.00
Results are shown as mean per well. Proliferation on cells on the surface of the bone chips 
was scored as T , migration out onto the plastic was scored as ‘2’. MTX, methotrexate; -DX, 
no added dexamethasone; +DX, dexamethasone 10nM.
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5.5 Effect of M ethotrexate on Colony Formation of Normal
Human Bone Marrow Stromal Cells
5.5.1 Pose Response Experiments
The method for these experiments is given in Section 4.7. A 28cm2 plate stained 
with Fast Red for alkaline phosphatase (AP) positive colonies is shown in Figure 
5.3, and one stained with both Fast Red and Methylene Blue (for all colonies) is 
shown in Figure 5.4.
Figure 5.3 Colonies expressing alkaline phosphatase stained by Fast 
Bed stain
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Figure 5.4 All colonies stained bv Fast Red and then Methylene Blue
Figure 5.5 shows the effect of Methotrexate (MTX) 1 to 1000nM on the numbers of 
colonies formed after twenty-one days in primary culture. There were very few AP- 
positive colonies, only five colonies in the forty plates (result not shown). In the 
presence of 10nM DX, MTX had a dose-dependent inhibitory effect on total colony 
formation, treatment with 100nM and 1000nM MTX being associated with 
significantly fewer colonies than controls.
The colonies which developed in the absence of DX were also fewer in the 
presence of 100nM and 1000nM MTX, but the difference from controls did not reach 
significance (Figure 5.5).
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Figure 5-5 Total colony formation in the presence of methotrexate, wnh
and w ithout 10nM dexam ethasone
10 l
Methotrexate concentration, nM
Colonies stained with Methylene Blue after 21 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference, n = 4.
* significant difference from OnM MTX, p = 0.006
** significant difference from OnM MTX, p = <0.0001, and from 1nM MTX, p = 0.006, and from 
10nM MTX, p = 0.0089
Figures 5.6 and 5.7 show the total colonies and alkaline phosphatase-positive (AP 
+ve) colonies which grew from a different donor in the absence (Figure 5.6) and 
presence (Figure 5.7) of 10nM DX respectively. There was no significant difference 
between control cultures (no MTX) and any of the doses of MTX for either AP 
positive or total colony numbers in either DX condition.
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Figure 5.6 Total and AP-positive colony formation in the,presenge.Qf
methotrexate and no dexamethgsoneU )
|  AP+ve 
H  Total
0 1 10 100 1000
Methotrexate concentration, nM
Colonies stained with Fast Red and then Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
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Figure 5.7 Total and AP-positive colony formation in the presence of
m ethotrexate and iQnM dexam eth asone (9)
■  AP+ve 
1  Total
0 1 10 100 1000 
Methotrexate concentration, nM
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
Figures 5.8 and 5.9 show the total colonies and alkaline phosphatase (AP) positive 
colonies which grew from a third donor. There were few AP positive colonies even 
in the presence of DX (Figure 5.9). Glucocorticoids at doses which correspond to 
physiological levels (such as those used here) have been shown to lead to the 
development of an osteoblast-like phenotype in human bone derived cells in culture 
(Gallagher et al, 1996). The total colony number was suppressed in the absence of 
DX in a dose-dependent manner, but only reaching significance at the highest 
concentration of MTX (Figure 5.8). In the presence of DX, in contrast to both the 
results above, MTX at the dose 100nM appeared to have a permissive effect on
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colony formation, although the standard error was large (Figure 5.9). Again, the 
highest dose of MTX, 1000nM was associated with significant reduction in colony 
number.
Figure 5.9 Total and AP-positive colony formation in the presence of 










0 1 10 100 1000
Methotrexate concentration, nM 
Colonies stained with Fast Red and Methylene Blue after 20 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
* Significant difference from OnM MTX, p = 0.0036 and from 10nM MTX, p = 0.0217 
$ Significant difference from 1nM MTX, p = 0.003, and from 100nM MTX, p = 0.003, and from 




Figure 5.9 Total and A E=M.aLtl^fi.colony formation in ..t he prese nce of
methotrexate and 10nM dexamethasone (b)
8 -
7 -
|  AP+ve 
M Total
0 1 10 100 1000 
Methotrexate concentration, nM
Colonies stained with Fast Red and Methylene Blue after 20 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
* Significant difference from 100nM MTX, p = 0.0253
Figure 5.10 shows colony formation in the absence of DX from another donor and 
illustrates both the total colony numbers and those which were osteoblast-like (AP- 
positive). The corresponding counts in the presence of DX are shown in Figure 
5.11. In this experiment, the effect of very low doses of MTX was explored (1 to 1000 
picomolar, equivalent to 1 nanomolar), diluting by a thousand-fold the doses used 
previously. The number of colonies which developed, both AP-positive and total, 
was much greater than in the previous experiments. In the absence of DX (Figure 
5.10), these small doses of MTX had no effect on total colony number. Figure 5.11 
shows that the lowest dose of MTX, 1pM, significantly suppressed both AP positive
206
and total colony formation compared to control, whilst in Figure 5.10 the number of 
AP positive colonies was increased in the presence of 1pM MTX and no DX.
F ig u re  5 - 1 Q T o ta l c o lo n y  and  A P -p o s it iv e  f QrmatiQn in th e  p r e s e nce of  
v ery  le w  d o se  m e th o tre x a te  and  w ith  n o d e x e m e th a sQne
20 i
|  AP+ve 
^1 Total
0 1 10 100 1000 
Methotrexate concentration, nM
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
* Significant difference from 10pM MTX, p = 0.0042, and from 100pM MTX, p = 0.0016, and 
from 1000pM (= 1nM) MTX, p = 0.0031.
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Figure 5.11 Total and AP-positive colony formation in the presence of
very low dose m ethotrexate and with 10nM dexamethasone
| AP+ve 
H  Total
0 1 10 100 1000
Methotrexate concentration, nM
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
* Significant difference from OpM MTX, p = 0.0017, from 10pM MTX, p = 0.0362, from 100pM 
MTX, p = 0.0362, and from 10OOpM (= 1 nM) MTX, p = 0.0011.
** Significant difference from OpM MTX, p = 0.0202, and from 100pM MTX, p = 0.01.
In summary, colony formation was inhibited in the presence of 100 and 1000nM 
MTX but the results were not consistent between donors. There was considerable 
variation in the number of colonies (both AP positive and total) in the control, 
untreated groups between experiments. Possible reasons for this are discussed in 
Section 5.5.4 below.
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5.5.2 Colony Formation with Folate-Free Medium
The medium used routinely for bone cell culture was Dulbecco's Modified Essential 
Medium (DMEM, Sigma, UK) with additions (see Tissue Culture appendix). DMEM 
contains 4mg/l folate whilst in humans the normal serum folate level is 1.8 to 
14.0pg/l. Folate is concentrated in the red blood cell where the normal levels are 
160 to 180jig/l. As one of the many actions of MTX is interference in folate 
metabolism (section 1.4.1), colony formation in folate-free medium was investigated. 
Results from the pilot experiment utilising folate-free medium (FFM) is shown in 
Figure 5.12 and no MTX was included in the design. Colony formation was 
significantly reduced with FFM, whether or not DX was present. The mean 
percentage reductions in AP-positive colonies were 90% and 71% in the absence 
and presence of DX respectively, and for total colony formation were 42% and 55% 
in the absence and presence of DX respectively.
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Figure 5 .12  Total and AP-positlve colony formation in folate-free  
medium
■  DMEM 
M FFM
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
For each condition (with and without DX) and for both total and AP-positive colonies, formation 
was significantly reduced in the folate-free medium, p < 0.001.
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5.5.3 Effect of Methotrexate with Folate-Free Medium on Colony
Formation from Normal Human Bone Marrow Stromal Cells
Subsequently, the effect of adding back 400pg/l folic acid to the FFM was explored 
and the results shown in Figures 5.13 and 5.14 with mean colony numbers shown 
in Table 5.3. This dose of folic acid did not overcome the inhibitory effects of FFM on 
the development of colonies. In fact, the number of colonies was greater in the FFM 
without folic acid supplement in the presence of DX (Figure 5.14), except for total 
colony formation in the presence of 100nM MTX. The number of colonies formed 
was generally lower for those cultures grown in FFM. In the presence of 10nM DX 
(Figure 5.14), the number of AP-positive colonies was remarkably similar in all four 
media conditions when 100nM MTX was present. This contrasts greatly with the 
outcome in the absence of DX (Figure 5.13), when AP-positive colony formation 
was suppressed in the FFM groups, especially when no folic acid had been added 
back. The addition of 100nM MTX did not suppress further the osteoblast-like (AP- 
positive) differentiation in these DX-free culture conditions when, in the absence of 
folate, AP-positive colonies were already very suppressed.
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F ig u re 5 .1 3  T o ta l and A P -positive colony form ation in fo la te -free
medium or DMEM and with or without folic acid and with no
dexam e thasone
25 l
I DMEM, 400(vg/l Folic acid 
^  DMEM, no Folic acid 
■  FFM, 400pg/l Folic acid 
B  FFM, no Folic acid
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
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Figure 5 ,1 4 .Total god AP-positive colony formation in folate-free  
medium or DMEM and with or without folic acid and with 10nM 
dexam ethasone
i DMEM, 400/vg/l Folic acid DMEM, no Folic acid 
FFM, 400^g/l Folic acid 
FFM, no Folic acid
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.


















0 0 Total 18 19.5 14.75 14
0 100 Total 21 23.25 14.75 15.75
0 0 AP 5.75 0.5 5 1.25
0 100 AP 8.5 6 2.5 1
10 0 Total 20.5 22.75 14.25 20
10 100 Total 16 17.25 15.5 14
10 0 AP 17 19 10.5 14.5
10 100 AP 10.25 5 9 0.5
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The final colony formation experiment was done using folinic acid 1pM as a 
supplement to the media instead of folic acid. Otherwise the experimental design 
was the same as previously and the results are illustrated in Figure 5.15 for cultures 
in the absence of DX and Figure 5.16 for colony development in the presence of 
10nM DX. Mean colony number for the different conditions is shown in Table 5.4. 
There were few AP-positive colonies with none developing at all in the FFM in the 
presence of DX. When the total colonies were counted, it was found that the 
addition of 1|iM folinic acid had in fact inhibited their formation in the FFM groups in 
the absence of DX (Figure 5.13). This result is interesting as folinic acid is the 
compound used to rescue cells from the effects of MTX toxicity as it is down-stream 
from folic acid in folate metabolism. The effect of adding folinic acid at this 
concentration did not have a significant effect on colony formation, either AP- 
positive or total, in the presence or absence of DX.
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F ig u re .5 ,1 5  T o ta l and AP-p o s itive g<?i.<?.ny fQrma.ti.Qn i n...tPlate -frse 
medium and with or without fo linic acid with no dexamethasone
DMEM, l^M Folinic acid 
DMEM, no Folinic acid 
FFM, 1^M Folinic acid 
FFM, no Folinic acid
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n = 4.
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Figure 5.1 6 Total and AP-positive colony formation in folate-free  
medium and with or without fo linic acid and with IQnM dexamethasone
3.5 -
I DMEM, Ij/M Folinic acid 
H  DMEM, no Folinic acid 
| FFM, 1/vM Folinic acid 
| FFM, no Folinic acid
x' x" K
£  X  f  X2 - i— 2_
z  r  Z  z
C C •r-0 4 0 4
Colonies stained with Fast Red and Methylene Blue after 18 days in culture.
Results shown as mean colony number ± standard error. Analysis by ANOVA with Fisher’s 
Protected Least Significant Difference post hoc testing, n =4.


















0 0 Total 2.75 3.25 1 2.25
0 100 Total 3.25 3.25 0.25 2
0 0 AP 0 0 0 0
0 100 AP 0 0.25 0 0
10 0 Total ~T75 '”"1 3.25 1.5 1
10 100 Total 1.75 1.75 1 ’ 1
10 0 AP 0.25 0.25 0 0
10 100 AP 1 0 0 0
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5 .5 .4  Summary of Colony Formation Experiments and Future Work
Compared to other workers in this field, generally low colony numbers were 
observed in this series of experiments. This may be related to the source of bone or 
plating density. It has been reported that in lung cancer there is reduced CFU-F 
formation (Chasseing et al, 1997). Several lung cancers, particularly squamous cell 
carcinomas, have associated non-metastatic features which are endocrine. 
Parathormone-related peptide (PTH-rP) was first described in patients with lung 
cancer but many other hormones with effects on bone may be synthesised by 
malignant cells. Other groups use higher plating densities with the development of 
higher colony numbers (Scutt et al, 1995). The low colony counts, particularly of AP 
positive colonies even in the control cultures makes it difficult to draw conclusions 
about the effect of MTX in this system. Additionally, MTX had differing effects 
between donors with an effect seen predominately either on total colony numbers or 
on osteoblast-like differentiation. Folate was shown to have an important role in 
colony formation as its removal lead to a dramatic reduction in colony number. 
Partial replacement of folate with either folate or folinic acid did not restore colony 
numbers to those seen with DMEM and paradoxically had an inhibitory effect under 
some conditions.
The size of individual colonies was not measured in this series of experiments. MTX 
may have no consistent effect on colony number (which reflects the transition from a 
non-adherent to an adherent state) but may effect colony size, which reflects 
proliferative potential.
In conclusion, MTX affected colony formation but not in a consistent way in marrow 
from these donors. Future investigations would aim to confirm and extend the above
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findings, using bone marrow from donors without malignancy, using different plating 
densities, assessing colony size and performing a larger number of experiments to 
try and overcome the problem of donor variation in this system.
5.6 Effect of Methotrexate on the Proliferation of Normal 
Human Marrow Stromal Cells
Primary human marrow-derived bone cells were cultured in DMEM with additions 
as in Chapter 4 appendix, 100p.M Asc-2-P, 15% FCS and with or without 10nM DX. 
After one week in culture, the cell layer was washed gently once with PBS and the 
media replaced with varying concentrations of MTX (0, 1, 10, 100 or 1000nM).
The cells were cultured to confluence (forty-four or sixty-eight days in culture) and 
were passaged for labelling prior to flow cytometry (section 5.7 below).
Proliferation was assessed by cell number determined by Coulter counter. Cells 
from each experimental condition were pooled and counted twice. The results are 
shown in Figure 5.17, with cell counts corrected for one 75cm2 flask. Doses of MTX 
of 10nM and above inhibited proliferation with maximum inhibition occurring at 
100nM. There was a trend towards greater inhibition in the cells cultured in the 
presence of 10nM DX.
218
Figure 5 .17  Cell counts of normal human bone marrow cells cultured in
the presence of methotrexate
Wk OnM Dexamthasone 
|  10nM Dexamethasone
0 1 10 100 1000 
Methotrexate concentration, nM
Cells were pooled from each condition prior to counting by Coulter counter.
There were no significant differences between cells grown in the presence or absence of 10nM 
Dexamethasone by paired t-test, n = 2.
*  1.5
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5.7 Effect of Methotrexate on the Surface Expression of Stro-1 
and Alkaline Phosphatase in Normal Human Marrow-Derived 
Bone Cells Assessed by Flow Cvtometrv
The full method for this series of three experiments is given in Section 4.11. Cells 
were dual-labelled with the monoclonal antibodies B4-78 and Stro-1 at the end of 
primary or secondary culture. B4-78 recognises bone, liver and kidney isoform of 
alkaline phosphatase and is therefore a marker for committed osteoblasts (Lawson 
et al, 1985). Stro-1 is a marker of less well differentiated cells and is thought to 
identify marrow stromal cells which have the potential to become osteoblasts 
(Gronthos et al, 1994). After labelling, the cells were fixed and analysed by flow 
cytometry the following day. They were sorted into four populations, depending on 
their labelling. The distribution of the cells between the four populations varied 
according to the culture conditions and representative dot plots are shown in Figure 
5.18.
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Figure 5.1 8 Representative dot plots from flow cytometry






78) 1 and B4-78)
only
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(B) Dual-labelled cells: no MTX, no DX. (C) Dual-labelled cells: 100nM MTX, no DX.
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(D) Dual-labelled cells: no MTX, 10nM DX. (E) Dual-labelled cells: 100nM MTX, 10nM DX.
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Cells were dual-labelled with B4-78 and Stro-1 monoclonal antibodies and sorted by flow 
cytometry into four populations. The percentage of cell events in each population is indicated 
in the quadrants of the figures. DX is Dexamethasone.
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Population shifts were observed according to the experimental conditions. The 
presence of DX was associated with a larger percentage of cells having a more 
mature osteoblastic phenotype, that is, more cells in the AP-positive (upper left 
quadrant in Figure 5.18) and dual-positive (AP- and Stro-1-positive, upper right 
quadrant in Figure 5.18) populations, as previously described (Stewart et al, 1996). 
Results from the three different experiments are shown in Figures 5.19 to 5.24. Each 
result is the mean and standard deviation of two aliquots of cells which were 
labelled separately.
Figures 5.19 and 5.20 show the results from the first experiment with no DX and 
10nM DX respectively. MTX at doses of 10nM and 100nM was used. MTX at 10nM 
in the absence of DX (Figure 5.19) increased the proportion of cells expressing both 
Stro-1 and AP, whilst decreasing the other three populations. The same dose in the 
presence of DX (Figure 5.20) also increased the dual-labelled population (AP- and 
Stro-1 positive) whilst having little effect on Stro-1-positive cells.
The effect of 100nM MTX was not noticeably different from that of 10nM MTX in the 
absence of DX, whilst in the presence of 10nM DX, it increased the proportion of 
double negative (neither AP nor Stro-1 labelled) cells and reduced the proportion of 
dual-labelled (Stro-1 and AP) cells.
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Figure 5.1 9 Flow cytometry of dual-labelled human bone marrow cells
cultured in the presence of methfllr.exa.te.and no dexam ethasone (a )
£  20
OnM MTX 
1 OnM MTX 
1 OOnM MTX
Cells were labelled with B4-78 (AP) and Stro-1 monoclonal antibodies. Results are shown as 
the mean percentage and standard deviation of two samples of cells for each sorted 
population.
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Figure 5.20  Flow cyto m etry of ttu ^ - la frftllftd .h iim a a bong .m arrow ce lls 
c u iture d J n the prese n ce of m eth o trexate and i Qn.M de xam e thasone (9)
60 1
i i  OnM MTX 





Cells were labelled with B4-78 (AP) and Stro-1 monoclonal antibodies. Results are shown as 
the mean percentage and standard deviation of two samples of cells for each sorted 
population.
Figures 5.21 and 5.22 show the results from a second experiment, in the absence of 
DX in Figure 5.21 and with 10nM DX in Figure 5.22. The experiment was planned to 
include MTX at the dose 1nM and 1000nM in addition to the 10nM and 100nM 
previously used. Unfortunately, the 1 nM MTX with no DX cultures became infected 
but all the other conditions were available for analysis.
In the cultures grown in the absence of DX (Figure 5.21), 1000nM MTX increased 
the proportion of cells in the committed osteoblast populations (AP-positive and
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dual-positive cells). In the presence of DX (Figure 5.22), 1000nM MTX increased the 
proportion of cells in the AP-positive and double negative populations. The dual­
positive (AP- and Stro-1-positive) cells were decreased in a dose-dependent way 
by MTX. In both experiments, 1000nM MTX had similar effects on both the dual 
positive and dual-negative cell populations (Figures 5.21 and 5.22).
Figure 5.21 Flow cytometry of dual-labelled human bone marrow cells 
cultured in the prese ngfi_QfjPAthptrexate 9nd no <texam g ttiaM .n g .(M
£  20
I I  OnM MTX
■  10nM MTX 
M lOOnMMTX
■  10OOnM MTX
Cells were labelled with B4-78 (AP) and Stro-1 monoclonal antibodies. Results are shown as 
the mean percentage and standard deviation of two samples of cells for each sorted 
population.
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Figure 5 .22 Flow cytometry of human bone marrow cells cultured in the
presence <?f m ethotrexate and i Qniyi ctexamethasQne (b)
OnM MTX 
1 nM MTX 
10nM MTX 
1 OOnM MTX 
10OOnM MTX
Cells were labelled with B4-78 (AP) and Stro-1 monoclonal antibodies. Results are shown as 
the mean percentage and standard deviation of two samples of cells for each sorted 
population.
The final flow cytometry experiment used a single dose of MTX, 100nM. The results 
without DX are shown in Figure 5.24 and those with 10nM DX in Figure 5.25.
The results were similar to those obtained in previous experiments as 100nM MTX 
in the absence of DX (Figure 5.24) decreased the double-negative population whilst 
increasing the double-positive population of cells. In the presence of DX, the 
opposite effect was seen and additionally, the proportion of Stro-1 positive cells was 
also reduced.
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Figure 5 .23 Flow cytometry of human bone marrow cells cultured in the 






Cells were labelled with B4-78 (AP) and Stro-1 monoclonal antibodies. Results are shown as 
the mean percentage and standard deviation of two samples of cells for each sorted 
population.
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F igure 5 .24  Flow cytometry of dual-labelled human bone marrow cells





Cells were labelled with B4-78 (AP) and Stro-1 monoclonal antibodies. Results are shown as 
the mean percentage and standard deviation of two samples of cells for each sorted 
population.
5.7,1 Summary of Flow Cytometry Experiments and Further Work.
These experiments demonstrated that MTX pushed osteoblast-like cells further 
down the path of osteoblast commitment, or increased their degree of differentiation. 
The effect is greater in the presence of DX, which is a recognized enhancer of 
osteoblast differentiation. This may be an effect secondary to the inhibitory effect on 
cell proliferation demonstrated in the experiments above (Sections 5.5 and 5.6).
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(Sections 5.5 and 5.6). Further work would confirm and extend the above results. 
The sorted populations of cells could be cultured and subjected to further flow 
cytometry to investigate whether the phenotypes are stable.
5.8 Effect of Methotrexate on the Proliferation and 
Differentiation of Passaged Trabecular-derived Osteoblast-like 
Bone Cells and the Influence of Dexamethasone and 
1.25 (OH). Vitamin D3
In this experiment, osteoblast-like bone cells were cultured from chips of trabecular 
bone as described in Section 4.5. When confluent, the cells were passaged, 
counted and established in secondary culture, in twenty-four well plates in a variety 
of experimental conditions. If cells had been cultured in the presence or absence of 
10nM DX during primary culture, this was continued. MTX in a range of doses (1 to 
1000nM) was added to the culture medium during the week of secondary culture. In 
some experiments, 1, 25 (OH)2 Vitamin D3 (calcitriol) was added to the cultures for 
the final forty-eight hours. Calcitriol, like DX, tends to enhance the differentiation of 
osteoblasts at the expense of proliferation. Proliferation was assessed by elution of 
Methylene Blue and spectometry at 650nm. This has been shown to correlate well 
with proliferation assessed by different means. Thymidine uptake was not used as 
this would be unreliable in the presence of MTX (Section 5.9).
Figure 5.25 shows the dose-dependent inhibition of proliferation by MTX and the 
additive effect of calcitriol.
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After 7 days in secondary culture, the cell layer was stained with Methylene Blue and the elute 
read at 650nm. Results are shown as the mean optical density ± standard error (n = 4).
Alkaline phosphatase activity in the cell layer and supernatant was measured using 
a Sigma assay (Section 4.10). Figure 5.26 shows that the level of AP activity was 
much greater in the presence of DX and was greatest when 1000nM MTX was 
present. This result was in keeping with the action of DX as a promoter of 
differentiation to the osteoblast phenotype.
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Figure 5 .26 Alkaline phosphatase activity of trabecular-derived
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Alkaline phosphatase activity was determined on day 8 of secondary culture. MTX was added 
on day 3 and calcitriol on day 6. Results are shown as the mean ± standard error, n = 4.
5-9.1 Summary pf S e c o n d a ry  Trabecular Experiments and Further 
W.Qrk
Further work would aim to confirm and extend the above findings. It would be 
informative to analyse the supernatant for osteoblast specific products such as 
osteocalcin and to study the synthesis of collagen in the presence and absence of 
MTX.
5.9 Summary of the Bone Cell Culture Experiments
The series of experiments described in this chapter were designed to investigate 
the effect of MTX on cells of the osteoblast lineage in culture. The techniques of
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bone cell culture developed by Dr JN Beresford’s group were utilised. Thus, 
marrow-derived cells were cultured in conditions to promote the development of 
osteoblast-like cells (expressing alkaline phosphatase), and the cells which grew 
out from trabecular bone chips were studied in secondary culture. In the time 
available it was not possible to study in depth the possible mechanisms of the 
observed effects, by for example, expression of mRNA (messenger ribonucleic acid) 
of osteoblast products. Rather, the differences in expression of alkaline 
phosphatase (AP) and the Stro-1 surface marker were explored in different culture 
conditions. MTX had a generally inhibitory effect of proliferation, as assessed by 
colony number (Section 5.5) and cell counts (Section 5.6). Proliferation was not 
estimated by incorporation of radiolabelled nucleotides or precursors such as 
tritiated thymidine, as one of the main actions of MTX is inhibition of thymidylate 
synthetase and counts would have been unreliable. MTX also affected 
differentiation, as the colony-formation and flow cytometry experiments (Section 5.7) 
demonstrated. However, there were large differences in proliferation and colony- 
formation rates observed between donors. These differences were sometimes 
greater than the treatment effects of MTX. Overall, whilst MTX consistently inhibits 
proliferation irrespective of the cells' origin (marrow or bone surface), there were no 
consistent effects on colony formation (Section 5.5) or differentiation (Section 5.8) 
and MTX had inhibitory rather than toxic effects on the cells cultured using these 
systems.
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6.1 .1  Bone H istom orphom etry
Histology is the study of a tissue by microscopic examination of thin sections which 
have been mounted on slides. The sections can be stained to highlight features of 
interest and provide qualitative information. Histomorphometry is a histological 
technique in which numerical values are assigned to various elements of a tissue. 
This enables quantitative differences between treatment groups or disease states to 
be measured. Inferences about underlying pathophysiological processes may then 
be drawn. Over the last twenty years histomorphometric techniques have been 
developed and applied to bone (Compston et al, 1991).
The first site to be studied was rib (Frost, 1969) but the optimum site for biopsy is the 
iliac crest, just behind the anterior superior iliac spine. This site has several 
advantages (Recker, 1994). It is easily accessible and the procedure is safe and 
relatively easy to perform with little patient morbidity. A full thickness biopsy can be 
obtained with both the inner and outer cortex and the tissue of interest, the 
cancellous bone, is present in abundance.
Examination of undecalcified bone sections which have been appropriately stained 
(Section 6.4) allows measurement of structures such as cancellous area, 
percentage osteoid extent and resorption cavities (Eriksen et al, 1994). These 
measurements are termed static and are listed together with normal values 
obtained from British subjects in Table 6.1 (Recker, 1994; Vedi, 1986; Vedi et al, 
1982; Garrahan et al, 1990).
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Table 6.1 Static measurements
Measurement Units Values in Normal 
Subjects
Cancellous bone area (B.Ar)
%
(of tissue area) *27.7; 29.6; 29.6
Osteoid perimeter (OP)
%
(of bone perimeter) *17.7; 14.5; 21.2
Osteoid width (OW) pm **7.70
Mean wall width (W.Wi) pm ***62.0; 50.4; 40.0
Resorption cavity maximum depth pm A28.9
Resorption cavity mean depth pm A15.6
Resorption cavity area pm2 M752
Reconstructed cavity length pm A229.5
* Values from Vedi, S. et al 1982. Age groups: 31 to 40 years (n = 6); 41 to 50 years (n = 3); 
51 to 60 years (n = 6).
** Value from Vedi, S. 1986 (Thesis). Value from 57 normal subjects, 24 males and 33 females 
aged 19 to 80 years old.
*** Values from Croucher, P.l. et al 1989. Age groups: 19 to 40 years (n = 11); 41 to 60 years 
(n = 13); 61 to 81 years (n = 4).
A Values from Garrahan, N.J. et al 1990 (13 normal subjects; 8 female and 5 male).
Additional information can be obtained if the subject has taken a compound which 
labels bone prior to the biopsy. The property of tetracycline antibiotics to bind avidly 
to bone surfaces undergoing mineralisation can be exploited to enable dynamic 
measurements to be made (Eriksen et al, 1994). In this study, two time-spaced 
doses of demethylchlortetracycline were taken by the subjects prior to the biopsies 
(Section 6.3). When unstained sections are examined under ultra-violet light, 
tetracyclines fluoresce and identify actively mineralising surfaces. The dynamic 
measurements of mineral apposition rate and mineralising perimeter were
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measured and normal values obtained from British subjects are shown in Table 6.2 
(Vedi et al, 1982; Compston et al, 1994).
Table 6.2 Dynamic measurements
Measurem ent Units Values in Normal 
Subjects
Mineral apposition rate (MAR)
M,m/day *0.60; 0.61; 0.61
Mineralising perimeter (MP)
%
(of bone perimeter) **10.8
* Values from Vedi, S. et al 1982. Female values only used. Age groups: 31 to 40 years (n = 
6); 41 to 50 years (n = 3); 51 to 60 years (n = 6).
** Values from Compston, J.E. et al 1994. Mean value from 40 healthy controls, 17 men aged 
38 to 74 and 23 women aged 32 to 80 years old.
6.1.2 Histomorphometric Considerations of the Remodelling Cycle
The bone remodelling cycle has been described in section 1.1.11. The realisation 
that bone cells exist in teams and co-ordinate their activities of resorption or 
synthesis came from Frost’s study of tetracycline incorporation into bone (Frost, 
1969). Histomorphometry allows study of these remodelling events at the bone 
multicellular unit (BMU) level. Resorption cavity, osteoid seam and mineralisation 
parameters can all be studied independently, or measures can be combined into 
derived indices of bone formation (Section 6.7.3).
6.1.3 Histomorphometry in Rheumatoid Arthritis
Studies by Compston’s group in non-steroid treated RA subjects have shown that 
male and females less than fifty years old have reduced trabecular plate thickness
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compared with controls consistent with premature bone loss (Mellish et al, 1987). 
The mean wall thickness of completed packets of trabecular bone was significantly 
reduced compared with controls, again in both sexes (Compston et al, 1989). These 
results are consistent with reduced bone formation.
A further study found low bone turnover as shown by reduced eroded perimeter, 
tissue based bone formation rate and activation frequency. Mean and maximum 
eroded depth and cavity area were also reduced when compared with controls 
(Compston et al, 1994), suggesting a reduction in osteoclast activity. It was 
concluded that the reduced bone mass in RA is due to a negative remodelling 
balance.
6.2 Subjects Who Underwent Bone Biopsy
All the women recruited to the study (Section 2.2.1) with recent onset rheumatoid 
arthritis (within two years) who were commencing Methotrexate (MTX) were asked if 
they would be willing to undergo bone biopsy but most refused. Reasons for refusal 
included unwillingness to stay in hospital overnight and work or child-care 
commitments. However, eight did agree to have the biopsy in the first year, but two 
of these were unsuccessful (no bone was obtained) and they did not undergo a 
second biopsy one year later. All six women attended for a second biopsy and one 
of these was unsuccessful. Thus, five paired biopsies were available for analysis. 
However, on sectioning one of the biopsies it was found to contain only fat and no 
bone. Furthermore, one of the biopsies fractured during the biopsy procedure and 
so structural analysis (Section 6.5.9) was not possible. Structural analysis was also 
not possible on a biopsy which was very oblique with a semi-circular rim of cortical
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bone. The characteristics of the subjects who provided the four paired biopsies 
which were available for analysis are given in Table 6.3.
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6.3 Biopsy Technique and Preparation
The subjects were given information sheets about the bone biopsy procedure and 
the tetracycline administration. They gave informed consent for each biopsy and the 
study was approved by the local ethics committee. Prior to each biopsy, the bone 
was labelled with demethylchlortetracycline, 300mg twice daily in the following 
schedule: the label was taken on days one, two, thirteen and fourteen with the 
biopsy obtained three to five days after the last dose. Subjects were asked to avoid 
dairy products for two hours before and two hours after the tetracycline doses to 
optimise absorption. Full thickness transiliac crest bone biopsies were taken with a
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Bordier trephine (8mm French Gauge internal diameter) from two centimetres below 
and behind the anterior superior iliac spine. The first biopsy was from the right iliac 
crest and the second from the left side after a year of MTX therapy. The procedure 
was done under local anaesthetic with mild intravenous sedation with midazolam. 
The patients were observed in hospital overnight following the biopsy. The biopsies 
were placed in 70% alcohol for at least two days and then dehydrated by using 
80%, 90% and finally 100% alcohol in turn, with a minimum period of forty-eight 
hours at each concentration. During dehydration the biopsies were gently agitated. 
The biopsies were sent to Dr Juliet Compston’s Laboratory in Addenbrooke’s 
Hospital, Cambridge, where they were embedded in LR White Resin (London Resin 
Company, UK) by Dr Shobna Vedi and stored in the dark until processing. Sections 
of 8pm or 15pm thickness were cut on a microtome (Bright Instrument Company Ltd, 
Huntingdon, UK).
6.4 Slide Preparation for Histomorphometric Analysis
6.4.1 Toluidine Blue Stain
The stain was prepared from 20 mg Toluidine Blue in 10 ml Mcllvan Buffer.
Mcllvan Buffer was 25 mis Solution A and 75 mis Solution B, pH 4.2, where 
Solution A was 28.3g disodium hydrogen orthophosphate in 1 litre distilled water 
and Solution B was 21 g Citric acid in 1 litre distilled water.
Sections of the bone biopsy cut at 8pm were free-floated in filtered Toluidine Blue
stain for ninety seconds. The sections were then washed twice for five minutes in 
distilled water before placing on slides (SuperFrost, BDH Laboratory Supplies, 
Poole, Dorset, UK) and blotted dry. Stained sections were mounted using Inhibisol
239
(TAAB Laboratories Equipment Ltd, Reading, Berks., UK) and DPX mounting
medium (AGAR Scientific Ltd, Stansted, Essex, UK).
6.4.2 Von Kossa Stain
Sections cut at 8pm were free-floated in 1.25% Silver Nitrate for two to three hours
in bright light until they went black. They were washed twice in distilled water and 
then fixed in 10% mono-sodium thiosulphate for two minutes. They were washed 
twice again in distilled water before being counter-stained with filtered van Gieson 
stain (20ml Acid Fucin in 80ml Picric acid) for twenty minutes. After two more 
washes in distilled water, the sections were mounted on slides using Inhibisol and 
DPX.
6.4.3 Tetracycline Label
Unstained 15pm sections of bone were mounted on slides using Inhibisol and Xam 
neutral medium (BDH Laboratory Supplies, Poole, Dorset, UK).
6.5 Histomorphometric Measurements 
6.5.1 Introduction
The measurements were made in Dr Juliet Compston’s laboratory at 
Addenbrooke’s Hospital, Cambridge. All measurements apart from the structural 
analysis (Section 6.5.9) were made using a “Digicad” digitizing tablet and cursor 
with an LED point light source (Kontron Limited) and an Olympus BHS-BH2 
binocular light microscope with a BH2-DA drawing attachment (Olympus Optical 
Company, London, UK).
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6 .5 .2  Cancellous Bone Area
This was derived from measurement of the bone area and bone perimeter and 
expressed as a percentage of total area of cancellous bone. Using a semi­
automated technique, three non-contiguous Von Kossa stained sections per biopsy 
were analysed at an objective magnification of x4 (final magnification of x100, 
Figure 6.1). The eyepiece was mapped and the lens calibrated at the start of each 
measuring session. The cancellous surface of the bone was traced using a 
computer mouse on a viewing pad. Then any holes present in the cancellous 
structure were defined. Finally the length of any osteoid seam was recorded before 
moving onto the next field. The number of fields in a section depended on the size 
of the biopsy and all the cancellous bone was measured. Care was taken not to 
include any cortical bone by starting measurements at a fixed distance away from 
the cortical edge, utilising the markings on the eyepiece. Similarly, the extreme 
edges of the biopsy, where there was usually some bone dust, were not included in 
measurements.
The bone area for a given section was given by the formula:
Total field area = a x n 
True bone area = b - h
Mineralised bone area (%) = (true bone area) /  (total field area) x 100%
= (b - h) /  (a x n) x 100%, 
where a was the field area, b the bone area, h the hole area and n was the number 
of fields.
The mean cancellous bone area of the biopsy was calculated by averaging the 
results from the three sections measured.
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Figure 6.1 Section of cancellous bone demonstrating cancellous bone 
area and osteoid perimeter
*
.Jr? * *' *
Von Kossa stain with van Gieson counterstain, magnification x 100
6.5 .3  Osteoid Perimeter
This was measured at the same time as the cancellous bone area above (Section 
6.5.2) and reflects bone turnover. The osteoid perimeter (OP) was expressed as a 
percentage of the total cancellous mineralised bone perimeter and was given by the 
formula:
OP (%) = (ol) / (bl+hl) x 100%,
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where ol was the osteoid length traced out, bl was the length of the cancellous bone 
perimeter and hi was the length of the holes. The mean osteoid perimeter was 
calculated by averaging the results from the three sections measured.
6.5.4 Osteoid Width
This measurement was also done on Von Kossa stained sections, but at objective 
magnification x20 (final magnification x500, Figure 6.2). The lens was appropriately 
calibrated and the eyepiece mapped. Osteoid seams were identified by scanning 
the section with the x10 objective lens, moving to the x20 for measurements. Points 
on opposing margins of the osteoid seam were marked, at four equidistant points. If 
a seam was less than 3|im wide it was not included as it was considered to be
endosteal membrane rather than osteoid. Every osteoid seam in three sections from 
each biopsy was measured. If a seam was very long or very short, the number of 
measurements made was increased or decreased accordingly. The osteoid width 
(OW) for a section was given by the formula:
OW (pm) = (L  distance recorded) /  ( I  number of measurements made).
The mean osteoid width for the biopsy was calculated from the average for the three 
sections.
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Figure 6.2 Section of cancellous bone demonstrating an osteoid seam
Von Kossa stain with van Gieson counterstain, magnification x 500
6 .5 .5  Mean Wall Width
Completed cancellous wall (or packet) width was measured using Toluidine Blue 
stained sections, a polarising lens and the x10 objective magnification (final 
magnification x250). The lens was appropriately calibrated and the eyepiece 
mapped. Completed packets were identified by the alignment of collagen fibres 
within the cancellous bone under polarised view (Figure 6.3). Non-polarised light 
was used to ensure that active formation was not continuing on the outside of the 
packet and to identify the cement line on the inner surface of the packet (Figure 6.4). 
The endosteal surface and then the cement line were traced using the computer 
mouse. The packet width (the distance between the two lines drawn) was 
automatically measured in jam at four equidistant points along the packet. For each
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biopsy, three sections were examined and at least ten packets for each section. The 
mean packet width for each biopsy was calculated.
Figure 6.3 Cancellous bone section demonstrating a completed bone 
gacket viewed under j x >!a_rised light
Toluidine Blue stain, polarised light, magnification x 250
245
Figure 6.4 Cancellous bone section demonstrating a completed bone
packet viewed under transmitted light
Toluidine Blue stain, normal transmitted light, magnification x 250 
6.5.6 Resorption Cavities
Resorption cavities were measured using Toluidine Blue stained sections, a 
polarising lens and magnification of x10 or x20 (objective). The computerised 
technique used to measure resorption cavities was developed by Dr Compston’s 
group (Garrahan et al, 1990). The section was viewed with unpolarised light to 
identify a suitable resorption cavity for measurement (Figure 6.5). It was ensured 
that the resorption cavity was not undergoing formation (no osteoid present) and 
under polarised light that ragged ends of resorbed collagen fibres were visible 
(Figure 6.6). The endosteal surface which included the resorption cavity was traced 
and the margins of the cavity identified. The endosteal surface on the opposite side
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of the trabecular strut from the resorption cavity of interest was also recorded. The 
computer programme then fitted a cubic spline curve to the cavity and calculated the 
cavity depth (mean and maximum), cavity area and reconstructed the endosteal 
surface over the cavity (reconstructed length).
Figure 6.5 Cancellous bone section demonstrating a resorption cavity 
viewed under transmitted light
Toluidine Blue stain, transmitted light, magnification x 250
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Figure 6.6 Cancellous bone section demonstrating a resorption cavity
v iewed under polarised light
Toluidine Blue stain, polarised light, magnification x 250 
6.5 .7  Mineral Apposition Rate
This dynamic measurement was done on unstained sections. An ultra-violet light 
source was used and the room was darkened to protect the fluorescent labels from 
deterioration and to enable their visualisation. Labels were identified using the x10 
objective magnification but the measurements were done using the x20 objective. 
As before, the eyepiece was mapped and the lens calibrated prior to a measuring 
session.
A section was methodically scanned using the medium power lens (x10 objective) 
until a label was seen. At x20 objective magnification it was ascertained whether the
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label was a double or single label as the measurement could only be done on 
double labels. Furthermore, it was decided whether the label related to the labelling 
period of interest. This was determined by the position of the label in the bone. If the 
label was in the centre of a trabecular strut rather than at the edge it was due to 
previous tetracycline exposure, either given deliberately to label the bone or 
therapeutically. If a label was judged to have been laid down in the past, it was not 
measured.
At x20 objective magnification, the inter-label distance was measured (Figure 6.7). 
Measurements were taken from the middle of the first label to the middle of the 
second label, perpendicularly opposite. If the label was blurred so that it was difficult 
to identify the middle of the label (due to the orientation of the section), no 
measurement was made. As for the osteoid seam width measurement (Section 
6.5.4), four equidistant measurements were made for each label along its length (or 
more or fewer depending on double label length). All the double labels in a section 
were measured and the mean inter-label distance (ILD, pin) for the section was 
given by the following formula:
ILD = (£ inter-label measurements) /  (number of measurements).
From this the mineral apposition rate (MAR, pm/day) was calculated by dividing the
mean inter-label distance by the number of days between the labels (twelve).
MAR = IL D /12.
The mean MAR for the biopsy was calculated from at least three sections.
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Figure 6.7 Cancellous bone section demonstrating a double
tetracycline label viewed under ultraviolet light
Unstained 15pm section, ultraviolet light, magnification x 250 
6.5.8 Mineralising Perimeter
This dynamic measurement assesses the percentage of the total cancellous bone 
perimeter undergoing active mineralisation during the labelling period. It is also 
known as the surface extent of tetracycline labelling.
The interpretation of tetracycline labelling can be difficult. Although two, time­
spaced labels were given, often only a single label was present on a given 
trabecular strut. Occasionally, no label was visible, as occurred in the first biopsy
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from subject 2 in this study (Section 6.7.2). In addition, fluorescence from previous 
tetracycline exposure was sometimes present (Section 6.5.7).
A single label may result from one of two possible mechanisms. Frost has described 
‘label escape’ which occurs if formation is either initiated or terminated during the 
inter-label period (Frost, 1969). The alternative cause of a single label is if formation 
continues, but mineralisation ceases (or starts) during the inter-label period. When 
measuring the surface extent of tetracycline labelling, the single (sL) and double 
labels (dL) are recorded separately. The mineralising perimeter can be calculated 
in four different ways, all expressed as a percentage of the cancellous bone 
perimeter.
sL + dL the sum of the single and double labelled surfaces
dL the sum of the double labelled surface only
sL the sum of the single labelled surface only
dL + (1/2 sL) the sum of the double labelled and half of the single labelled surfaces
This last, dL + (1/2 sL) is the most commonly used and was used in this study. It 
recognises that of the single labelled surfaces, some will have started and some 
stopped undergoing mineralisation during the inter-label period. Single and double 
labels are illustrated in Figure 6.8.
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Figure 6.8 Cancellous bone section demonstrating single and double 
tetracycline labels
Unstained 15pm section, ultraviolet light, magnification x 250
The measurements of the surface extent of tetracycline labelling were made on 
unstained sections, as for the mineral apposition rate (Section 6.5.7). The light 
source was ultra-violet light and the sections were not exposed to natural or artificial 
light. The x10 objective lens was calibrated and the eyepiece mapped as before. In 
each field, the bone perimeter (BP) was traced round, and then any double (dL) and 
single (sL) labels traced individually. The x20 lens was used to determine whether a 
label was single or double before it was measured. For each section, the 
mineralising perimeter (MP) was given by the following formula:
MP (%) = (dL + (1/2 sL)) / BP.
The values from the sections were averaged to give a measurement for each 
biopsy.
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6 .5 .9  Strut (Pattern) Analysis
The structural or strut analysis measurements were made on a separate measuring 
system using a camera mounted on a light box. Toluidine Blue stained slides were 
used and an image of the entire section was captured on a compatible computer. 
The image was segmented into a binary image. This could then be edited by 
removing features such as bone dust or heavily stained resin which did not 
correspond to trabecular struts. After editing, the image was skeletonised 
automatically and trabecular junctions (nodes) and the ends of trabeculae (termini) 
identified. Analysis of three sections from each biopsy was done and the mean 
number of nodes, termini and the node to terminus ratio and other measures of 
interest were calculated for each biopsy.
6 .6  V a lid a tio n  of M e a s u re m e n ts
Before the study biopsies were measured, inter- and intra-observer variability were 
calculated for each measurement. Three sections from six different biopsies 
previously prepared and measured by an experienced histomorphometrist (Dr Vedi) 
were used and were measured twice for all parameters except the mineralising 
perimeter and strut analysis. The first values were used to compare with results 
obtained by Dr Vedi to give an inter-observer variation rate (Table 6.4). The same 
sections were re-measured after at least a week and compared with the results 
obtained previously. From this, an estimate of intra-observer variability was 
obtained (Table 6.5).
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The observer variance (S) of the difference was given by the equation 
S = (Z d2) / (2n),
where d is the difference between the first and the second measurement and n is 
the number of biopsies studied.
The standard deviation (SD) of the difference is the square root of the observer 
variance of the difference.
SD = V (S)
The standard error (SE) of the difference is given by the formula:
SE = SD / V n, where SD is the standard deviation of the difference.
The coefficient of variation (CV) for the two series of measurements is given by the 
formula:
CV (%) = 100% x V (variance) /p = 100% x SD/p, where p is the mean of the 
measurements.
6 .6 .1  In ter-O b server V aria tion
The coefficients of variation for the inter-observer variation for the different 
measurements are shown in Table 6.4 and the range is from 5.58% for the mineral 
apposition rate to 48.67% for the mineralising perimeter. The author had 
consistently lower values than Dr Vedi for the measurements of osteoid extent and 
the dynamic measurements (mineral apposition rate and mineralising perimeter). In 
the case of the osteoid perimeter, this measurement, along with the cancellous 
bone area were done first whilst training was occurring. In the case of the dynamic 
measurements, the fluourescent labels may have faded with time. However, the 
large variation in measurements obtained on the same sections and equipment but
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by two different observers emphasises the importance of inter-observer variation. 
All measurements of the study biopsies were done by one observer, the author, 
thus eliminating inter-observer variation.
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6.6 .2  Intra-Observer Variation
The coefficients of variation for the intra-observer variation are shown in Table 
6.5. The mineralising perimeter measurements were not repeated. The 
coefficients of variation range from 1.76% for wall width to 31.74% for osteoid 
perimeter. The coefficient of variation for all the measurements except for osteoid 
perimeter was less than 10% confirming lower variability than in the case of 
inter-observer measures.
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6.7 Results
All results are presented as the unadjusted two-dimensional values, with no 
correction to three-dimensional values. This is justified as comparison between the 
pre- and post-treatment values is of interest and correction would affect all values 
equally.
6.7.1 Static Measurements
The results for these measurements as mean values and standard deviations are 
given in Table 6.6. The mean cancellous bone area as a percentage of marrow 
area for the four subjects before and after treatment with MTX is shown in Figure 
6.9. There was an increase in mean bone area in each subject after MTX therapy 
compared with the baseline measurements.
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The mean osteoid perimeter as a percentage of cancellous bone perimeter is 
shown in Figure 6.10. In three out of the four subjects, there was an increase in 
osteoid perimeter over the year of treatment with MTX.
The mean osteoid seam width for the four subjects is shown in Figure 6.11. In two 
out of the four subjects there was an increase in mean osteoid width over the study 
period. There was a decrease in the remaining two subjects.
The mean completed wall width of the four subjects is shown in Figure 6.12. As for 
the cancellous bone area, there was an increase in all four subjects.
Table 6 .6  Results fo r static m easurem ents
Cancellous Osteoid Osteoid seam Wall width
bone area (%) perimeter (%) width (pm) (pm)
Subject 1 10.63 4.38 7.07 40.7
1st biopsy ±0.66 ±0.54 ±0.52 ±1.32
Subject 1 19.99 5.43 8.96 44.36
2nd biopsy ±5.01 ±0.95 ±0.93 ±3.07
Subject 2 13.86 10.47 10.5 39.74
1st biopsy ±1.83 ±4.74 ±1.64 ±2.08
Subject 2 24.94 13.14 10.83 40.97
2nd biopsy ±11.23 ±6.58 ±4.40 ±2.49
Subject 3 16.84 2.88 10.77 36.36
1st biopsy ±1.90 ±1.71 ±1.41 ±0.57
Subject 3 17.1 6.53 7.15 41.31
2nd biopsy ±2.85 ±0.87 ±0.24 ±2.08
Subject 4 29.09 3.25 10.33 39.57
1st biopsy ±2.08 ±1.07 ±0.67 ±2.24
Subject 4 33.22 2.17 7.04 40.84
2nd biopsy ±4.11 ±2.16 ±0.62 ±4.09
Results shown as mean ± standard deviation of the mean for at least three sections from each 
biopsy
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Figure 6.9 Mean cancellous bone area
Subject 1 Subject 2 Subject 3 Subject 4
Results shown as cancellous bone area as % of medullary area
Figure 6.1 0 Mean osteoid perimeter
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D Biopsy 1 
□  Biopsy 2
Results shown as % of total bone perimeter
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Figure 6.1 1 Mean osteoid seam width
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Resorption cavity measurements are given in Table 6.7 and shown in Figures 6.13 
to 6.16. Figure 6.13 shows the mean resorption cavity area, Figure 6.14 the mean 
cavity depth and Figure 6.15 the maximum cavity depth for the eight biopsies. The 
reconstructed cavity length is shown in Figure 6.16 and is a measure of the 
endosteal surface extent of the cavity. There were no clear trends apparent in the 
resorption cavity measurements made in this study. For cavity area, maximum cavity 
depth and reconstructed cavity length, there were equal increases and decreases in 
the subjects (two increased and two decreased for each). For the measurement of 
mean cavity depth, there was an increase in the measurement in three out of the 
four subjects.
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Figure 6 .13  Mean resorption cavity area
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Figure 6 .14  Mean resorption cavity depth
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Figure 6 .16  Mean reconstructed cavity length
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6.7.2 Dynamic Measurements
Dynamic measurements could be made on only seven out of eight biopsies. 
Despite examination of many sections from different depths, no tetracycline label 
could be found in the pre-treatment biopsy of subject 2. This biopsy was 
unfortunately fractured during its removal from the subject, and much of the 
trabecular bone was rubbed off during the processing. Thus only three paired 
biopsies had dynamic measurements made on them from which derived indices 
can be calculated (Section 6.7.3). The mean results and standard deviation of the 
mean are given in Table 6.8 and are shown graphically in Figure 6.17 (mineral 
apposition rate) and Figure 6.18 (mineralising perimeter). For each measurement, 
there was an increase in two out of three subjects.





Subject 1 0.69 5.5
1st biopsy ±0.02 ±3.27
Subject 1 0.80 5.57
2nd biopsy ±0.08 ±1.19
Subject 2 
1st biopsy
No label No label
Subject 2 0.91 5.44
2nd biopsy ±0.04 ±0.98
Subject 3 0.93 1.54
1st biopsy ±0.06 ±0.37
Subject 3 0.75 4.67
2nd biopsy ±0.01 ±1.72
Subject 4 0.74 2.66
1st biopsy ±0.17 ±0.95
Subject 4 0.83 1.50
2nd biopsy ±0.02 ±0.50
Results shown as mean ± standard deviation of the mean. No label was present in the first 
biopsy of subject 2
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Figure 6 .17 Mean mineral apposition rate
Q Biopsy 1 
□  Biopsy 2
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Results shown as p.m/day











Subject 1 Subject 2 Subject 3 Subject 4
Results shown as % of total perimeter
□  Biopsy 1
□  Biopsy 2
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6.7.3 Definitions of the Derived Indices
Derived indices of bone formation were calculated from the static and dynamic 
measurements given above.
The derived indices are calculated from the following formulae.
AjAR (pm/day) = MAR x MP/OP,
where MAR is the mineral apposition rate (pm/day, Section 6.5.7), MP is the 
mineralising perimeter (%, Section 6.5.8) and OP is the osteoid perimeter (%, 
Section 6.5.3).
BFR/BP (pm2/pm/day) = MAR x MP/BP,
where MAR is the mineral apposition rate (pm/day, Section 6.5.7), MP is the 
mineralising perimeter (% of the bone perimeter, Section 6.5.8) and BP is the bone 
perimeter (always 100%).
Acf (/year) = (BFR/BP) /  (365 x W.Wi),
where BFR is the bone formation rate (pm2/pm/day, see above), BP is the bone 
perimeter (pm) and W.Wi is the mean wall width (pm, Section 6.5.5).
FP (days) = W.Wi/AjAR,
where W.Wi is the mean wall width (pm, Section 6.5.5) and AjAR is the adjusted 
apposition rate (pm/day, see above).
6.7.4 Results of the Derived Indices
These results are given in Table 6.9. The adjusted apposition rate (AjAR, pm/day) is 
shown in Figure 6.19, the bone formation rate (BFR, pm2/pm/day) in Figure 6.20, the 
activation frequency (Acf, /day) in Figure 6.21 and the formation period (FP, days) in 
Figure 6.22.
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The adjusted apposition rate decreased slightly in all three subjects for whom 
paired results were available, whilst the BFR and Acf increased in two out of three 
subjects. The FP increased in all three subjects.















1st biopsy 0.871 0.038 0.00093151 46.7
Subject 1 
2nd biopsy 0.82 0.045 0.0010137 54.12
Subject 2 
1st biopsy No label No label No label No label
Subject 2 
2nd biopsy 0.378 0.05 0.00120548 108.39
Subject 3 
1st biopsy 0.56 0.016 0.00043836 64.92
Subject 3 
2nd biopsy 0.537 0.035 0.00084932 76.92
Subject 4 
1st biopsy 0.606 0.02 0.00049315 65.33
Subject 4 
2nd biopsy 0.574 0.012 0.00030137 71.1
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Figure 6 .19  Adjusted apposition rate
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6.7.5 Analysis of Results
The mean differences between pre-treatment and post-treatment values for all the 
measurements described above are shown in Table 6.10, together with the p values 
by paired t-test at the 95% confidence level. The only difference to reach 
significance was the derived index of formation period (p = 0.0459). The mean 
difference in formation period was eight days, which is probably not clinically 
relevant.
Table 6.10 Analysis of results
Measurement Mean difference (Biopsy 
2 minus Biopsy 1)








Mean cavity depth 0.655 0.6488










6.7.6 Structural Analysis Results
Structural analysis was only possible on two paired biopsies. This was because the 
first biopsy of subject two was fractured and the second biopsy of subject four was 
very oblique, with a rim of cortex in a semi-circle around the trabecular bone in the 
centre. The available results are shown in Table 6.11. The node to node distance in 
the second biopsy was calculated as -0.47 which is clearly impossible. Statistical 
analysis on such a small sample (n of two) was not attempted.












0.97 2.02 1.44 1.53 1.39
Node count 0.56 2.47 0.60 1.25 2.08
Total
Strut count 1.27 3.67 1.52 2.55 3.66
Node / Free end 
(% total strut 
length) 22.10 30.17 29.33 44.92 19.03
Nooe / Node (% 
total strut 
length) 24.87 39.86 15.98 -0.47 27.79
Nooe /  Free end 
ratio 0.57 1.22 0.42 0.82 1.5
6.8 Summary of Results
Histomorphometric analysis of this small sample revealed no toxic effect of MTX on 
bone formation. Indeed, cancellous bone area and mean wall width which is an 
indicator of osteoblast function (Croucher et al, 1989) increased in all four subjects 
during the treatment period. There were no differences in resorption cavity
271
parameters and osteoid width and extent measurements did not suggest a defect of 
mineralisation. Statistical analysis of the measures found only one significant 
difference: the mean formation period which increased by a mean of eight days. 
This is unlikely to be significant clinically.
In conclusion, no effect of low-dose MTX was found in this study of four women with 
early RA. This is reassuring and is in keeping with other findings of bone mineral 
density and markers of bone turnover in the larger cohort of subjects (Chapter 3). 
However, because the sample size was very small, only consistent and relatively 





The inflammatory joint disease rheumatoid arthritis (RA) predisposes to increased 
bone loss and ultimately osteoporosis (Goldring, 1996). The anti-folate drug 
methotrexate (MTX) is used increasingly to treat RA (Weinblatt, 1996). MTX is 
generally well tolerated by patients and often has beneficial effects on symptoms 
such as joint pain, joint swelling and early morning stiffness. However, there are 
reports of osteoporosis and fragility fractures developing in patients given MTX for a 
variety of conditions (Preston et al, 1993). This is of concern as many patients on 
MTX for RA have additional risk factors for osteoporosis such as reduced mobility or 
oestrogen deficiency in postmenopausal women. Any medication which may 
increase bone loss in this vulnerable population should therefore be avoided.
7.2 Study Design
This study was designed to determine whether MTX has a measurable and 
clinically relevant effect on bone mineral density (BMD) and bone turnover in 
subjects taking it for RA. The null hypothesis was that MTX had no effect on these 
parameters. The research methods used were (i) a large clinical study of subjects 
with RA, (ii) histomorphometry of bone biopsies from a sub-group of the RA subjects 
and (iii) in vitro studies of human bone cell cultures. Thus, the effects of MTX were 
studied at the level of the whole organism, the remodelling unit and the bone- 
forming cell population.
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7 .3  The C linical Study
The clinical study was a pragmatic, observational study as it was not feasible for a 
single investigator to undertake a double-blind or single-blind, randomised study in 
the research setting of the Royal National Hospital for Rheumatic Diseases. The 
study would have been more rigorous had these conditions been imposed, but 
many fewer subjects would then have been recruited.
The first year was spent recruiting one hundred and sixteen subjects into the four 
study groups: those starting MTX; those starting sulphasalazine (SPZ); those who 
had been on MTX for at least five years; and those who had been on other disease- 
modifying anti-rheumatic drugs (DMARDs) for at least five years. None had taken 
oral corticosteroids for RA. It was not known at the outset how many patients 
attending the Royal National Hospital for Rheumatic Diseases would fulfil the entry 
criteria for any group and so the notes were reviewed for every out-patient clinic to 
identify suitable subjects. Statistical advice obtained before commencing the study 
had indicated that to find a potentially clinically relevant difference of 5% in BMD at 
any given site between the groups treated with MTX and other DMARDs would 
require at least one hundred subjects in each group. The numbers recruited fell 
short of this target but, with the benefit of hindsight, it is clear that the author’s time 
constraints would have precluded the satisfactory assessment over one or two 
years of a larger cohort.
7.3.1 Analysis of the Clinical Data
The clinical data set was studied by a statistician (Dr Daphne Kounali). Her help 
was sought as the analysis between the four groups had to take account of many 
potentially confounding factors present in the subjects. The primary outcome
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group after they had been split by sex and menopausal status was between five 
and nineteen. The only category of subject in which there were enough subjects 
in all four treatment groups to undertake a detailed regression and discriminant 
analysis was the postmenopausal women. This is the group at most risk of 
adverse effects of treatment due to the higher prevalence of osteoporosis 
following oestrogen withdrawal.
7.3.2 Demographic Features of Subjects
There were no significant differences between the four groups in prevalence of 
osteoporotic risk factors such as previous fragility fracture, family history of 
osteoporosis, smoking or alcohol use. Postmenopausal females predominated 
in each group. Subjects starting either MTX or SPZ tended to be younger and 
had much shorter RA disease duration. The group continuing MTX treatment was 
different from those continuing other DMARDs as they had ‘failed’ between one 
and six DMARDs previously and may have had more aggressive RA which was 
thus difficult to treat.
7.3.3 Rheumatoid Arthritis Disease Activity
Most subjects in all four treatment groups had high or moderate disease activity 
(disease activity score, DAS) throughout the study. Both MTX and SPZ caused a 
rapid and statistically significant reduction in DAS from baseline over the first 
year of treatment, which was maintained at two years, but there was no 
difference betweeen groups. The DAS did not change significantly over the year 
of the study in those subjects continuing on MTX or another DMARD.
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7.3.4 Functional Status
The functional status was very similar between the four groups when assessed 
by the length of time spent walking outdoors each day. The mean Health 
Assessment Questionnaire (HAQ) score was higher at baseline in the groups 
continuing on their DMARD suggesting that longer duration of RA was 
associated with more disability, although the differences did not reach 
significance. In the groups starting a DMARD, there was a significant difference 
between those starting MTX and SPZ by repeated measures ANOVA. The HAQ 
in the group starting SPZ was reduced whilst the mean HAQ did not significantly 
change over the first two years of treatment in the group starting MTX. The 
unresponsiveness of the HAQ in the group starting MTX may be related to the 
longer mean duration of RA in this group.
7.3.5 Radiographic Score of Damage
Unsurprisingly, subjects who had a longer history of RA (groups continuing MTX 
or other DMARDs) had more erosions than those with a shorter history (those 
starting MTX or SPZ). There was, however a difference between the groups; 
those who had taken MTX for more than five years had significantly more 
erosions at the hand and elbow (but not wrist) joints than those continuing other 
DMARDs. It is worthy of note that the group starting MTX developed significantly 
more erosions at the wrist (but not hand or elbow) over the first year of the study 
when compared to the group starting SPZ. In the subjects with early RA who 
started MTX there was a significant increase in both hand and wrist Larsen 
scores at both the one and two year points, whilst there was no significant 
increase during the study in the wrist scores in subjects starting SPZ. 
Unfortunately, at the time of the study, it was hospital policy to
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do oblique radiographic views of the feet, precluding scoring of these films. It 
was not felt justifiable (ethically or financially) to obtain additional feet 
radiographs as most subjects had had recent hand and feet films taken during a 
clinic visit.
7.3.6 Bone Mineral Density Results
Analysis of the unadjusted whole data set revealed significantly reduced age- 
and sex-adjusted BMD (Z scores) at the proximal third forearm site in the group 
continuing MTX compared to the other three treatment groups 
(p <  0.0001). The BMD was also significantly lower in this group at both the total 
and mid-portion regions of the forearm. In contrast, the ultra-distal portion of the 
forearm was spared.
When the BMD results from the postmenopausal women were examined by 
regression and discriminant analysis by, the only region where MTX treatment 
was associated with lower BMD after adjustment for confounding factors, was the 
midportion region of the forearm. This suggested that the reduced BMD at the 
proximal third forearm site in those on MTX for more than five years could be 
explained by more aggressive RA disease activity.
In the subgroups with early RA of less than two years’ duration, the baseline 
BMD of subjects starting MTX were well-matched with those starting SPZ. During 
the first year of treatment there was a reduction in BMD at all sites measured in 
the group starting MTX. However, compared to the group starting SPZ the 
percentage change was not significant at any site. There were no significant 
differences in the percentage change in BMD between the two groups either 
during the second year of follow-up or at two years compared to baseline.
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The subgroup of male subjects behaved differently from the other groups and 
from the data set as a whole. The numbers in each group were very small (six to 
eight), but there were no differences between the groups at baseline for any site 
where age- and sex-adjusted BMD was estimated. Similarly, there was no 
significant difference between treatment groups for the rate of change of age- 
and sex-adjusted BMD over the first year of the study.
7.3.7 Bone Turnover Results
In the subjects with early RA, there were no significant changes found over one 
or two years in any of the three markers of bone turnover between the groups 
starting MTX and SPZ.
When all the subjects were considered together, serum osteocalcin (OC) and 
bone-specific alkaline phosphatase (AP) were significantly higher in the group 
continuing MTX. There were no differences between the four groups in urinary 
deoxypyridinoline corrected for urinary creatinine (Dpd). In the groups continuing 
treatment, the only significant change in the markers of bone turnover after one 
year was for AP where the group continuing MTX had a reduction of 11 % whilst 
the group continuing other DMARDs had an increase of 5%. Again, there was no 
significant change in Dpd.
In the men, the group starting MTX had significantly lower OC at baseline than 
the group continuing on MTX (p < 0.05), and those starting MTX had a significant 
increase in OC over the first year of the study.
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In the subgroup of postmenopausal women, the group continuing on MTX had 
significantly higher markers of bone formation compared to both those continuing 
other DMARDs and those starting SPZ at baseline and at one year. Both OC and AP 
decreased significantly compared to baseline in all four groups.
Although OC is termed a marker of bone formation, it is also released during bone 
resorption and so significant changes must be interpreted with caution. The 
introduction of either MTX or SPZ was associated with an increase in mean Dpd 
during the first year and a return to near the baseline at two years which may 
represent regression to the mean. No difference in treatment effect was found for 
either OC or AP during the two years of the study for those subjects with early RA. 
This may be because there was no treatment effect or perhaps a larger study would 
be necessary to detect small differences between MTX and SPZ, given the inherent 
variability of the assays.
7.4 Histomorphometry of Bone Biopsies
It had been planned to obtain twenty paired bone biopsies for analysis by 
histomorphometry from women who were premenopausal, had RA of less than two 
years’ duration and were commencing MTX. Although eight women did agree to the 
procedure, only four paired samples were eventually available for analysis, which 
was disappointing. This limits the conclusions that can be drawn. However, there 
were no toxic effects of MTX on cancellous bone formation as osteoid seam width 
and osteoid perimeter were not significantly different between the pre- and post­
treatment biopsies. Also the resorption cavity measurements were unchanged. 
Large and consistent adverse effects of MTX would probably be detected in such a 
small sample, but a larger sample would be necessary to detect more subtle effects.
280
A longer treatment period before the second biopsy may be necessary to reveal 
differences, as the remodelling cycle takes 200 days in trabecular (cancellous) 
bone. Given the finding in the clinical study of an effect of MTX on the mid-portion 
forearm BMD, examination of the amount and structure of cortical bone in these 
biopsies might prove informative.
7.5 Bone Cell Culture
The series of experiments performed to study the effect of clinically relevant doses 
of MTX on culture human bone-derived revealed inhibitory rather than toxic effects 
of the drug on their activity. The number of colonies formed from marrow cell 
suspensions and the proportion which were osteoblast-like (expressing alkaline 
phosphatase) were reduced by MTX in a generally dose-dependent manner. It is 
not clear whether this is due to decreased attachment of marrow precursors in the 
presence of MTX, increased apoptosis or delayed growth. As MTX interrupts the 
metabolism of folate, thus impairing DNA synthesis, the inhibition of proliferation is 
likely to be an important mechanism.
MTX also had an effect on the surface expression of the differentiation markers Stro- 
1 and B4-78 (alkaline phosphatase) which were detected by flow cytometry. By 
reducing proliferation, MTX, like dexamethasone, appeared to behave as a 
promoter of differentiation to the osteoblast-like phenotype.
It was hoped to study effects of MTX on the synthesis of collagen type I but 
unfortunately time did not allow for this.
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7 .6  C onclus ions
This ambitious study has demonstrated that there is unlikely to be a clinically 
relevant adverse effect of MTX on cancellous (trabecular) bone formation and 
turnover when used at the doses commonly used to treat RA. The histomorphometry 
study did not demonstrate an adverse effect of MTX on cancellous bone formation in 
vivo and this is in agreement with the serum markers of bone formation, which were 
highest in subjects treated with MTX. After controlling for confounding factors, 
regression analysis of the BMD and markers of bone turnover in the 
postmenopausal women subjects found a significant treatment effect of MTX only in 
the midportion of the forearm region, which is not prone to osteoporotic fracture. The 
mid-portion region has a higher cortical bone content than, for example, the ultra- 
distal region of the forearm. This study provides prospective data in support of the 
proposition made by Dequeker’s group that MTX affects cortical bone preferentially 
when used in RA (Maenaut et al, 1996).
Bone cell culture experiments found that MTX did influence the colony-forming 
efficiency, proliferation and differentiation of normal human bone-derived cells, with 
dose-dependent reduction in proliferation.
Overall, these results suggest that the most important effect of MTX on the skeleton 
in RA is beneficial through its modulation of the immune system which suppresses 
the RA disease activity. No independent effect of MTX was seen on markers of bone 
turnover. This study is reassuring for clinicians and patients using MTX, as 
cancellous (trabecular) bone is unaffected. The mechanism of cortical bone loss is 
unknown, but it is becoming clear that neuropeptides are expressed in both 
synovium and bone (Rosen et al, 1998). It is tempting to speculate that MTX may
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inhibit neuropeptide synthesis which could result in envelope-specific effects on 
remodelling preferentially affecting cortical bone.
7.7 Proposals for Further Study
A larger, double-blind clinical study over a longer time period would have had more 
power and may have demonstrated subtle differences between treatments, 
although they may not necessarily have had clinical relevance. In view of the 
reports of fragility fractures occurring in the distal tibia (Preston et al, 1993), serial 
total body BMD estimation may be informative as variations in the different regions 
of the axial and appendicular skeleton could be studied. Radiographic scores of 
damage in the knees, ankles and feet joints would then be important confounders, 
as would mobility and time spent weight-bearing.
A larger sample, treated for longer and including analysis of cortical parameters in 
addition to the cancellous (trabecular) bone would be necessary to confirm the lack 
of adverse effect demonstrated by histomorphometry in this study.
Finally, the bone cell culture work should be confirmed and extended. If a more 
normal source tissue of bone and marrow cells could be identified, studies could 
include the effect of MTX on collagen synthesis and expression of messenger RNA 
for relevant bone proteins including osteocalcin, alkaline phosphatase, oestrogen 
and the receptors for vitamin D3. Any effect of MTX on programmed cell death 
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